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Summary 
There is much interest in Hsp90 inhibitors as anti-cancer drugs. It is therefore of fundamental 
biological and medical importance to identify all Hsp90 client and Hsp90 regulated proteins, 
elucidate the mechanisms and new features of Hsp90 inhibitors to direct for future usage and 
development of Hsp90 inhibitors as drugs. 
 
Imatinib (Glivec) is the standard treatment for CML (chronic myeloid leukemia); however, some 
patients develop resistance to imatinib. Hsp90 inhibitors can overcome imatinib resistance that is 
due to over-expression of Lyn in MYLR CML cells. DIGE (two-dimensional fluorescence 
difference gel electrophoresis), Phospho-RTK antibody arrays, Western blotting and siRNA 
techniques provided a comprehensive analysis of protein differences between MYL and MYLR 
cells, as well as before and after Hsp90 inhibitor treatment. Proteins differentially abundant 
between MYL and MYLR cells were generally related to imatinib resistance and Lyn kinase 
signaling. The Hsp90 inhibitors SNX-7081 and SNX-5422, overcome imatinib resistance by 
decreasing the levels or activity of pro-survival signaling proteins, including Lyn kinase, BCR-
ABL, Akt, and Stat5, reducing the phosphorylation of the Hsp90 client proteins TrkA and 
FGFR3, and increasing Lyn-related ubiquitin/proteasome proteins and anti-oxidant proteins. 
 
In chronic lymphoid leukemia (CLL) treatment, p53 mutated patients respond poorly to the front-
line fludarabine (2-FaraA) based chemo-immunotherapy treatment. Finding an alternative 
treatment for these p53 mutated patients is an unmet need. The Hsp90 inhibitor SNX-7081, 
induces apoptosis in p53-mutated MEC1 cells. iTRAQ analysis detected 7 proteins increased, and 
44 proteins decreased by more than 2-fold (p < 0.05) after SNX-7081 treatment. Pathway 
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analysis determined that 3 of the differentially abundant proteins (cyclin D1, c-Myc and pRb) 
were functionally related. Western blotting validation showed that proteins DDB1, MCM2, c-
Myc, and PCNA decreased, pRb and cyclin D1 increased, and the p53 level did not change in p53 
wild-type Raji cells, p53-mutated MEC1 and U266 cells and p53-null HL60 cells upon SNX-
7081 treatment. These data suggest that SNX-7081 arrests the cell cycle, and inhibits DNA 
replication and repair via a p53-independent pathway, providing a rationale for synergistic 
combinations of Hsp90 inhibitors and DNA damaging agents such as 2-FaraA. 
 
To profile changes in the immunophenotype induced on MEC1 cells by the Hsp90 inhibitor 
SNX-7081, we used DotScan™ microarray to detect the surface CD (cluster of differentiation) 
antigens after SNX-7081. In the microarray analysis, 11 CD antigens (CD27, CD20, CD19, 
CD319, CD47, CD53, CD69, CD262, kappa, CD80 and CD98) increased, and 3 CD antigens 
(CD22, CD150, CD212) decreased (p < 0.05) after SNX-7081. CD20 increased 2.73-fold, CD19 
increased 1.55-fold, and CD262 (DR5) increased 5.59-fold after SNX-7081. Anti-cancer drugs 
like rituximab, XmAb5574 and TRAIL specifically induce apoptosis of cells expressing CD20, 
CD19 and TRAIL receptor, combining an Hsp90 inhibitor with one of these drugs could be 
synergistic in treating B-cell malignancies.  
 
We found that SNX-7081 is synergistic with 2-FaraA that damages DNA, in collaboration with 
clinical scientists at the Kolling Institute, Royal North Shore Hospital, we demonstrated drug 
synergy effect for three p53-mutated cell lines (MEC1, MEC2 and U266) and 23 CLL patient 
samples (Best, O.G., et al., The Hsp90 inhibitor SNX-7081 synergizes with and restores 
sensitivity to fludarabine in chronic lymphocytic leukemia cells with lesions in the TP53 pathway: 
a potential treatment strategy for fludarabine refractory disease. Leuk Lymphoma, 2012). Using 
 Summary 
xv 
 
label-free quantitative shotgun proteomics, we found that in the p53-mutated MEC1 CLL cell 
line, SNX-7081 decreased the abundance of DNA replication and repair proteins when used as a 
single agent (13) or in combination with 2-FaraA (9), while 2-FaraA alone or in combination 
with SNX-7081 increased the abundance of 9 and 14 DNA damage proteins respectively. The 
DNA damage marker pH2AX, increased significantly in response to SNX-7081+2-FaraA, over 
levels induced by exposure to either agent alone, in MEC1, MEC2 and U266 cell lines. We 
propose that the mechanism of drug synergy is that 2-FaraA causes DNA damage, and SNX-
7081 down-regulates DNA repair proteins which causes cells to accumulate DNA damage and 
undergo apoptosis.   
 
In this study, we used comprehensive proteomics techniques to identify the protein changes 
induced by Hsp90 inhibitors. The results extend the list of Hsp90-regulated proteins (client) and 
suggest Hsp90 inhibitor mechanisms such as down-regulating Lyn kinase, inhibiting DNA repair, 
arresting the cell cycle, increasing the surface CD antigens CD19, CD20 and CD262. Hsp90 
inhibitors could be used to overcome various forms of drug resistance, such as imatinib resistance 
in human chronic myloid leukemia MYLR cells, and 2-FaraA resistance in human chronic 
lymphocytic leukemia MEC1 cells. Combination of Hsp90 inhibitors with other anti-cancer drugs 
such as 2-FaraA may lead to more effective chemotherapy regimens, and potentially solve the 
high toxicity encountered Hsp90 inhibitor clinical trials. 
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General Introduction 
 
 
 
 
 
 
 
 
 
 
 
 Chapter 1: General Introduction 
1 
 
1.1 Leukaemia 
Leukaemia (Greek for “white blood”) is a cancer of the blood or bone marrow characterised by 
an abnormal proliferation of blood cells, usually leukocytes. Leukemia is part of the group of 
diseases affecting the blood, bone marrow, and lymphoid system, known as hematological 
neoplasms. Multipotential haematopoietic stem cells in bone marrow are capable of 
differentiating into myeloid and lymphoid progenitor cells (Figure 1.1). During differentiation, 
cells develop functional characteristics of their specific lineage and lose their capacity for 
proliferation. This process is called haematopoiesis.  
             
 
Figure 1.1: The process of haematopoiesis. The bone marrow is rich in haematopoietic stem cells (HSCs) that can 
differentiate into a variety of lineages. Multipotent HSCs may develop into lymphoid or myeloid precursors. The 
lymphoid lineage produces T-cells, B-cells and natural killer (NK) cells. The myeloid lineage produces erythrocytes, 
mast cells, megakaryocytes, neutrophils and monocytes, as well as cells not directly associated with the 
haematopoietic system, such as osteoclasts. (http://en.wikipedia.org/wiki/File:Hematopoiesis_simple.svg) 
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Leukocytes, or white blood cells, are cells of the immune system involved in defending the body 
against infectious diseases and foreign materials. Leukocytes can be classified into two groups, 
granulocytes (polymorphonuclear leukocytes) and agranulocytes (mononuclear leukocytes), 
according to the presence of the granules. Granulocytes include neutrophils, basophils, and 
eosinophils, named according to their staining properties. Agranulocytes include lymphocytes, 
monocytes, and macrophages. Leukocytes live for between 6 hours and two days. They are found 
throughout the body, including the tissues, blood and lymphatic system. 
 
During transformation of leukocytes to cancers, chromosomal translocations and other mutations 
may occur, leading to aberrant transcription factors, cell differentiation, and proliferation. As a 
consequence, the blood and lymph nodes are flooded with immature, non-functional leukocytes, 
resulting in a leukaemia or lymphoma, respectively. Leukaemic transformation results from 
mutations in the DNA, resulting in inappropriate expression of oncogenes or loss of function of 
tumour suppressor genes. The mutated cell may be a lymphoid or myeloid precursor, or a 
multipotential haematopoietic stem cell capable of differentiating into myeloid and lymphoid 
cells. 
 
Based on the cases diagnosed from 2005-2009, there are 12.5 patients per 100,000 people 
diagnosed with leukemia each year, with a higher rate in males (16 per 100,000 men) than in 
women (9.8 per 100,000 women). About 90% of all leukemias are diagnosed in adults, with a 
median age of 66 years old. Although survival rates of leukaemia patients have steadily increased 
over the last 25 years, the overall 5-year relative survival is only 55.0% [1]. 
 
Leukaemia is categorised into acute and chronic forms depending on the rate of proliferation. 
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These two forms are further distinguished by the type of abnormal haematopoietic precursor 
involved, either lymphoid or myeloid, giving four leukaemic sub-categories:  
 
• Chronic myeloid leukaemia (CML) 
• Chronic lymphocytic leukaemia (CLL) 
• Acute myeloid leukaemia (AML) 
• Acute lymphoblastic leukemia (ALL)  
 
1.1.1 Chronic myeloid leukemia and treatment 
Chronic myeloid leukemia (CML) is classified under the chronic myeloproliferative diseases and 
accounts for approximately 15% of newly diagnosed cases of leukemia in adults. CML has a 
worldwide annual incidence of 1-2 cases per 100,000 population [2]. The median age of 
presentation is 67 years, and there is a slight male predominance [3]. CML is distinguished from 
the other leukaemias by the presence of a genetic abnormality, called the Philadelphia 
chromosome. In 1960, two physicians studying chromosomes in cancer cells noticed that 
chromosome No. 22 in CML patients was shorter than the same chromosome in normal cells. 
They named this shortened chromosome the Philadelphia chromosome, because the observation 
was made at the University of Pennsylvania in Philadelphia [4]. In this translocaton, parts of the 
No. 9 and No. 22 chromosomes switch places, causing part of the BCR gene from No. 22 
chromosome to be fused with the ABL gene on No. 9 chromosome. ABL has a tyrosine kinase 
domain that can add phosphate groups to tyrosine residues, the protein encoded by the BCR-ABL 
fusion gene is an unregulated tyrosine kinase [5], leading to dysfunctional regulation of cell 
growth and survival, responsible in part for development of CML. 
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CML begins with an indolent chronic phase (CP) that can last for 3 to 5 years. If untreated, it 
progresses into accelerated phase (AP) and within a year, blast phase (BP) with survival at this 
point of less than 1 year. The only known curative therapy for CML is allogeneic bone marrow 
transplant (BMT) following high dose chemotherapy. However, toxicity is formidable, with 
treatment-related mortality of ~ 30%. Thus, treatment that maintains the patient with CML in CP 
with minimal toxicity is the goal [6]. Current CML therapies include imatinib, Dasatinib, 
Nilotinib, and Bosutinib [7]. 
 
1.1.2 Chronic lymphocytic leukemia and treatment 
Chronic lymphocytic leukemia (CLL) accounts for about 29% of all leukaemias and is the most 
common lymphoid malignancy in Western countries with an annual incidence of 5.17 per 
100,000 person-years [8]. At diagnosis, ~95% of patients are over age 50 and the incidence of the 
disease increases dramatically with age. CLL sometimes occurs in younger adults, but hardly 
ever affects children. The median age at diagnosis is 72 years, and 70% of patients are >65 years 
of age at diagnosis, with <2% being younger than 45 at the time of diagnosis. The male-to-female 
ratio is 2:1 [9]. B-cells originate in the bone marrow, develop in the lymph nodes, and normally 
fight infection by producing antibodies. B-CLL is characterized by accumulation of long-lived 
functionally inactive, apparently differentiated B-lymphocytes arrested in G0 phase of the cell 
cycle [10]. The clonal excess of B-cells is mainly caused by a decrease in cell death rather than 
increased proliferation or altered regulation of the cell-cycle [11, 12]. The most characteristic 
feature of CLL is a peripheral blood lymphocytosis of >5.0 × 109/L, but usually >15.0 × 109/L 
and sometimes >100.0 × 109/L.  
 
CLL treatment focuses on controlling the disease and its symptoms, the disease is incurable. CLL 
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is treated by chemotherapy, radiation, antibody therapy, or bone marrow transplantation. The 
first-line single agent treatments for CLL patients have been a nucleoside analog (fludarabine) or 
an alkylating agent (chlorambucil). However, Fludarabine has largely replaced chlorambucil. In 
the CLL study comparing fludarabine with chlorambucil patient (median age 70 years), there was 
a significantly higher response rate with fludarabine [13]. Other drugs used to treat CLL include 
alkylating agents like bendamustine and cyclophosphamide, and therapeutic antibodies such as 
alemtuzumab, directed against CD (cluster of differentiation) 52, rituximab and ofatumumab, 
directed against CD20 [14]. 
 
1.1.3 Acute myeloid leukemia and treatment 
Acute myeloid leukemia (AML) is characterised by rapid accumulation of myeloid precursor 
cells in the bone marrow that interfere with the production of normal blood cells. Acute 
leukaemia is a diverse group of blood cancers with a median age of 67 years [15, 16]. If left 
untreated, 50% of AML patients will die in 2-3 months. AML involves abnormal cells in the bone 
marrow that grow rapidly and replace healthy cells. The bone marrow, that enables the body fight 
infections, eventually stops working. Patients with AML are more prone to infections and have an 
increased risk of bleeding as the number of healthy blood cells decrease.   
 
The French-American-British (FAB) classification system divides AML into eight subtypes, M0 
through to M7, based on the type of cell from which the leukemia developed and its degree of 
maturity. AML is characterized by recurrent genetic abnormalities of prognostic significance. The 
most commonly identified are balanced abnormalities: t(8;21)(q22;q22), inv(16)(q22;q12) or 
t(16;16)(p13.1;q22), t(15;17)(q22;q12) and t(9;11)(p22;q23) [2]. Each of these structural 
chromosome rearrangements creates a fusion gene encoding a chimaeric protein that is required, 
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but usually not sufficient, for leukaemogenesis [2]. There is no single dominant lesion in AML, 
AML with t(8;21)(q22;q22) involves the RUNX1 translocation (the gene previously called 
AML1) found in 5% of cases of AML [2].  In the recent Eastern Cooperative Oncology Group 
E1900 clinical trial, the abnormalities in FLT3, NPM1 and DNMT3A were identified as 37%, 
29% and 23% of the cases respectively [17]. Disruption of transcription factor function can arrest 
normal cellular differentiation and lead to AML [18]. The overall survival of younger patients 
(<60 years) has increased due to high dose chemotherapy (daunorubicin, cytarabine) [19]. The 
drug combination cytosine arabinoside (Ara-C) with an anthracycline, was developed nearly 40 
years ago and remains the standard of care [20]. Approximately 70-80% of patients <60 years of 
age will achieve complete remission [21, 22], but most will ultimately relapse and overall 
survival is only 40-45% at 5 years. Among patients >60 years of age, 40-50% of those with a 
good performance status can achieve complete remission, but cure rates are <10% and median 
survival is <1 year [23, 24].  
 
1.1.4 Acute lymphoblastic leukemia and treatment 
Acute lymphoblastic leukemia (ALL) is the most common type of leukemia in young children, 
accounting for about 80% of the acute childhood leukaemias and 25% of all cancers in children 
[25]. The incidence of ALL among 1-4-year-old children is more than 9 times greater than the 
rate for young adults over the age of 20. This disease also affects adults, especially those of 65 
and older. ALL is further sub-classified into T-lymphocytic and B-lymphocytic types (T-ALL or 
B-ALL), depending on whether the cells are similar to normal T- or B-lymphocytes. ALL is 
characterized by a number of chromosomal translocations resulting in structurally altered genes, 
that play key roles in cell proliferation, differentiation, apoptosis and gene transcription [26].  
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The survival rate for ALL has improved from zero about four decades ago, to an overall cure rate 
in children of ~80%, and 45-60% for adults [25], largely due to clinical trials on new 
chemotherapeutic agents and improvements in stem cell transplantation (SCT) technology [27]. 
Because of rapid growth, most ALL patients need to start chemotherapy right away. Most patients 
are treated with an anthracycline, such as daunorubicin (cerubidine), doxorubicin (adriamycin 
PFS) or idarubicin (idamycin). An anthracycline is combined with cytarabine (cytosine 
arabinoside, Ara-C, Cytosar-U). Other drugs may be added or substituted for higher-risk, 
refractory or relapsed patients [28]. 
 
1.2 Cell lines 
The following human cell lines were used in this project. 
 
1.2.1 MYL and MYLR cell lines 
MYL cells were originally harvested from a patient with CML; MYLR cells were derived from 
the parental MYL cell line by exposure to increasing concentrations of imatinib in culture [29]. 
MYL is sensitive to the anti-CML drug imatinib, MYLR is resistant to imatinib. Importantly, 
MYLR cells do not have further BCR-ABL kinase mutations and do not over-express BCR-ABL, 
indicating the resistance is based on BCR-ABL-independent mechanism. MYLR showed 
elevated levels of Lyn mRNA, Lyn protein, and phosphorylated Lyn. Silencing of Lyn by short-
interfering RNA (siRNA) in MYLR, but not in MYL, induced significant growth-inhibition, 
increased caspase-3 activity, and induced partial recovery from imatinib-resistance. Lyn may play 
an important role in imatinib-resistance in MYLR [29]. 
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1.2.2 MEC1 Cell Line  
The MEC1 cell line (204508/S288c American Type Culture Collection, Manassas, VA, USA) was 
grown from the blood of a 61 year-old Caucasian male with aggressive B-CLL [30]. In liquid 
culture, MEC1 cells grow adhering to the flask and as tiny clumps. Cell lines derived from CLL 
are controversial because CLL is an indolent leukaemia and further mutations would be required 
to transform the cells for active growth. MEC1 cells were shown to be a good model for 
investigation of the biology of B-CLL [30]. They share expression of most mature B-cell markers; 
express the same light (κ) and heavy chains (µ, δ) as the fresh parental B-CLL cells; have a 
deletion in chromosome 17p13, a frequent chromosomal aberration in B-CLL. The pattern of 
Bcl-2 family gene expression in MEC1 cells is shifted toward blockade of apoptosis, similar to 
fresh leukaemic B-cells [31]. MEC1 cells have a deletion in the short arm of chromosome 17 
(17p-), the locus for p53, and a mutation in the remaining allele, which most likely explains their 
resistance to 2-FaraA [30, 32]. MEC1 represents a good model for investigating the potential of 
drugs for the treatment of p53-mutated CLL. 
 
1.2.3 Raji cell line  
The Raji cell line was established from a 12 year-old African boy with B-cell Burkitt’s lymphoma 
(BL) and carries the Epstein-Barr Virus (EBV), associated with lymphoid malignancies including 
BL [33]. Raji cells show the typical immunophenotype of BL including expression of CD19, 
CD20, CD10, and lack of terminal deoxynucleotide transferase (TdT) [34, 35]. Loss of annexin I 
was detected in several non-Hodgkin’s lymphomas and in the Raji cell line [36]. In addition, Raji 
cells carry the t(8;14) translocation, the most common translocation in patients with Burkitt’s 
lymphoma, with a karyotype that closely resembles the donor’s [34]. Both alleles of the p53 gene 
in Raji cell have point mutations, but neither of the alleles is inactivated by the mutation [37]. 
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p53 in Raji responds to 2-FaraA treatment [32], and Raji has been used as a p53 wild-type cell 
[38]. 
 
1.2.4 HL60 cell line 
The HL60 cell line is a promyelocytic cell line derived from peripheral blood leukocytes obtained 
in 1977 from a 36-year-old Caucasion female with acute promyelocytic leukemia (PML) [39]. 
HL60 cells spontaneously differentiate down several myeloid lineages, also stimulated with 
agents including butyrate, hypoxanthine, phorbol myristic acid (PMA), dimethylsulfoxide 
(DMSO, 1% to 1.5%), actinomycin D, and retinoic acid. HL60 cells lack p53 expression, and is 
used as a p53-null cell model [40]. 
 
1.2.5 U266 cell line 
U266 is a human multiple myeloma cell line established from the peripheral blood of a 53-year-
old man with IgE-secreting myeloma (refractory, terminal) in 1968 [41]. Cells produced IgE 
lambda; a possible fusion partner for hybridoma production and express mRNA for the bcl-2 
gene [41]. U266 cell has a mutant p53 with a codon 161 mutation [42]. 
 
1.3 Anti-cancer drugs 
1.3.1 Imatinib  
1.3.1.1 Mechanism of imatinib 
Chronic myeloid leukemia (CML) therapy has dramatically 
improved in the last decade due to the introduction of the tyrosine 
          Figure 1.2. Imatinib 
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kinase inhibitor, imatinib (Figure 1.2). The drug was approved by the U.S. Food and Drug 
Administration in 2001 and then approved as front-line therapy for chronic phase (CP) CML in 
2003. It is marketed by Novartis as Gleevec (USA) or Glivec (Europe/Australia/Latin America) 
as imatinib mesylate.  
 
Imatinib was the first of a new class of small molecule drugs that specifically inhibit a soluble 
tyrosine kinase BCR-ABL [43]. Tyrosine kinases transfer phosphate from ATP to tyrosine 
residues on substrate proteins, providing an "on" or "off" switch for many cellular processes such 
as proliferation, differentiation, and survival [44]. Imatinib is a model for targeted therapies. As 
illustrated in Figure 1.3, the BCR-ABL tyrosine kinase (p210) binds ATP and transfers a 
phosphate to tyrosine residues on downstream substrates, causing excess proliferation of myeloid 
cells in CML. Imatinib functions by blocking the binding of ATP to the BCR-ABL tyrosine 
kinase, inhibiting its activity. Therefore, substrates for BCR-ABL aren’t phosphorylated and 
subsequent cellular events are blocked, causing tumor cell apoptosis [44].  
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Figure 1.3: The mechanism of action of imatinib. The BCR-ABL tyrosine kinase binds ATP and transfers 
phosphate to tyrosine residues on downstream substrates, some of which are transcription factors resulting in 
proliferation of myeloid cells in CML. Imatinib functions by binding to the ATPase site on p210 preventing ATP 
from participating in the kinase reaction and downstream proliferative signaling is blocked.  
 
1.3.1.2 Imatinib drug resistance 
Compared to most anti-cancer drugs, imatinib has relatively few side-effects and can be taken 
orally at home. With this remarkable drug, more than 90% of CML patients will be able to keep 
the disease in check for at least 5 years, so that CML becomes a chronic, manageable condition 
[45]. Although imatinib is a very successful drug, ~33% of CML patients are resistant to imatinib 
[46, 47], indicating the need for alternative therapies for patients with imatinib-resistant CML. 
This resistance of two types: primary resistance, and secondary resistance (those who have 
previously achieved remission and subsequently lost their response). The mechanisms of 
resistance to imatinib can be either BCR-ABL-dependent (gene amplification or point mutations), 
or BCR-ABL-independent [7]. From 35-75% of cases of drug resistance are caused by the 
appearance of CML clones expressing mutant forms of BCR-ABL. More than 50 distinct point 
mutations encoding single amino-acid substitutions in the kinase domain of BCR–ABL have been 
reported [47-52]. Over-expression of other tyrosine kinases such as the Scr-related Lyn kinase 
can provide BCR-ABL-independent resistance [53]. In this project, we have investigated Lyn 
related BCR-ABL-independent imatinib resistance. 
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1.3.2 Fludarabine 
1.3.2.1 Mechanism of 2-FaraA 
Fludarabine (9-β-D-arabinofuranosyl-2-fluoroadenine, 2-FaraA) was 
synthesized as an anticancer drug by Montgomery and Hewson in 
1969 [54]. The term 2-FaraA refers to the more soluble prodrug, the 
5’-monophosphate derivative of 2-FaraA (Figure 1.4), that is given to 
patients and dephosphorylated to the nucleoside 2-FaraA before 
entering the cell.  
 
2-FaraA is transported into cells via an equilibrative nucleoside transporter [55]. 2-FaraA is 
successively phosphorylated 2-FaraAMP → 2-FaraADP → 2-FaraATP by deoxycytidine kinase 
(dCK), adenylate kinase and nucleoside diphosphate kinase [56]. Cells maintain a pool of 
deoxynucleotides (dNTPs) for DNA synthesis. Phosphorylated purine analogues like 2-FaraATP 
compete with those dNTPs for DNA synthesis.  
 
The anticancer activity of 2-FaraA was first established when used to treat relapsed or refractory 
CLL patients [57, 58], and is now a standard treatment for CLL refractory to alkylating agents 
[59]. 2-FaraA is also effective as a first-line therapy for CLL. In a long-term follow-up of a large 
group of CLL patients receiving 2-FaraAMP as primary therapy, 174 patients with progressive or 
advanced CLL were treated and obtained a complete response rate of of 38% [60].  
 
2-FaraA has been successfully combined with several therapeutic antibodies for treatment of CLL 
[61]. Combinations of 2-FaraA with alkylating agents produces higher response rates and a 
longer progression-free survival than single agents: 
Figure 1.4: Chemical 
structure of fludarabine 
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FC (2-FaraA with cyclophosphamide) [62]  
FR (2-FaraA with rituximab) [63] 
FCR (2-FaraA, cyclophosphamide, and rituximab) [64]  
 
1.3.2.2 Drug resistance of 2-FaraA and the p53 pathway 
CLL patients with p53 mutations or deletions respond poorly to therapy with purine analogues. 
Although induction of apoptosis linked to double strand breaks in DNA may occur through p53-
dependent or p53-independent mechanisms [65], p53-dependent apoptosis plays a central role in 
2-FaraA cytotoxicity [66-68]. 
 
DNA strand breaks or incorporation of purine analogues into DNA are likely to be sensed by 
DNA damage sensors, which then activate pro-apoptotic or survival pathways [69]. p53 
facilitates the apoptotic cell death process.  p53 is a tumour suppressor protein that protects the 
genome by eliminating damaged cells through induction of apoptosis or enabling DNA repair 
during cell cycle arrest [70]. p53 may form a sensor complex with DNA-dependent protein kinase 
(DNA-PK) or ATM (ataxia telangectasia mutated) and ATR (ATM- or Rad3-related kinases) to 
detect DNA strand breaks caused by incorporation of nucleoside analogues and may induce cell 
cycle arrest or cell death to prevent proliferation of damaged cells [70-72]. Disruption of p53 may 
occur either by mutation or as a consequence of deletion of the chromosomal region on 
chromosome 17p coding for the p53 gene. A lack of functional p53 leads to loss of the coupling 
of DNA damage to cell cycle arrest and apoptosis [70, 73],  so p53-mutated human MEC1 CLL 
cells tend to show drug resistance to DNA damage reagents like 2-FaraA [74-76].  
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1.3.3 Hsp90 inhibitors 
1.3.3.1 Mechanism of Hsp90 inhibitors 
Hsp90 (heat shock protein 90) is a molecular chaperone and is one of the most abundant proteins 
in cells [77]. It is a member of the heat shock protein family that is up-regulated in response to 
stress. They account for 1–2% of the total proteins in un-stressed cells, however, when cells are 
heated, the fraction of heat shock proteins increases to 4–6% of cellular proteins [78]. 
 
The Hsp90 chaperone protein (Figure 1.5) consists of three domains: an amino terminal region 
(N domain) that contains an ATP and drug-binding site and co-chaperone-interacting motifs; a 
middle (M) domain that provides docking sites for client proteins and co-chaperones, and that 
participates in forming the active ATPase; and a carboxy-terminal (C) domain that contains a 
dimerization motif. The C-terminal domain binds to a client protein and is also a second drug-
binding region with interaction sites for other co-chaperones [79-81]. 
 
Figure 1.5: Hsp90 protein. In normal status (left), inhibited by 
Hsp90 inhibitor SNX-7081 (right). 
NTD, N-terminal domain; MD, middle domain; CTD, C-terminal 
domain. 
 
The Hsp90 protein has more than 200 ‘client’ proteins including signaling proteins like kinases 
and transcription factors, many of which are oncogenic proteins such as Her2, Akt, BCR-ABL, c-
Kit, EGFR, cdk4 and mutant BRAF. These proteins form complexes with Hsp90 and co-
chaperones to attain their active conformations or enhance stability [82]. Cancer cells use the 
Hsp90 chaperone machinery to protect an array of mutated and over expressed oncoproteins from 
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misfolding and degradation. Inhibition of Hsp90 function disrupts these complexes and leads to 
degradation of client proteins resulting in the shutdown of multiple oncogenic signaling pathways 
[82, 83], which is why Hsp90 inhibitors have anticancer activity. Although Hsp90 is required in 
all cells, tumor cells are especially sensitive to Hsp90 inhibitors as they are ‘oncogene addicted’ 
and require especially high levels of Hsp90 as a crucial facilitator of oncogene addiction and 
cancer cell survival [84-87]. Therefore, Hsp90 inhibitors display selectivity for cancer cells as 
compared to normal cells [88].  
 
 1.3.3.2 Hsp90 inhibitors as drugs 
There are 18 Hsp90 inhibitors under clinical trials listed in Table 1.1, chemical structures that 
have been disclosed in the scientific literature are shown in Figure 1.6. All inhibitors interact with 
the N-domain ATP-binding pocket, prevent ATP binding, and stop the chaperone cycle, leading to 
client protein degradation. These inhibitors include ansamycin-derived natural products such as 
geldanamycin and the derivatives 17-AAG and 17-DMAG, the macrolide radicicol and 
derivatives such as NVP-AUY922, STA-9090, and synthetic small molecules like SNX-5422 and 
SNX-7081.  
 
The fundamentals of Hsp90 inhibition have been investigated thoroughly with the ansamycin 
natural product class, starting with geldanamycin [89]. Owing to toxicity, geldanamycin was not 
pursued for clinical development. 17-allylamino-17-demethoxygeldanamycin (17-AAG) is a 
semi-synthetic derivative from geldanamycin [90]. 17-AAG demonstrated potent anti-tumor 
activity and is less toxic than geldanamycin in animal testing [90]. Moreover, Hsp90 in cancer 
cells bound 17-AAG with >100-fold higher affinity than Hsp90 in normal cells [88]. 17-AAG 
was the first Hsp90 inhibitor to undergo clinical trials and has been in more than 30 clinical trials 
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as both a single agent and in combination with approved therapies such as bortezomib, imatinib, 
docetaxel, irinotecan, sorafenib, rastuzumab, and rituximab, beginning in 1999 [91]. Although 
17-AAG possessed encouraging biological and pharmacologic properties, it has poor aqueous 
solubility and formulation difficulties, which caused the termination of a clinical trial II/III by the 
BMS Company. Kosan Biosciences developed 17-(2-dimethylaminoethyl)amino-17-
demethoxygeldanamycin (17-DMAG, or alvespimycin hydrochloride) that retained potent Hsp90 
inhibition with improved aqueous solubility as the salt of the basic amino group [92, 93]. 17-
DMAG has completed several phase I studies, including in combination with trastuzumab, but 
development has been limited by uncertainty in the optimal compromise between dose, frequency 
of administration, and toxicity [94]. Infinity Pharmaceuticals developed IPI-504, a highly soluble 
hydroquinone hydrochloride derivative of 17-AAG, and enabled simple aqueous-based 
formulations for intravenous administration [95]. IPI-504 is under a phase II clinical trial in 
combination with docetaxel, a Phase III trial with gastrointestinal stromal tumors was terminated 
because of toxicity. 
 
Another class of natural product is derivatives of resorcinol as Hsp90 inhibitors [96]. NVP-
AUY922 in an intravenous formulation is under phase II clinical trial by Novartis for NSCLC 
(Non-small-cell lung carcinoma) and breast cancer, in combination with bortezomib, trastuzumab, 
erlotinib, cetuximab, or capecitabine [97]. AT-13387 is another Hsp90 inhibitor derived from 
resorcinol; that is under phase I clinical trial by Astex Therapeutics for metastatic solid tumors. 
AT-13387 induces by a long duration of client protein suppression in preclinical studies [98]. 
STA-9090 is under phase I/II clinical trial by Synta Pharmaceuticals for leukemias including 
AML and CML. 
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There are some other small molecule Hsp90 inhibitors. The orally bioavailable BIIB021 (or 
CNF-2024) is a synthetic purine Hsp90 inhibitor [99], that mimics the shape adopted by ATP 
when bound to Hsp90. BIIB021 is being developed by Biogen Idec with multiple phase I trials in 
solid tumors and CLL completed, and in two Phase II clinical trials underway in patients with 
gastrointestinal stromal tumor and breast cancer [100, 101].  
 
A novel class of Hsp90 inhibitors, structurally distinct from other reported scaffolds, was 
developed by researchers at the company Serenex from rational design and optimization of a 
compound identified from a chemical library. A library was screened against the purine-binding 
proteome to identify novel scaffolds that selectively bind to the ATP pocket of Hsp90. A purine-
based affinity resin was used to capture purine-binding proteins. Compounds that displaced 
Hsp90 family members from this column were then identified by sequencing using mass 
spectrometry [102]. These amino-quinazoline derivatives, selectively bind to Hsp90 and inhibit 
its cellular activities at nanomolar concentrations [103]. The chemical scaffold ‘a benzamide 
moiety coupled to a tetrahydroindolone’ binds competitively to the ATP-binding site of Hsp90. 
X-ray structures demonstrate that the benzamide group acts as a structural isostere to the adenine 
ring of ATP. These low molecular weight inhibitors have good pharmacokinetic properties, 
including bioavailability from oral dosing [104]. This scaffold group is unrelated in structure to 
the natural product–based Hsp90 inhibitors (e.g., geldanamycins and radicicols) and to the 
purine-based compounds. SNX-5542, a prodrug of SNX-2112, is a water-soluble and orally 
bioavailable compound of the serenex group that displayed a favorable pharmacodynamic profile 
and is undergoing multiple phase I clinical trials by Pfizer with an oral formulation. In the present 
study, we investigate the mechanism of SNX-7081, a similar compound to SNX-5422. SNX-7081 
is significantly more potent as an Hsp90 inhibitor than 17-AAG against primary CLL cells and a 
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range of haematological cell lines, irrespective of lesions in the p53 pathway [102]. 
 
Table 1.1. Hsp90 inhibitors under clinical trials. 
  Hsp90 inhibitor Clinical stage Route Company 
Geldanamycin 
derivative 
17‐AAG  II/III (stopped) Intravenous BMS 
17‐AAG (ABI‐010) I Intravenous Abraxis Bioscience 
17‐DMAG I Intravenous/oral Kosan/BMS 
IPI‐504  II/III Intravenous Infinity Pharmaceuticals 
IPI‐493  I Oral Infinity   
Resorcinol 
scaffold 
NVP‐AUY922 I/II Intravenous Novartis 
STA‐9090 II/III Intravenous Synta 
AT13387 I Intravenous Astex Therapeutics 
Other small 
molecules 
BIIB021   II Oral Biogen Idec 
BIIB028 I Intravenous Biogen Idec 
KW‐2478 I/II Intravenous Kyowa Hakko Kirin 
SNX‐5422   I Oral Pfizer 
XL888  I Oral Exelixis 
HSP990  I Oral Novartis 
MPC‐3100  I Oral Myriad Pharmaceuticals 
DS‐2248 I Oral Daiichi Sankyo 
Debio 0932 I Oral Debiopharm 
PU‐H71 I Intravenous Memorial Sloan‐Kettering 
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Figure 1.6: Hsp90 inhibitor drug structures. 
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Other inhibitors that are under preclinical development include those binding to the C-terminal 
dimerization domain of Hsp90, such as novobiocin. Alternatively Hsp90 may be modified 
postranslationally using histone deacetylase or proteasome inhibitors [79, 86, 105, 106], so far 
without clinical trials.  
 
1.4 Proteomics 
1.4.1 What is Proteomics? 
The term "Proteome" was coined in the mid-1990s by Prof. Marc R. Wilkins (then at Macquarie 
University, Australia) by analogy with the term genome, and addressing the total ‘protein 
complement encoded by a genome’ [107]. The proteome of a cell includes all the proteins at a 
particular time, under specific conditions. The human proteome is much more complex than the 
human genome, as in the process of protein translation from RNA read from DNA, there are 
splice variants and post-translational modifications like phosphorylation, acetylation, proteolysis, 
glycosylation, ubiquitination and methylation. Thus one gene can result in many different protein 
isoforms. The human cell only has 23,000 genes, there are up to 1,000,000 distinct protein 
isoforms [108]. One organism will have radically different protein expression in different tissues, 
and every cell in turn will have different protein composition in different stages of the cell cycle 
and in different environmental conditions. Proteomics is of growing importance in many areas 
including medicine. The comparison of cellular proteomes before and after drug treatment can 
indicate the drug mechanism [109].  
 
1.4.2 Proteomic research techniques 
The recently developed proteomic technology features high-throughput parallel analysis of the 
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proteome, including DIGE, LC-MS and antibody microarrays.  
 
1.4.3 Two-dimensional polyacrylamide gel electrophoresis 
Two-dimensional polyacrylamide gel electrophoresis (2D-PAGE) has been the gold standard for 
separation of proteins from complex mixtures from cells, tissues or whole organisms for almost 
30 years. 2D-PAGE is a high-resolution method for separating proteins in two dimensions 
according to isoelectric point (pI) in the first dimension and molecular weight in the second 
dimension [110, 111]. For the first dimension, proteins are separated in a small gel strip that 
contains an immobilized pH gradient (IPG); proteins migrate through the pH gradient until they 
reach their pI. The IPG strip is then applied to a polyacralamide gel for the second dimension. An 
electric current moves the pI focused proteins out of the strip into the gel and separates the 
proteins according to their size due to the sieving action of the gel [110, 112]. Up to ~2000 
proteins can be detected on a 2D gel, and the proteins can be visualized by a range of staining 
techniques including: Coomassie blue (200-500 ng protein per spot), silver (0.1 ng protein/spot), 
fluorescent stains (e.g., Sypro Ruby, 1-2 ng protein/spot) or using radioactive isotopes [112]. The 
individual proteins can then be cut as plugs from the gel and digested by a proteolytic enzyme to 
generate peptides that are analysed by mass spectrometry. 
 
1.4.4 Two-dimensional fluorescence difference gel electrophoresis  
Traditional 2D-PAGE is limited in comparison between different gels due to gel to gel variation. 
Two-dimensional fluorescence difference gel electrophoresis (DIGE) can overcome this 
limitation. It enables multiple samples to be run on the same gel, with the labeling by 3 different 
fluorescent dyes (Cy2, Cy3 and Cy5). Normally Cy3 and Cy5 are used to label two comparison 
samples (e.g., control/drug treated), and Cy2 labels a global standard mixture of all the samples; 
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labeled Cy2, Cy3 and Cy5 samples are mixed and run on 2D-PAGE. The gel is scanned at 3 
different wavelengths, the images are compared, and differences determined using image analysis 
software. Every protein from every sample can be compared to the global standard to generate a 
ratio of relative expression [113]. Each CyDye has an NHS-ester reactive group that covalently 
attaches to the epsilon amino group of lysine residues in proteins via an amide linkage. Only 3-
5% of the total proteins in the sample are labeled, with one dye molecule per protein molecule. 
The single positive charge on the dyes replaces the single positive charge present in lysine at 
neutral or acidic pH, ensuring that the pI of the protein is not significantly altered. In addition, 
CyDyes are size-matched, only adding 500 Da to the labeled protein [114].  
 
1.4.5 Liquid chromatography–mass spectrometry 
Liquid chromatography–mass spectrometry (LC-MS) is an analytical technique that combines the 
physical separation capabilities of high-performance liquid chromatography (or HPLC) with the 
mass analysis capabilities of mass spectrometry. LC-MS is a popular technique used in 
proteomics for its high throughput in protein identification and quantitation [115].  
 
1.4.6 High-performance Liquid Chromatography 
High-performance liquid chromatography (HPLC) is a technique that allows separation of 
molecules in solution, based on their interactions with stationary and mobile phases [116]. HPLC 
enables a high throughput, high resolution, sensitive and versatile separation of proteins and 
peptides and is particularly amenable to automation and coupling with detection systems, like 
mass spectrometry (MS) [117]. There are 1D-LC (reverse phase-LC), 2D-LC and multi-
dimensional-LC. Each separation step in shot-gun proteome analysis increases the time and the 
amount of sample required, as well as compounding sample losses. Two-dimensional separation 
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is commonly used, with the first dimension separating peptides by strong cation exchange (SCX), 
and second dimension by reverse phase (RP) [118]. This allows separation of peptides based on 
their charge and then by hydrophobicity. This 2D-LC system has the advantage of good peak 
capacity in the SCX step, excellent compatibility with mass spectrometry in the second step of RP, 
as well as high resolution and efficient separation [117, 119]. 
 
1.4.6.1 Strong cation exchange chromatography 
The first dimension of liquid chromatography always uses SCX (strong cation exchange), where 
a negatively-charged resin binds positively charged analytes. Peptides only need one positive 
charge to be adsorbed to the column, while tryptic peptides usually have a charge state of at least 
2+ under acidic conditions, as trypsin cuts on the carbonyl side of lysine or arginine residues and 
peptides have an N-terminus [120], so most tryptic peptides are able to bind to a SCX column. 
Increasing salt concentration displaces peptides according to their charge due to competition for 
binding on the stationary phase. Tryptic peptides usually have a charge of 2+ or 3+, while those 
with four or more positive charges are rare, such as disulfide-linked peptides or those with missed 
cleavages [120]. Thus, the majority of peptides would elute at lower salt concentrations. SCX 
chromatography is usually run at pH 2-4, the pH that peptides are positively charged [121]. There 
are many formats for separation in this dimension, including peak detection-based switch, 
discrete salt injections, step-wise salt buffer increases or step-gradient elutions. The number of 
fractions in the first dimension of SCX is an important consideration, as fewer fractions reduces 
the peak capacity from sub-optimal separation power, but too many fractions reduces dynamic 
range by spreading eluates over multiple fractions and increases analysis time [122]. Therefore, 
sample complexity and dynamic range must be taken into account and the fractionation tailored 
for specific sample types. 
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1.4.6.2 Reverse phase liquid chromatography 
Reverse phase liquid chromatography is the opposite of normal phase liquid chromatography. 
Where the stationary phase is hydrophilic and has a strong affinity for hydrophilic molecules in 
the mobile phase. Thus, the hydrophilic molecules in the mobile phase tend to bind to the column, 
while the hydrophobic molecules are eluted first; hydrophilic molecules can be eluted from the 
column by increasing the polarity of the mobile phase. Reverse phase chromatography is the 
opposite of normal phase, the hydrophobic molecules are adsorbed onto the hydrophobic solid 
support, and a polar mobile phase is applied to elute the hydrophobic molecules. Decreasing the 
mobile phase polarity by adding more organic solvent reduces the hydrophobic interaction 
between the solute and the solid support resulting in desorption. The more hydrophobic the 
molecule, the more time it will spend on the solid support and the higher the concentration of 
organic solvent required for elution. 
 
Reverse phase liquid chromatography is always used as the second dimension separation of 
peptide samples. The stationary phase in RP consists of spherical silica beads (3-5 micron) with a 
hydrophobic surface like C18 attached via co-valent bonds. The C18 groups are very 
hydrophobic (non-polar) and can bind quite polar molecules such as charged peptides in a highly 
polar solvent such as water. Peptides to be separated by their polarity are injected onto the 
column in a polar solvent, like 1% formic acid in water (usually referred to as Buffer A) and bind 
to the C18 groups on the beads. The flow of buffer A is continued until all unbound molecules are 
washed away. A non-polar solvent like acetonitrile (usually referred to as Buffer B) is then mixed 
with buffer A in increasing proportion, represented as a percentage of buffer B (%B). When the 
mixture of buffer A and buffer B exceeds the non-polarity of a molecule bound to the C18 groups, 
the molecule will elute into the buffer. As the buffer flows over the entire column the same 
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molecule will elute the same polarity of solvent. This will generate a peak of each molecule 
eluting from the column. 
 
1.4.7 Slice and dice 
Different types of separation may be coupled to the liquid chromatography, including the ‘slice 
and dice’ technique that uses SDS-PAGE gels to separate proteins according to their molecular 
weight. Basically, samples are separated using 1-D SDS-PAGE. Post separation, the gel lane is 
sliced into equal sized segments, containing proteins with similar molecular weights. Proteins are 
digested into peptides in the gel plug using trypsin. These peptides can be further separated by 
liquid chromatography, e.g., reverse phase liquid chromatography on a C18 column before 
analysis by mass spectrometry.  
 
1.4.8 Mass spectrometry 
MS is the central analytical tool in proteomics used to measure the mass of a peptide or protein 
with high sensitivity and accuracy [199]. MS-based proteomics facilitates both the identification 
and quantitation of proteins in discovery-driven analysis [243]. Mass spectrometers consist of an 
ion source, a mass analyser, and a detector.  
 
1.4.8.1 Ionization methods 
Mass spectrometry is an analytical technique that separates peptide ions according to their mass-
to-charge ratio (m/z), so peptides must be ionized first. Due to their large and polar nature, 
proteins are not easy to ionize until late 1980, when electrospray ionization (ESI) [123] and 
matrix-assisted laser desorption ionization (MALDI) [124] techniques were introduced and 
revolutionized MS for proteomics research. MALDI-MS is used to analyse simple peptide 
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mixtures, electrospray ionization (ESI-MS) is preferred for analysis of complex samples.  
MALDI is usually coupled to a TOF analyser that measures the mass of intact peptides, whereas 
ESI has mostly been coupled to ion traps and triple quadrupole instruments and used to generate 
fragment ion spectra, collision-induced (CID) spectra of selected precursor ions. 
 
1.4.8.2 MALDI 
Matrix-assisted laser desorption ionisation (MALDI) is a laser-based soft ionization method. The 
sample is embedded in a chemical matrix, usually α-cyano-4-hydroxycinnamic acid or 
dihydrobenzoic acid. The matrix plays a key role in this technique by absorbing the laser light 
energy and causing a small part of the target substrate to vaporize. The matrix solution is mixed 
with the analyte (e.g., peptide-sample), and spotted onto a metal MALDI plate. The solvents 
vaporize, leaving the analyte molecules embedded in MALDI crystals. When the crystals are hit 
by the pulsed UV laser, the energy is absorbed by the matrix, which is partially vaporised and 
carries intact analyte molecules into gas phase. During the process, proton exchange occurs from 
the analyte to the matrix, resulting in singly charged analyte molecules [125]. MALDI is most 
commonly combined with time-of-flight (TOF) mass spectrometers, which determine m/z ratio of 
ion based on the time taken to fly along a flight tube to the detector. Compared to ESI, MALDI is 
more tolerant to sample contaminants like buffers and salts. It also offers specific advantages in 
spectral acquisition, such as the ability to examine a fraction for longer than ESI allows, or return 
to previous fractions if needed [125]. 
 
1.4.8.3 Electrospray ionisation  
Over the last decade, electrospray ionisation has emerged as an important ionization technique 
for mass spectrometry analysis (ESI-MS). The development of electrospray ionization for the 
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analysis of biological macromolecules (e.g., proteins and peptides) was rewarded with the Nobel 
Prize in Chemistry to John Bennett Fenn in 2002. ESI uses electrical energy to assist the transfer 
of ions from solution into the gaseous phase before they are subjected to mass spectrometric 
analysis. As shown in Figure 1.7, in ESI, the analytes pass through a hypodermic needle at high 
voltage to form an aerosol composed of small highly charged drops  (<10 µm) [125]. They are 
normally positively charged in proteomics experiments, due to an excess of protons. Once the 
droplets are airborne, the solvent evaporates, which decreases the size and increases the charge 
density of the droplets. Desolvated ions are generated by the desorption of analyte ions from the 
droplet surface due to high electrical fields and/or the formation of very small droplets due to 
repetitive droplet fission until each droplet contains only one analyte ion [126, 127]. The 
advantage of ESI is that analyte ions may acquire multiple charges. The multiple peak spectra of 
the analyte are useful for molecular mass determination at low resolution. ESI is often combined 
with ion traps and triple quadrupole mass analysers [128]. 
                            
Figure 1.7: Mechanism of electrospray ionisation (from [126]). 
 
1.4.8.4 Mass analyzer for mass spectrometer 
Mass analysers store ions and separate them based on m/z ratios, which can be done by different 
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means. There are four basic types of mass analyser currently used in proteomics research, ion trap, 
time-of-flight (TOF), quadrupole and Fourier transform ion cyclotron (FT-MS) analysers [129]. 
These analysers can be ‘stand alone’ or assembled in tandem to take advantage of the strengths of 
each. 
 
Time-of-flight (TOF)  
In reflector time-of-flight (TOF) instruments (Figure 1.8), the ionized peptides are accelerated to 
a fixed kinetic energy and travel down a flight tube. Ions separate according to different flight 
time. The small ions have a higher velocity and are recorded on a detector before the larger ones, 
producing a time-of-flight (TOF) spectrum. The pathway for the ions in a TOF is reversed and 
enlarged using an electrostatic mirror to reflect ions. This mirror allows a deeper penetration of 
faster ions and therefore compensates for small kinetic energy differences in a given ion 
population. The ions are detected by a channeltron electron multiplier [130]. The mass-to-charge 
ratio is proportional to the time it takes an ion to reach the detector. The Voyager DE STR mass 
spectrometer used in this project is a MALDI-TOF MS, which couples a MALDI ionization 
source with a TOF mass spectrometer. 
 
                                        
Figure 1.8: Time-of-flight (TOF) (from [128]). 
 
 Chapter 1: General Introduction 
31 
 
Single quadrupole 
As the name implies, a quadrupole consists of 4 circular rods, set parallel to each other, 
responsible for filtering sample ions based on their mass-to-charge ratios (m/z).  Ions are 
separated in a quadrupole based on the stability of their trajectories in the oscillating electric 
fields applied to the rods.  
 
Triple quadrupole  
The quadrupole mass analyser was developed in parallel with the quadrupole ion trap by the 
Nobel Prize winning mass spectrometry pioneer, Wolfgang Paul. A triple quadrupole mass 
spectrometer is a tandem mass spectrometer consisting of three quadropoles as shown in Figure 
1.9. The first (Q1) and third (Q3) quadrupoles serve as mass filters, whereas the middle (Q2) 
quadrupole serves as a collision cell. This collision cell is an RF (radio frequency) only 
quadrupole (non-mass filtering) using an inert gas such as Ar, He, or N2 to provide collision-
induced dissociation of a precursor ion selected in Q1. Subsequent fragments pass through to Q3 
where they may be filtered or scanned.  
 
                                   
Figure 1.9: Triple quadrupole mass spectrometer (from [128]). 
 
Quadrupole time-of-flight (Q-TOF)  
The quadrupole TOF instrument combines the front part of a triple quadruple instrument with a 
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reflector TOF section for measuring the mass of the ions as shown in Figure 1.10. The AB Sciex 
Qstar Elite used in this project for iTRAQ study is a Q-TOF.   
                                    
 
Figure 1.10: Quadrupole time-of-flight (Q-TOF) instrument (from [128]). 
 
Ion-trap  
The (three-dimensional) ion trap captures the ions as in the case of the linear ion trap, fragment 
ions of a particular m/z, and then scans out the fragments to generate the tandem mass spectrum 
(Figure 1.11). The LTQ-XL ion-trap mass spectrometer used in this project for label-free 
quantitation is based on an ion-trap. 
 
The LTQ-Orbitrap combines a linear quadrupole ion trap and an orbitrap [131]. Analyte ions are 
introduced to the instrument and pass through into the linear quadrupole ion trap. Ions can be 
measured in the linear trap at high sensitivity or passed out of the trap and diverted into the 
orbitrap through the C-trap for high mass accuracy and resolution. The typical mode of operation 
for a LTQ-Orbitrap is to measure intact masses in the orbitrap but measure the fragments at 
higher sensitivity in the linear quadrupole trap. There is a hexapole located after the C-trap that 
allows quadrupole-type CID (collision-induced dissociation ) spectra to be acquired [132]. It is 
also used as a transmission cell for introduction of anions for electron transfer dissociation (ETD) 
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fragmentation [133]. 
 
                                                 
Figure 1.11: Ion trap (from [128]). 
 
Fourier transform ion cyclotron (FT-MS) analysers  
Fourier transform ion cyclotron (FT-MS) analysers are a type of mass analyzer for determining 
the mass-to-charge ratio (m/z) of ions based on the cyclotron frequency of the ions in a fixed 
magnetic field [134]. Ions are trapped in the centre of a magnetic field, where they move in a 
cyclotron pattern dependent on the m/z ratio. Figure 1.12 shows the combination of FT-MS with 
the linear ion trap for efficient isolation, fragmentation and fragment detection in the FT-MS 
section. Ions pass plates on either side of the chamber in an ion cyclotron resonance motion, with 
Fourier transformation that converts time-domain signals to m/z [135]. FT-MS have high mass 
precision, resolution, and broader mass to charge range [134]. 
                                            
Figure 1.12: Fourier transform ion cyclotron resonance mass spectrometry (FT-MS) (from [128]). 
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Tandem mass spectrometry  
Tandem mass spectrometry (MS/MS) enables identification of proteins by sequencing of their 
peptides. The first mass analyser selects one peptide of the mixture to be dissociated by collision 
with an inert gas, such as argon or nitrogen. The second mass analyser separates the peptide into 
fragments, producing the tandem MS/MS spectrum [130]. Peptide sequences can be obtained by 
manual annotation of the MS/MS spectra to identify the parent protein identified by database 
searching.  
 
During peptide fragmentation, cleavage occurs through the amide bond, that is the lowest energy 
pathway [127]. This leads to b-ions when the charge is retained by the amino-terminal fragment, 
or y-ions when the charge is retained by the carboxy-terminal fragment (Figure 1.13).  
 
                              
 
Figure 1.13: Schematic peptide showing ion fragmentation during tandem mass spectrometry. 
 
1.4.8.5 Quantitative mass spectrometry 
Relative quantitation in LC-MS proteomics is generally performed by labelling samples with 
chemically equivalent differential mass tags, either metabolically, enzymatically or chemically at 
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the protein or peptide level [136]. These tags allow the contribution of different samples to the 
combined total peptide abundance to be determined by MS, without affecting their analytical or 
biochemical properties. Examples include stable isotope labeling by amino acids in cell culture 
(SILAC) [137], 18O proteolytic labelling [138], peptide mass shift labelling by ICAT (isotope 
coded affinity tag) [139] and isobaric labelling by iTRAQ (isobaric tags for relative and absolute 
quantitation) [139], and isotopomer labeling by TMT (tandem mass tags) [140]. The choice of 
method can depend on the sample type, number of sample to compare, the extraction method, and 
the mass spectrometer available. For example, SILAC is only available for cultured cells, trypsin-
based labelling by 18O proteolytic labelling can only compare two samples, and ICAT is limited 
to cysteine-containing peptides. By comparison, iTRAQ labelling is amenable to most sample 
types, including those derived from in vitro and in vivo systems, and can quantify and compare up 
to 8 samples at once with multiplexing, and is isobaric, with quantitative output in the MS/MS 
mode [141]. 
 
1.4.8.6 iTRAQ 
The iTRAQ (isobaric tag for relative and absolute quantitation) technique is based on covalent 
labeling of the N-terminus and side-chain amines of peptides from protein digestions with tags of 
varying mass. There are currently two reagents: 4-plex and 8-plex. The 8-plex isobaric tags have 
a total mass of 305 Da and consist of a reporter group (m/z = 113-119, 121), a carbonyl balance 
group (m/z= 192-186, 184) and a peptide reactive group (Figure 1.14). The iTRAQ reagent forms 
a covalent link to the N-terminus of the peptides, each sample is labeled with a unique tag and 
then all the samples are combined. These samples are then pooled and usually fractionated by 
nano liquid chromatography and analyzed by tandem mass spectrometry (MS/MS). 
Quantification is achieved through analysis of the MS/MS spectrum. The 8-plex iTRAQ system 
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can simultaneously assess protein abundance in 8 different samples labeled with the iTRAQ 
reagents 113, 114, 115, 116, 117, 118, 119 or 121. A database search is then performed using the 
fragmentation data to identify the labeled peptides and hence the corresponding proteins. The 
fragmentation of the attached tag generates a low molecular mass reporter ion that can be used to 
relatively quantify the peptides and the proteins from which they originated. For each peptide 
detected, relative quantification consists in processing the MS/MS mass spectrum in the 
following way: a) integrating the area under the curve (MS peak) for each reporter ion; and b) 
computing the different ratios of reporter ion peak areas (e.g.: 114/113, 115/113, 116/113, 
117/113, 118/113, 119/113, and 121/113 for the 8-plex), these ratios corresponding to the ratios of 
peptide concentrations in the tested experimental conditions (e.g.: 113 = control vs. 114 = treated).  
 
       
 
Figure 1.14: iTRAQ Reagent Structure. The iTRAQ reagent consists of a charged reporter group (unique to each 
of 8 reagents), a peptide reactive group (labels all N-termini and lysine side-chains) and a neutral balance portion to 
maintain an overall mass of 305. 
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1.4.8.7 Label-free quantitation 
Although label-based quantification approaches are accurate, they have potential limitations: 
complex sample preparation, the requirement for increased sample concentration, and incomplete 
labeling. A protein has to be detected in all samples to be able to perform the quantitative 
comparison. The label-free quantification approach can address these issues [142-144].  
 
Unlike label-based methods for protein quantification, label-free quantification does not use a 
stable isotope-containing compound to chemically bind and thus label the protein. Label-free 
quantitation encompasses several MS based techniques for identification and quantitation of 
differentially expressed proteins in several complex biological samples. One type of label-free 
quantitation uses peptide ion chromatogram peak intensities to measure the changes in expression 
pattern between multiple samples, with each sample analyzed individually and their peptide ion 
chromatograms re-constructed and compared [145, 146]. This technique is theoretically based on 
analysis of ion peak areas (ESI-MS intensities), that have long been known to be proportional to 
absolute amounts of peptides [147]. Another type of label-free quantitation known as peptide 
spectral counting uses the number of MS/MS spectra matched to a given protein within an 
experiment as a measure of relative protein abundance. Calculation of normalized spectral 
abundance factors (NSAF) is a recent development in the spectral counting approach [148]. Raw 
spectral counts are corrected for the length of identified proteins, due to the fact that less peptides 
are identified for small proteins as compared to larger ones, and also the number of peptides 
identified is normalized within a dataset to correct for differences in sample loading [149]. The 
two techniques were equivalent in reproducibility and linearity. However, spectral counting was 
preferred as it was simpler and faster. The label-free technique used in this study is based on 
NSAF.  
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1.4.9 DotScan™ CD antibody microarray  
The term CD (cluster of differentiation) antigen, was proposed for classification of the many 
monoclonal antibodies (mAbs) generated by different laboratories around the world against 
epitopes on the surface molecules of leukocytes. The CD antigens are membrane proteins 
expressed on leukocytes and other human cells. CD antigens have roles in the human immune 
response, with a variety of functions such as cytokine and growth factor receptors, transporters, 
ion channels, cell-cell interactions and adhesion molecules. Detection of CD antigens provides 
diagnostic methods for many human diseases [150, 151]. 
 
Our laboratory, and the spin-off company Medsaic Pty Ltd (Eveleigh, NSW), have developed an 
antibody microarray (DotScan™) for live cell capture [152, 153]. DotScan™ (originally called 
the LD array after Mrs. Lee Dixon who suffered from M4 AML) consists of nitrocellulose 
covered glass microscope slide with duplicate arrays of CD antibody dots (10 nL). The antibody 
microarray used in this study has 195 antibodies in duplicate. Cells that express surface CD 
antigens recognized by an antibody on the microarray are captured by the immobilized antibody 
on the microarray, while unbound cells are washed off. The dot patterns of captured cells on 
microarrays are scanned using the Medsaic DotReader™, and the intensity of cell binding is 
quantified using Medsaic software. The DotScan™ microarray has been used to obtain surface 
profiles (immunophenotypes) to classify leukaemias, lymphomas [154, 155], colorectal cancer 
and melanoma. DotScan has also been used to identify drug mechanisms by comparing 
proteomic profiles of untreated and drug-treated cancer cells [156-158]. 
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1.4.10 Advances and challenges 
Major advances in proteomic techniques have been made over the last decade with the 
introduction of compatible and reliable label and label-free quantitative MS [159].  Significant 
improvements have been made in the application of MS for the determination of protein 
sequences [160]. Currently, there is no single platform that represents the “best” technology for a 
certain proteomic study, and integration of multiple technologies is often required for detection 
and quantitation of low abundance proteins [159]. The need for improved reproducibility, 
throughput, dynamic range, and quantitation will continue to drive technology development, so a 
big challenge for proteomics is informatics and statistical analysis. Due to the huge amount of 
data produced by a proteomics study, development of specialized software that enables the 
identification and characterization of proteins will enhance the outcome of proteomics analyses. 
With improvements in quantitation accuracy, throughput, and robustness, the proteomic platform 
will eventually become a powerful tool that provides simultaneous measurements of a large 
number of analytes. 
 
1.4.11 Proteomics and drug mechanisms 
Proteins are the major drug targets and play critical roles in drug design. Comparative proteomics 
can distinguish subtle changes in protein abundance at a depth of several thousand proteins under 
different conditions, i.e., control vs drug treated. Proteomic analysis provides insight for drug 
mechanisms, examining signaling pathways, discovering the reason for drug resistance, 
identifying drug targets, and identifying biomarkers [109]. The results from proteomic research 
speeds the clinical validation of drug candidates and the development of more effective drugs 
[161]. Several review papers summarize the use of comparative proteomics to identify drug 
resistance mechanisms and biomarkers for cancers [162-164]. 
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1.5 Aims of the study 
1. To determine the effects of Hsp90 inhibitors on Lyn-dependent imatinib resistance in 
human CML MYLR cells using two-dimensional fluorescence difference gel 
electrophoresis (DIGE) and mass spectrometry (MS) based proteomic analysis. 
Identification of proteins differentially abundant between MYL and MYLR cell lines will 
deepen our understanding of Lyn-dependent imatinib resistance. 
 
2. To gain a better understanding of how Hsp90 inhibitors induce apoptosis in p53-mutated 
MEC1 CLL cells, the quantitative proteomic technique iTRAQ LC-MS/MS will be used 
to determine protein abundance changes after treatment with an Hsp90 inhibitor. Analysis 
of these data may identify affected pathways and the mechanism of this drug. 
 
 
3. Identify changes in the immunophenotype of MEC1 cell lines treated with an Hsp90 
inhibitor using DotScan™ microarrays. These results will be integrated with data obtained 
using other proteomic techniques.  
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2.1 Buffers and solutions 
2.1.1 RPMI 1640 cell growth medium, pH 7.3  
RPMI 1640 medium       16.4 g/L  
Gentamycin      50 µg/ml 
Fetal calf serum (FCS)    10% (v/v)  
L-glutamine was added to a final concentration of 2 mM every two weeks. 
 
2.1.2 Lysis buffer I, pH 7.9 at 4°C  
HEPES      10 mM  
KCl        10 mM 
MgCl2       1.5 mM 
(The following were freshly added prior to use)  
PMSF  (phenylmethylsufonyl fluoride) 0.5 mM  
NaF        10 mM 
Na3VO4      1 mM 
NP-40       0.05% (v/v)  
Okadaic acid      0.2% (v/v)  
 
2.1.3 Lysis buffer II 
HEPES      10 mM  
KCl         10 mM 
MgCl2       1.5 mM 
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2.1.4 Lysis buffer III 
NP-40             1% (v/v) 
Tris-HCl (pH 8.8)          20 mM 
NaCl          137 mM 
glycerol           10% (v/v) 
EDTA        2 mM 
Na3VO4           2.5 mM 
EDTA-free protease inhibitor cocktail    1% (v/v) 
Phosphatase cocktail      1% (v/v) 
 
2.1.5 MSST-DTT buffer 
Urea         5 M 
Thiourea         2 M 
CHAPS         2% w/v 
Sulfobetaine 3-10         2% w/v 
Tris-HCl (pH 8.8)        40 mM 
Carrier ampholyte         1.0% v/v 
DTT         65 mM 
TBP          2 mM 
 
2.1.6 Nuclear isolation buffer, pH 7.4 
Sucrose        0.25 M 
MgCl2          10 mM 
Tris-HCl (pH 8.8)        20 mM 
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DTT (freshly added prior to use)  1 mM   
 
2.1.7 Mitochondria isotonic buffer 
Tris-HCl (pH 8.8)        10 mM 
Sucrose       0.25 M 
EDTA       1 mM 
 
2.1.8 Tris buffer 
Tris-HCl (pH 8.8)        50 mM 
NaCl      150 mM 
(The following were freshly added prior to use)  
EDTA      1 mM 
PMSF      0.5 mM 
 
2.1.9 1.0 M Sucrose buffer, pH 7.4  
Tris-HCl (pH 8.8)    10 mM  
Sucrose      1.0 M  
 
2.1.10 1.5 M Sucrose buffer, pH 7.4  
Tris-HCl (pH 8.8)    10 mM  
Sucrose      1.5 M  
 
2.1.11 1.3 M Sucrose buffer, pH 7.4  
Tris-HCl (pH 8.8)    10 mM  
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Sucrose      1.3 M  
 
2.1.12 2.3 M Sucrose buffer, pH 7.4  
Tris-HCl (pH 8.8)    10 mM  
Sucrose      2.3 M  
 
2.1.13 SDS-PAGE loading buffer 
Glycerol       40% (v/v) 
Tris-HCl (pH 6.8)      240 mM 
SDS        8% (v/v) 
Bromophenol blue       0.04% (v/v) 
Beta-mercaptoethanol       5% (v/v) 
 
2.1.14 SDS-PAGE running buffer, pH 8.3   
Glycine              192 mM  
SDS                    0.1% (w/v)  
Tris-HCl (pH 8.8)                24.8 mM  
 
2.1.15 Separating gel, pH 8.8  
Bis-acrylamide                     10% (w/v)  
Tris-HCl (pH 8.8)                  375 mM  
SDS                       0.1% (w/v)  
Ammonium persulfate                         0.05% (w/v)  
TEMED                       0.1% (v/v)  
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2.1.16 Stacking gel, pH 6.8  
Bis-acrylamide                    5% (w/v)  
Tris-HCl (pH 8.8)                  125 mM  
SDS                        0.1% (w/v)  
Ammonium persulfate                         0.05% (w/v)  
TEMED                   0.1% (v/v) 
 
2.1.17 Western blotting transfer buffer, pH 8.3  
Glycine                 192 mM  
Tris-HCl (pH 8.8)               25 mM  
Methanol                    20% (v/v)  
SDS                      0.1% (w/v)  
 
2.1.18 TBST buffer, pH 7.5  
Tris-HCl (pH 8.8)              25 mM  
NaCl                150 mM  
Tween-20                    0.1% (v/v)  
 
2.1.19 Blocking solution  
Non-fat dry skim milk                5% (v/v) 
Made up in TBST 
 
2.1.20 Protein extraction buffer 
Urea           5 M 
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Thiourea           2 M  
CHAPS             2% w/v  
Sulfobetaine 3-10           2% w/v 
Tris-HCl (pH 8.8)              40 mM 
Carrier ampholyte               1.0% v/v 
DTT                    65 mM 
TBP                2 mM 
PMSF              0.5 mM 
NaF           10 mM 
Na3VO4              1 mM 
Okadaic acid            0.1% (v/v) 
 
2.1.21 DIGE buffer  
Urea             5 M 
Thiourea              2 M 
CHAPS                  2% w/v 
Sulfobetaine 3-10           2% w/v 
Tris-HCl (pH 8.8)             40 mM 
 
2.1.22 Equilibration buffer 
Urea         6 M 
Glycerol        20% (v/v) 
SDS          2% (w/v)   
TBP (tributylphosphine)      5 mM 
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Acrylamide        2.5% (v/v) 
Tris-HCl (pH 8.8)          50 mM 
 
2.1.23 Colloidal Coomassie solution   
Ammonium sulphate     17% (w/v)  
Phosphoric acid     3% (v/v)  
Coomassie G-250     0.1% (w/v)  
Methanol      34% (v/v) 
 
2.1.24 RIPA buffer plus protease and phosphatase inhibitor cocktail 
NaCl                   150 mM 
Na2HPO4             9.1 mM 
NaH2PO4               1.7 mM 
NP-40                  1% (v/v) 
deoxycholic acid          0.5% (v/v)    
Na3VO4               150 µM 
Phenylmethylsulfonyl fluoride     0.25 mM  
Leupeptin                  5 µg/ml 
Microcystin          10 nM 
 
2.1.25 Phosphate buffered saline stock solution (PBS), pH 7.3 
NaCl                                                               150 mM 
KCl                                                                 2.7 mM 
Na2HPO4                                                        1.4 mM 
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KH2PO4                                                          4.3 mM 
 
2.1.26 Array fixative solution 
Formaldehyde in PBS                                     3.7% (w/v) 
 
2.2 General methods 
2.2.1 Cell culture  
The following human cell lines were used:  
MYL (chronic myeloid leukemia) 
MYLR (chronic myeloid leukemia, imatinib resistant) 
MEC1 (chronic lymphocytic leukemia) 
Raji (Burkitt’s lymphoma)  
HL60 (acute myeloid leukaemia)  
U266 (myeloma) 
 
MYL and MYLR cells were from Department of Hematology and Oncology, Hiroshima 
University, Hiroshima, Japan. All other cell lines (MEC1, Raji, HL60 and U266) were obtained 
from the American Type Culture Collection (ATCC, Manassas, VA, USA).  
 
Human cell lines were cultured in RPMI 1640 medium (Invitrogen, Carlsbad, CA, USA) 
supplemented with 10% foetal bovine serum (In Vitro Technology, Noble Park North, VIC, 
Australia) and 50 µg/ml gentamicin (Sigma Aldrich, St. Louis, MO, USA) in 25 cm2, 75 cm2 or 
175 cm2 culture flasks at a density of 3 × 105 cells/ml at 37°C in a non-humidified incubator 
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(Heraeus, Hanau, Germany). Cultures were passaged every 2-3 days to maintain them in 
exponential growth phase (1-7 × 105 cells/mL). Approximately every three months, fresh cells 
were brought up from liquid nitrogen storage to replace old cultures. All cell culture work was 
performed under sterile conditions using aseptic technique in a Class II biological safety cabinet 
(Westinghouse Pty. Ltd., Sydney, Australia).  
 
2.2.2 Storage of cells in liquid nitrogen  
To provide a stock of a certain cell line, cells were harvested (300 × g, 5 min, room temperature) 
and resuspended in foetal bovine serum to a final concentration of 107
 
cells/mL. An equal volume 
of foetal bovine serum with 20% (v/v) DMSO was added drop-wise while swirling the cell 
suspension, resulting in a final cell density of 5 × 106
 
cells/mL in fetal bovine serum and 10% 
(v/v) DMSO. Aliquots of 2 mL were stored in cryovials in a -80°C freezer overnight and then 
transferred into a liquid nitrogen container for long-term storage. 
 
2.2.3 Reconstitution of cells after storage in liquid nitrogen  
Cryovials containing frozen cells were thawed quickly in a 37°C water bath and resuspended in 
10 mL of pre-warmed (37°C) RPMI growth medium. Cells were centrifuged (300 × g, 5 min, 
37°C), the supernatant was discarded to eliminate the remaining DMSO, and the cell pellet was 
resuspended to a density of 3 × 105 cells/mL in RPMI growth medium. All the cells were 
maintained at a density of 3 × 105 cells/mL before drug treatment or being harvested for an 
experiment. 
 
2.2.4 Cell density and viability determination  
For checking cell density and viability in cell culture, we used the trypan blue exclusion method. 
 Chapter 2: Materials and Methods 
51 
 
The cell sample (50 µL) was mixed with 50 µL of 0.4% trypan blue solution in a microcentrifuge 
tube, and then 10 µl of this mix was pipetted into the chamber of a Neubauer haemocytometer. 
Trypan blue only can permeate and stain dead cells. Using a Nikon TMS microscope (Nikon, 
Kanagawa, Japan), the cell density and viability were obtained using the following equations: 
 
Xv [cells/mL] = (Cv x D)/(N × 10-4 mL) (viable cell density)                       (i) 
Xd [cells/mL] = (Cd x D)/(N × 10-4 mL) (dead cell density)                (ii) 
V [%] = Cv/(Cv + Cd) (viability)                 (iii) 
 
Where Xv is the viable cell density in cells/mL 
Xd is the dead cell density in cells/mL 
Cv is the number of viable cells 
Cd is the number of dead cells 
D is the dilution factor for the cell solution/ trypan blue = 2 
N is the number of haemocytometer squares counted = 5 
V is viability 
10-4 is the volume of the haemocytometer in mL 
 
2.2.5 Drug treatments 
Imatinib (LC Laboratories, Woburn, MA, USA), SNX-7081 (provided by Dr. Steven Hall, 
Serenex, Inc. Durham, NC, USA), SNX-5422 (provided by Dr. Tim Haystead, Duke University, 
Durham, USA) and 17-allylamino-17-demethoxy-geldanamycin (17-AAG; Sigma Aldrich, St. 
Louis, MO, USA) were dissolved in DMSO. SNX-5422 is the glycyl ester of SNX-7081. 
Gemcitabine, Ara-C (Sigma Aldrich, St. Louis, MO, USA) and DADMe-Immucillin-H (provided 
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by Dr. Vern Schramm, Department of Biochemistry, Albert Einstein College of Medicine, Bronx, 
NY, USA) were prepared in H2O. DADMe-Immucillin-H treatment was performed with 10 µM 
deoxyguanosine as previously described [165]. Control cultures were incubated with the 
appropriate carrier solvent (H2O or DMSO).  
 
2.2.6 Isolation of sub-cellular proteomes  
Cells (> 5 × 108) were collected by centrifugation (300 × g, 5 min, room temperature), washed 
twice in PBS, resuspended in 5 mL of lysis buffer I, incubated on ice for 5 min and lysed with 10 
gentle strokes using a Dounce glass homogenizer. The cell suspension was vortexed for 30 s and 
centrifuged (800 × g, 10 min, 4°C) to remove crude nuclei and cellular debris as a pellet. The 
supernatant was centrifuged (15,000 × g, 30 min, 4°C) to isolate crude mitochondria, followed by 
centrifugation (100,000 × g, 60 min, 4°C) to isolate the final cytosolic fraction as the supernatant 
depleted of the microsomal fraction as pellet. Crude mitochondria were resuspended in 5 mL 
mitochondria isotonic buffer and further purified by centrifugation on a two-step 1.0/1.5 M 
sucrose gradient (14 mL of 1.0 M sucrose buffer layered over 20 mL of 1.5 M sucrose buffer) and 
centrifuged with the brake off (100,000 g, 1.5 h, 4°C). The mitochondrial fraction sedimented at 
the 1.0/1.5 M sucrose interface and was carefully collected by transfer pipette, diluted two-fold in 
Tris-HCl buffer and centrifuged (15,000 g, 20 min, 4°C) to pellet the final purified mitochondria 
fraction. The crude nuclear pellet was resuspended in nuclear isolation buffer. To further purify 
the nuclei, the suspension was appealed to a two-step sucrose gradient (10 ml of 1.3 M sucrose 
buffer layered above 15 ml of 2.3 M sucrose buffer), then centrifuged (5,000 × g, 45 min, 4°C). 
The purified nuclear pellet was carefully resuspended in lysis buffer II and centrifuged again 
(1,000 × g, 5 min, 4°C), to yield the final purified nuclear fraction. Figure 2.1 shows the 
differential centrifugation steps used. The different protein fractions were stored at -80°C until 
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use. 
 
         
 
      
 
Figure 2.1 Schematic representation of sub-cellular fractionation using differential centrifugation. 
 
 
2.2.7 Protein clean-up kit 
Protein purification was performed using the ReadyPrep™ 2D Cleanup Kit (Bio-Rad, Hercules, 
CA, USA). According to the manufacturer’s protocol as follows: Protein mixture (100 µL, 1-500 
µg of protein) was placed in a microcentrifuge tube, vortexed with 300 µL of precipitating agent 
1 and incubated on ice for 15 min. Precipitating agent 2 (300 µL) was added, the solution mixed 
by vortexing and centrifuged (12,000 × g, 5 min, 4°C) to form a tight protein pellet. Supernatants 
were decanted, and the tubes briefly centrifuged to bring the remaining liquid to the bottom of the 
tube for removal. The pellet was washed with 40 µL of wash reagent 1, centrifuged (12,000 × g, 5 
min, 4°C) and the liquid was discarded. The protein pellet was dispersed with 25 µL of H2O, 
followed by addition of 1 mL of wash reagent 2 with 5 µL of wash 2 additive. The mixture was 
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vortexed for 1 min to disperse and wash the protein pellet, then incubated (30 min, -20°C), and 
vortexed for 30 sec every 10 min during the incubation period. After incubation, the tubes were 
centrifuged (12,000 × g, 5 min, 4°C) to form a tight protein pellet, that was dried at room 
temperature for 5 min and then resuspended in the appropriate buffer as indicated in each 
experiment condition. All procedures were performed at 0-4°C.  
 
2.2.8 Protein quantification using the 2D Quant Kit  
The protein concentrations of samples were determined using the 2D Quant Kit (GE Healthcare, 
Little Chalfont, Buckinghamshire, UK). The procedure uses a combination of a unique 
precipitant and co-precipitant to quantitatively precipitate proteins while leaving interfering 
contaminants (e.g., salts, detergents, reductants, carrier ampholytes) in solution. The protein is 
pelleted by centrifugation and resuspended in an alkaline solution of cupric ions. The cupric ions 
bind to the polypeptide backbone of all proteins. A colorimetric agent that reacts with unbound 
cupric ions is then added. The colour density is therefore inversely related to the concentration of 
protein in the sample and is determined by comparison to a standard curve. The following 
protocol, provided with the kit, was used for protein quantification.  
 
All procedures were performed at room temperature. Samples for a standard curve were prepared 
using a 2 mg/mL BSA standard solution provided with the kit. Tubes containing protein samples 
(1-50 µL) were prepared in duplicate. Precipitant (500 µL) was added to both BSA standards and 
protein samples. All tubes were vortexed and incubated for 3 min, 500 µL of co-precipitant were 
added, the tubes were briefly vortexed and centrifuged (12,000 × g, 5 min, room temperature). 
Supernatants were decanted, and the tubes briefly centrifuged to bring all remaining liquid to the 
bottom of the tube for removal. The precipitated protein pellet was then resuspended in 100 µL 
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copper solution and 400 µL of H2O. Working colour solution (1 mL, 100 : 1 colour reagent A : B) 
was rapidly added to all tubes with rapid mixing. After incubation for 20 min, the absorbance at 
480 nm was read using a Cary UV-Visible spectrophotometer with Cary Win UV vr. 2.0 software 
(Varian Australia Pty. Ltd., Mulgrave, Victoria, Australia). H2O was used to zero the spectrometer. 
Protein concentrations of the unknown samples were then calculated from the equation obtained 
by regression to the BSA standard curve. 
 
 
2.2.9 Sodium dodecyl sulfate polyacrylamide gel electrophoresis  
Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) was carried out to 
separate proteins prior to Western blotting or label-free mass spectrometry-based proteomic 
analysis (Chapter 6). Protein samples were quantified using the 2D Quant Kit as described in 
section 2.2.8, and 15-30 µg of each sample was diluted in SDS-PAGE loading buffer, heated at 
95°C for 5 min and cooled on ice prior to loading onto the tracks of the gel. Pre-stained molecular 
weight markers were loaded onto the first track of each gel. SDS-PAGE was performed using a 
Bio-Rad Mini-Protean II gel electrophoresis apparatus utilising a 5% polyacrylamide stacking gel 
and a 10% polyacrylamide separating gel (7 × 8 × 0.05 cm). Electrophoresis was carried out at 120 
V for approximately 1.5 h, until the Bromophenol blue reached the bottom of the gel. Following 
electrophoresis, the gels were either stained in colloidal Coomassie solution over-night for label-
free mass spectrometry-based proteomic analysis (Chapter 6), or directly blotted onto PVDF 
membranes for Western blotting. 
 
2.2.10 Western blotting  
Protein samples (15 µg) were separated by 10% SDS-PAGE as described in section 2.2.9, and 
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transferred to a PVDF membrane (Immun-Blot™, Bio-Rad Laboratories, Hercules, CA, USA) 
using a Criterion™ Blotter filled with transfer buffer (Bio-Rad Laboratories, Hercules, CA, USA) 
for 1 h at 300 mA. The membrane was washed with TBST buffer (3 × 5 min) and blocked for 1 h 
at room temperature with blocking solution. The blocked membrane was incubated overnight at 
4°C with the primary antibody. After washing with TBST buffer (3 × 5 min), the membrane was 
incubated for 1 h at room temperature with a horse radish peroxidase (HRP)-conjugated 
secondary antibody: goat-anti-mouse-HRP (Santa Cruz Biotechnology, Santa Cruz, CA, USA) or 
donkey anti-rabbit-HRP (Abcam, Cambridge, MA, USA) depending on the type of primary 
antibody. Proteins were visualized using Rapid Step ECL Reagent (Merck, Kilsyth, VIC, 
Australia) and ECL chemiluminescence film (GE Healthcare, Little Chalfont, Buckinghamshire, 
UK). Films were scanned on a Molecular Imager GS-800™ densitometer (Bio-Rad, Hercules, 
CA, USA). Bands were quantified using ImageQuantTL density analysis software (GE 
Healthcare, Little Chalfont, Buckinghamshire, UK). 
 
2.2.11 Pathway analysis  
To identify the pathways associated with differentially abundant proteins, we used the Ingenuity 
Pathway Analysis (IPA) software (Ingenuity® Systems, http://analysis.ingenuity.com). This 
software contains the largest curated database of individually modeled relationships between 
millions of proteins, genes, complexes, cells, tissues, drugs and diseases. IPA calculates the 
probability that the genes associated with our dataset (identified proteins) are involved in 
particular biological or canonical pathways. The software computes a p-score that is derived from 
a p-value for each network or canonical pathway based on the input proteins, and indicates the 
statistical likelihood that the proteins have been identified by chance. The p-score = -log10 (p-
value). Scores of 1.3 or higher have at least a 95% confidence of not being generated by chance. 
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Scores of 2 or higher have at least a 99% confidence of not being generated by chance. When 
generating networks, the IPA software adds proteins from its own database to the network to 
generate a wider network of proteins. The significance of the association between the data set and 
the canonical pathway was measured in 2 ways: (1) a ratio is displayed for the number of genes 
from the data set that map to the pathway divided by the total number of genes that map to the 
canonical pathway. (2) Fischer’s Exact Test was used to compare the number of proteins that 
occur in a given pathway relative to the total number of occurrences of those proteins in all 
functional annotations stored in the Ingenuity Pathways Database [166]. 
 
2.3 Materials and methods for result chapter 3  
2.3.1 Cell culture and drug treatment 
The human CML cell lines MYL and imatinib-resistant MYLR, were cultured as described in 
section 2.2.1, and imatinib (500 nM, 1 µM, 5 µM, 10 µM, 48 h), SNX-7081, SNX-5422 (25 nM, 
50 nM, 100 nM, 500 nM, 1 µM at 48 h, and 25 nM, 50 nM, 100 nM at 24 h, 48 h and 72 h), 17-
AAG (50 nM, 100 nM, 500 nM, 1 µM, 5 µM, 10 µM at 48 h, and 25 nM, 50 nM, 100 nM at 24 h, 
48 h and 72 h), Gemcitabine, Ara-C and DADMe-Immucillin-H (0.5 nM, 5 nM, 50 nM, 500 nM, 
5 µM, 50 µM, 48 h) treatments of MYL and MYLR were performed as described in section 2.2.5. 
 
2.3.2 Cell viability  
MYL and MYLR cell viability were monitored by the MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) assay (CellTiter, Promega, Madison, 
WI, USA). Cells were plated at 5 × 104 cells/ml in 96-well plates, and drugs were added to wells 
in triplicate at the indicated concentrations. Cells were incubated at 37°C with 5% CO2. After 
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incubation, the MTS reagent was added according to the manufacturer’s protocol, plates were 
incubated for 1-4 h, and absorbance was read at 490 nm on a SpectraMAX plate reader 
(Molecular Devices, Sunnyvale, CA, USA). Cells were also stained with trypan blue and counted 
using a hemocytometer to determine viable cell density as described in the methods section 2.2.4.  
 
2.3.3 Phospho-RTK antibody arrays  
Phosphorylated receptor tyrosine kinases (RTK) were profiled using the Proteome Profiler 
Human Phospho-RTK Array System (R and D Systems, Minneapolis, MN, USA) according to 
the manufacturer’s instructions. Briefly, cells were lysed in lysis buffer III. After blocking with 
5% skim milk, membranes were incubated with total cell lysate (500 µg) overnight at 4°C, 
followed by 3 washes in buffer supplied with the kit for 10 min each.  Membranes were then 
incubated with a secondary antibody for 2 h at room temperature. After 3 × 10 min washes, 
membranes were incubated with ECL reagent (Thermo Fisher Scientific, San Jose, CA, USA) 
and exposed to autoradiography film. Densitometry of the exposed and developed film was 
performed using a FluorChem FC2 imager (Cell Biosciences, Santa Clara, CA, USA). The 
Phospho-RTK antibody array has 42 RTK kinases as listed below: ALK/CD246, Axl, DDR1, 
DDR2, Dtk, EGF R, EphA1, EphA2, EphA3, EphA4, EphA5, EphA6, EphA7, EphA10, EphB1, 
EphB2, EphB3, EphB4, EphB6, ErbB2, ErbB3, ErbB4, FGF R1, FGF R2 alpha, EGF R3, EGF 
R4, Flt-3/Flk-2, HGF R/c-MET, Mer, MSP R/Ron, MuSK, PDGF R alpha, PDGF R beta, c-Ret, 
Ryk, SCF R/c-kit, Tie-1, Tie-2, TrkA, VEGF R1/Flt-1, VEGF R2/KDR, VEGF R3/Flt-4.  
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2.3.4 Two-dimensional fluorescence difference gel electrophoresis  
MYL and MYLR cells were treated in triplicate with SNX-7081 (50 nM, 48 h) or DMSO carrier. 
Triplicates of 4 cell samples, MYL, MYLR, MYL-SNX-7081-treated, MYLR-SNX-7081-
treated, were collected by centrifugation (350 g, 5 min, 4°C) and lysed in protein extraction 
buffer. The cell suspension was sonicated 5 times for 1 min each in an ice bath and then 
centrifuged (10,000 g, 5 min, 4°C), the supernatant was the whole cell extract. Protein was 
further purified with the ReadyPrep™ 2D Cleanup Kit (section 2.2.7), resuspended in DIGE 
buffer in the last step, and the concentrations were determined using the 2D Quant Kit (section 
2.2.8). Protein extracts were labelled using fluorescent CyDyes (GE Healthcare, Little Chalfont, 
UK) following the manufacturer’s protocol according to the design in Table 2.1. Lyophilised 
CyDyes were re-constituted in 5 µL anhydrous DMF, vortexed briefly and centrifuged. From this 
stock solution, working CyDye solutions were prepared by mixing CyDye stock with anhydrous 
DMF in the ratio of 1 : 1.5. Protein extracts (50 µg) were labeled with 400 pmol of Cy2, Cy3, or 
Cy5 for 30 min on ice. Control and treated samples were randomly labeled with Cy3 or Cy5; the 
internal standard sample, created by pooling the same amount of each protein sample, was 
labeled with Cy2 as illustrated below. 
Table 2.1 CyDye labeling of cell extracts treated with SNX-7081 
  Cy2 Cy3 Cy5 
Gel 1 Internal standard MYL control MYLR control 
Gel 2 internal standard MYLR control MYL control 
Gel 3 internal standard MYL control MYLR control 
Gel 4 internal standard MYL treated MYLR treated 
Gel 5 internal standard MYLR treated MYL treated 
Gel 6 internal standard MYL treated MYLR treated 
Treated indicates treatment with SNX‐7081 (50 nM, 48 h) 
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The labelling mixtures were incubated on ice in the dark for 30 min and the reaction was 
terminated by addition of 10 nmol L-lysine followed by incubation on ice for 10 min. The Cy3- 
and Cy5-labelled samples were then combined with the Cy2-labelled internal standard and 
resuspended in MSST-DTT buffer (final volume 350 µL). The sample mixture was rehydrated 
into 17 cm pH 3-10 NL (non-linear) strips (Bio-Rad Laboratories) overnight  to allow passive in-
gel rehydration, followed by isoelectric focusing using an IEF cell (Bio-Rad Laboratories) by the 
following program.  
Step 1: 100 V 3 h  
Step 2: 300 V 2 h  
Step 3: 1000 V 2 h  
Step 4: 2500 V 2 h  
Step 5: 5000 V 20 h  
Step 6: 100 v 24 h (hold step)  
 
Strips were incubated in room temperature in equilibration buffer for 10 min. The second 
dimension of SDS-PAGE was run on 8–18% polyacrylamide gels overnight using a Protean IIxi 
system (Bio-Rad Laboratories, Hercules, USA) at 8°C with a two-step program; 2 mA per gel for 
7 h, followed by 8 mA per gel overnight. The run was stopped 2 h after the bromphenol blue 
reached the bottom of the gel. DIGE gels were scanned while still between the glass plates using 
a fluorescence scanner (Typhoon 9400, GE Healthcare); each gel was scanned 3 times (Cy2, Cy3, 
Cy5). Gel images (18), comprising 12 individual samples and 6 global standards, were analyzed 
using the Progenesis Samespots software (Nonlinear Dynamics Limited, Newcastle, Garth 
Heads, UK).  Student t-test analysis was used to calculate significant protein abundance changes 
(p < 0.05) for MYL versus MYLR, MYL versus MYL-SNX-7081-treated, and MYLR versus 
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MYLR-SNX-7081-treated. To enable the excision of protein spots, gels were additionally stained 
with colloidal Coomassie solution overnight and then washed in 1% (v/v) acetic acid. All fixing, 
staining and washing procedures were performed with gentle shaking. 
 
2.3.5 Identification of proteins by mass spectrometry 
Protein spots of interest were excised from Coomassie blue-stained 2D gels. Tryptic digestion 
and electrospray ionization-tandem mass spectrometry (ESI-MS/MS) were performed. Briefly, 
gel plugs were de-stained in 60% (v/v) 20 mM ammonium bicarbonate, 40% (v/v) acetonitrile 
(ACN) for 1 h at room temperature. If needed, this step was repeated until all Coomassie blue 
was washed out of the gel plugs, which were then dehydrated in ACN and dried completely using 
a centrifugal evaporator (Concentrator 5301, Eppendorf, North Ryde, NSW, Australia). The dried 
gel plugs were incubated with 12 ng/µl sequencing grade porcine trypsin (Promega, Sydney, 
Australia) for 1 h at 4°C. Excess trypsin solution was removed and the rehydrated gel plugs were 
incubated at 37°C overnight in 15 µl of 20 mM ammonium bicarbonate. Peptides were 
concentrated and desalted using C18 micro-columns (Millipore, Billerica, MA, USA) according 
to the manufacturer’s protocol, then eluted in 5 µl of 70% acetonitrile and 0.1% formic acid into 
a low-bind 96-well plate (Eppendorf, Dusseldorf, Germany) and then diluted with 45 µl of 0.1% 
(v/v) formic acid. Peptides in 0.1% (v/v) formic acid were injected onto a ZORBAX 300SB-C18 
trap (5 µm, 5 × 0.3 mm, Agilent Technologies) and separated using an in-house prepared fritted 
nano column packed with Reprosil–Pur C18 (3 µm, 75µm × 150 mm; Dr Maish GmbH, 
Ammerbuch, Germany) on an Agilent 1100 HPLC system coupled to an AB SCIEX Q-STAR 
Elite Q-TOF mass spectrometer. Peptides were eluted using a gradient of 5–40% buffer B mixed 
with buffer A (buffer A: 0.1% (v/v) formic acid; buffer B: 0.1% (v/v) formic acid in 100% ACN) 
at a flow rate of 0.3 µl/min. MS survey scans were performed over a range of 350–1750 m/z 
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followed by 3 data-dependent MS/MS scans over a range of 65-2000 m/z. Peak lists were 
generated using ProteinPilot Command Driver vr 0.3 software (AB SCIEX) and analysed using 
the Mascot version 2.4 database (Matrix Science, London, UK) against the NCBInr 2012-10-02 
database of human proteins. One missed cleavage per peptide, a parent ion tolerance of 0.2 Da, a 
fragment ion tolerance of 1.0 Da, variable modification by oxidation of methionine, and 
propionamide of cysteine were allowed in the Mascot search. Significant Mascot scores (p < 
0.05) above 40, with at least 2 peptides matched, were considered a positive identification of the 
protein.  
 
2.3.6 Western blotting 
MYL and MYLR cells were collected, washed twice with PBS and lysed using RIPA buffer plus 
protease and phosphatase inhibitor cocktail. Lysed cell samples were briefly sonicated, 
centrifuged (14,000 × g, 10 min, 4°C) and the supernatant saved for analysis. The samples were 
separated by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and 
analyzed by Western blotting (section 2.2.9 and 2.2.10). Primary antibodies against GAPDH 
(Sigma Aldrich, St. Louis, MO, USA), RhoGDI2, actin, Lyn kinase (Santa Cruz Biotechnology, 
Santa Cruz, CA, USA), Stat5, pStat5, BCR-ABL, Akt, pLyn kinase (Cell Signaling, Danvers, MA, 
USA) were used. 
 
2.3.7 Small interfering RNA (siRNA) 
SMARTpool siRNA (Thermo Fisher Scientific) were incorporated into cells using the Amaxa 
nucleofection system (Walkersville, MD, USA; >90% transfection efficiency with >90% cell 
viability, data not shown). Briefly, 1.0-1.5 × 106 cells were washed with PBS and re-suspended in 
nucleofection solution (Mirus Bio LLC; Madison, WI, USA). MYLR cells were nucleofected 
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with siRNA for Lyn or scrambled siRNA (control), using the T-16 nucleofector program and was 
added to 4.5 ml of nutrient-rich medium. Cells were cultured in a 5% CO2 humidified atmosphere 
at 37°C for 24 h before experimentation. 
 
2.4 Materials and methods for result chapter 4  
2.4.1 Cell culture and drug treatment  
MEC1, Raji, U266 and HL60 cells were cultured as described in section 2.2.1 and treated by 
drugs as described in section 2.2.5. MEC1 cells were treated with SNX-7081 at concentrations of 
0.01, 0.05, 0.1, 0.5 and 1 µM for 24, 48, and 72 h. For Western blotting confirmation of protein 
changes, Raji, U266 and HL60 cells were treated with SNX-7081 at 500 nM for 24 h.  
 
2.4.2 Cell viability assay  
The MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] assay was used to 
measure MEC1 cell viability following SNX-7081 treatment according to the manufacturer’s 
instructions. Triplicate control and treated MEC1 samples, contained 3 × 105 cells in 96-well 
plates in a final volume of 200 µl. For the final 3 h of SNX-7081 treatment, MTT (0.25 µg) was 
added to each well and the plates returned to a 37°C incubator. The reaction was quenched, the 
crystals formed were solubilised by addition of 100 µl DMSO, and absorbance was determined 
using a Powerwave XS plate reader (BioTek, Winooski, VT, USA).  
 
2.4.3 Cell cycle analysis 
Following SNX-7081 (500 nM, 24 h), control and treated MEC1 cells were fixed and 
permeabilised in ice-cold 70% ethanol for 2 h at -20°C. Cells were then pelleted (300 × g, 5 min, 
 Chapter 2: Materials and Methods 
64 
 
4°C) and stained in a solution containing 50 µg/ml propidium iodide, 0.1 mg/ml RNAse A and 
0.1% Triton-X100 for 30 min at room temperature. The DNA content of the cells was analysed 
by flow cytometry (FACSCalibur, Becton Dickinson, Franklin Lakes, NJ, USA) and the 
proportion of cells in each phase of the cell cycle was calculated using ModFitTM software 
(Verity Software House, Topsham, ME, USA). 
 
2.4.4 Preparation of sub-cellular fractions of MEC1 cells  
MEC1 cells, treated with SNX-7081 (500 nM, 24 h) or DMSO were collected from 4 
independent experiments. Nuclear, cytosolic and mitochondrial fractions were isolated using 
sucrose density gradients and differential centrifugation (section 2.2.6). Proteins from nuclear and 
mitochondrial fractions were extracted using MSST-DTT buffer, the cytosolic fraction was 
already in solution, and the enriched nuclear, mitochondrial and cytosolic fractions were 
precipitated and purified using the ReadyPrep™ 2-D Cleanup Kit (section 2.2.7), and re-
suspended in 25 mM NaHCO3 and 0.1% SDS in the last step. Protein concentrations were 
determined using the 2D Quant assay (section 2.2.8). 
 
2.4.5 iTRAQ labelling  
Proteins (50 µg) from the nuclear, cytosolic or mitochondrial fractions of MEC1 cells were 
reduced with 3 mM TCEP (tris(2-carboxyethyl)phosphine) for 30 min at 37°C in the dark. 
Proteins were then alkylated using 8 mM iodoacetamide for 30 min at room temperature in the 
dark. Each sample was digested with sequencing-grade porcine modified trypsin (Promega, 
Madison, WI, USA) at a trypsin to protein ratio of 1:10 at 37°C for 16 h. The iTRAQ 8-plex kit 
(AB SCIEX, Foster City, CA, USA) was used to label the 4 technical replicates (treated and 
control) for each sub-cellular fraction according to the manufacturer’s instructions. For the 
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nuclear, cytosolic and mitochondrial fractions, control samples were labelled with iTRAQ 
reagents 113, 115, 117 and 119, and treated samples were labelled with reagents 114, 116, 118 
and 121. Following incubation for 2 h at room temperature, the 8 labelled samples in each sub-
cellular fraction were combined as one set. To remove any unbound label, trypsin and SDS, the 
combined samples were cleaned using strong cation exchange (SCX) chromatography followed 
by reverse phase (RP) chromatography using an Opti-Lynx cartridge holder (AB SCIEX, Foster 
City, CA, USA) and a syringe pump (KD Scientific, Holliston, MA, USA) at a flow rate of 9.5 
mL/h [167]. The eluent was vacuum-dried and the peptide pellets dissolved in 0.05% HFBA 
(heptafluorobutyric acid)/1% formic acid. 
 
2.4.6. LC-MS/MS and data analysis  
Soluble peptides were injected twice to provide 2 separate LC/MS/MS technical replicates by on-
line strong cation exchange (SCX) and nano-C18 LC using an Ultimate HPLC, Switchos and 
Famos autosampler system (LC-Packings, Amsterdam, Netherlands). Peptide samples were 
loaded onto a small SCX micro trap (~500 µm × 12 mm, Poros S10, AB SCIEX, Foster City, CA, 
USA) and were eluted sequentially with 5, 10, 15, 20, 25, 30, 40, 50, 100, 250, 500, and 1,000 
mM ammonium acetate (20 µl). The initial unbound fraction and each salt step fraction were 
concentrated and desalted on a micro-C18 pre-column (500 µm × 2 mm; Michrom Bioresources, 
Auburn, CA, USA) at 15 µl/min. After a 10-min wash, the pre-column was switched (Valco 10 
port valve, Dionex ) in-line with a fritless nano analytical column ( 75 µm × ~10 cm) containing 
C18 reverse phase media (5 µm, 200 Å, Magic, Michrom Bioresources, Auburn, CA, USA) 
eluted with a linear gradient of 100% ACN (acetonitrile) in 0.1% (v/v) formic acid from 2% to 
36% ACN for 74 min, followed by 1 min at 90% ACN at ~300 nl/min, and the column was re-
equilibrated with 0.1% (v/v) formic acid for 10 min prior to the next injection. The column was 
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connected via a fused silica capillary to a low-volume tee (Upchurch Scientific, Oak Harbor, WA, 
USA) where high voltage (2,300 V) was applied and the column tip was positioned ~1 cm from 
the orifice of a QStar Elite mass spectrometer (AB SCIEX, Foster City, CA, USA). The QStar 
was operated in information-dependent acquisition (IDA) mode. A time-of-flight (TOF) MS 
survey scan was acquired (m/z 350-1750). The 3 most abundant multiply charged ions 
(counts >25) were sequentially selected by the quadrupole for TOF MS/MS analysis. Tandem 
mass spectra were accumulated for up to 2.5 s (m/z 65-2,000) using the advanced IDA parameters 
automatic MS/MS accumulation (set to 20) and automatic collision energy. Protein identification 
and relative abundance of proteins were determined using the ParagonTM algorithm in 
ProteinPilotTM 2.0 software (AB SCIEX, Foster City, CA, USA). Each MS/MS spectrum was 
compared with known sequences in the UniProtKB/Swiss-Prot database download on the 23rd 
November 2007. Search parameters were set to: sample type, iTRAQ 8-plex (peptide labeled); 
cysteine alkylation, iodoacetamide; digestion, trypsin; special factor, urea denaturation; 
identification focus, biological modifications; search effort, thorough ID. Ratios of the areas 
under the peaks at 113, 114, 115, 116, 117, 118, 119, and 121 Da were calculated to determine a 
protein’s relative abundance across all samples in the iTRAQ set. The following criteria were 
imposed on the data to identify significantly differentially abundant proteins: an unused protein 
score >1.3, that corresponds to a confidence limit of 95%; at least 2 unique peptides with 
confidence >95% detected; p < 0.05 (Student’s t-test, assuming equal variance) and relative 
abundance changes greater than 2-fold. To correct for small differences in protein loading, the 
generated ratios of all detected proteins were normalized by bias correction with the 
ProteinPilotTM software. Biological and canonical functions of the differentially abundant 
proteins identified were explored using the Ingenuity Pathway Analysis (IPA) software as 
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described in section 2.2.11. 
 
2.4.7 Western blotting  
MEC1 sub-cellular fractionated proteins were precipitated using acetone and re-suspended in a 
solubilizing buffer (5 M urea, 2 M thiourea, 2% w/v CHAPS, 2% w/v sulfobetaine 3-10, 40 mM 
Tris-HCl (pH 8.8), carrier ampholyte (1.0% v/v), 65 mM DTT, 2 mM TBP). Whole cell lysates 
were produced by sonication (Unisonics, Brookvale, NSW, Australia) of cell pellets in the same 
solubilizing buffer and recovered from the supernatant after centrifugation (14,000 × g, 4°C, 5 
min). Protein samples (15 µg) were separated by 10% SDS-PAGE, and transferred to a PVDF 
membrane (Immun-Blot™, Bio-Rad Laboratories, Hercules, CA, USA). After blocking with 5% 
skim milk, the membranes were incubated (4 °C, 16 h) with the following primary antibodies: 
mouse anti-HLA-DR, mouse anti-MCM2, mouse anti-Hsp70, mouse anti-PDIA6, mouse anti-
PCNA, mouse anti-β-actin (Abcam, Cambridge, MA, USA), mouse anti-p53, mouse anti-DDB1 
(Santa Cruz Biotechnology, Santa Cruz, CA, USA), rabbit anti-Hsp90, rabbit anti-GRP78, rabbit 
anti-c-Myc, mouse anti-pRb, mouse anti-cyclin D1 (Cell Signaling, Danvers, MA, USA), 
followed by incubation (1 h, room temperature) with a horse radish peroxidase (HRP)-conjugated 
secondary antibody: goat-anti-mouse-HRP (Santa Cruz Biotechnology, Santa Cruz, CA, USA) or 
donkey anti-rabbit-HRP (Abcam, Cambridge, MA, USA). Proteins were visualized using Rapid 
Step ECL Reagent (Merck, Kilsyth, VIC, Australia) and ECL chemiluminescence film (GE 
Healthcare, Little Chalfont, Buckinghamshire, UK). Films were scanned on a Molecular Imager 
GS-800™ densitometer (Bio-Rad, Hercules, CA, USA). Bands were quantified using 
ImageQuantTL density analysis software (GE Healthcare, Little Chalfont, Buckinghamshire, 
UK). 
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2.4.8 RT-PCR  
For RT-PCR (real time polymerase chain reaction), total RNA was extracted from triplicate 
control and SNX-7081-treated (500 nM, 24 h) MEC1 cells, using TRI reagent (TRIzol) following 
the manufacturer’s protocol (Sigma Aldrich, St. Louis. MO, USA). Total RNA was reverse-
transcribed into cDNA using the SuperScript®VILOTM cDNA synthesis kit (Invitrogen, 
Carlsbad, CA, USA) following the manufacturer’s instructions. Forward and reverse primers (80-
120 bp) were designed using the on-line primer design tool 
(http://biotools.umassmed.edu/bioapps/primer3_www.cgi). Quantification was performed by 
calculating the fluorescence density during the amplification cycle. RT-PCR was conducted using 
Taqman RT-PCR on the ABI 7500 Fast Sequence Detection system, using the SYBR Green 
Master Mix (Life Technology, Carlsbad, CA, USA). Amplification proceeded over 40 cycles, 
with each cycle comprising a denaturing step (15 s, 95°C) and an annealing/extending step (60 s, 
60°C). Microsoft® Excel formatted data (including cycle number to reach the same threshold) 
were exported and fold-changes were calculated following normalization against the house-
keeping gene encoding the 18S ribosomal RNA [168] using the following formula.  
 
Sample ∆Ct=Ctsample-Ct18S         (iv)                          
∆∆Ct=treated ∆Ct-control ∆Ct                    (v) 
The fold of treated/control=2-∆∆Ct                         (vi) 
 
Where Ct is cycle threshold, ∆ is difference. 
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2.5 Materials and methods for result chapter 5  
2.5.1 Cell culture and drug treatment  
MEC1 cells were grown as described in section 2.2.1. Cells at a density of 3 × 105
 
cells/ml were 
treated with SNX-7081 (500 nM, 48 h) as described in section 2.2.5 and harvested for analysis of 
CD (cluster of differentiation) antigens. SNX-7081 was solubilised in DMSO, control cultures 
were treated with the same concentration of DMSO without the drugs.  
 
2.5.2 Immunophenotyping of cells with DotScan™ CD antibody microarrays  
Triplicate MEC1 control and treated samples (3 × 106
 
cells) were washed, resuspended in 300 µL 
PBS and immunophenotyped on DotScan™ microarrays. DotScanTM
 
microarrays were obtained 
from Medsaic (Eveleigh, NSW, Australia). Construction of CD antibody microarrays has been 
described [152, 154]. The microarray used in this project has 195 duplicate antibodies dots (10 
nL), 182 specific CD antibodies plus 13 isotype controls for testing non-specific binding, and 
alignment dots around the border consisting of a 1:1 mixture of CD44 and CD29 antibodies that 
are positive controls for cell binding (microarray key shown in Figure 5.1, chapter 5). The 
microarray was moistened with PBS and any excess liquid around the nitrocellulose film was 
carefully wiped off with Kimwipe tissues. MEC1 Cells (3 × 106) were collected by centrifugation 
(450 × g, 5 min, room temperature) washed in PBS solution twice and resuspended in 300 µL of 
PBS to a final concentration of 107
 
cells/mL, and 300 µL of the resuspended control and drug-
treated cells were incubated on DotScanTM
 
microarrays in a humidified chamber at room 
temperature. After 15 min, unbound cells were poured off and the microarray was gently washed 
with PBS (2 × 10 s), and placed into array fixative solution for at least 1 h, preferably overnight, 
to fix the cells to the antibodies of the microarray. All procedures were carried out at room 
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temperature. 
 
2.5.3 Recording and analysis of DotScan™ data  
After incubation, the array fixative solution was washed off with PBS and dot patterns of cells 
captured on CD antibody microarrays were imaged and analysed using a Medsaic scanner and 
software (Eveleigh, NSW, Australia) [154]. The software quantifies the density of cells bound to 
each antibody dot on an 8-bit pixel greyness scale from 1-256, and presents these data graphically 
as an expression profile of average density of cell binding on duplicate antibody dots versus CD 
number. Average dot densities were normalized between microarrays using the equation:  
 
I
n 
= (I*256)/I
max
                 (vii) 
 
Where I
n 
is the normalized density of a dot, I is the observed density, and I
max 
is the density of the 
dot with highest binding on the microarray. This normalization procedure assumes that at least 
one of the antibody dots in the microarray was saturated with cells and this is then equated with 
the maximum 8-bit dot intensity of 256.  
 
2.6 Materials and methods for result chapter 6  
2.6.1 Cell culture and drug treatment 
MEC1, MEC2, and U266 cells were cultured as described in section 2.2.1, and treated with the 
Hsp90 inhibitor SNX-7081 (100 nM, 48 h), 2-FaraA (10 µM, 48 h) or 100 nM SNX-7081 + 10 
µM 2-FaraA (48 h) as described in section 2.2.5. The  concentrations and times of treatment were 
chosen based on the synergy of these drugs reported previously [169].  
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2.6.2 Protein extraction and separation by SDS-PAGE  
Triplicates of control, SNX-7081 (100 nM, 48 h) treated, 2-FaraA (10 µM, 48 h) treated or 100 
nM SNX-7081 + 10 µM 2-FaraA (48 h) treated MEC1 cells were collected by centrifugation (350 
g, 5 min, 4°C) and cells were lysed in protein extraction buffer. The lysate was centrifuged 
(10,000 g, 5 min, 4°C), the supernatant was the whole cell extract which was then precipitated 
with the Ready Prep 2-D Clean-up Kit (section 2.2.7), and resuspended in 8 M urea. Protein 
concentrations were determined using the 2D Quant Kit (section 2.2.8), and 200 µg protein each 
sample were separated by SDS-PAGE as described in section 2.2.9. Gels were visualized using 
colloidal Coomassie solution. 
 
2.6.3 Trypsin in-gel digestion 
Coomassie blue-stained SDS-PAGE gels were washed twice in water (10 min per wash), each 
lane was cut into 16 equal pieces from top to bottom, each piece was shredded, and placed into a 
well of a 96-well plate. Destaining was carried out by briefly washing the gel fragments with 100 
mM NH4HCO3, then with 200 µL ACN (acetonitrile) (50%, v/v) in 100 mM NH4HCO3 for 10 
min, then dehydrated with 100% ACN. The samples were air-dried and reduced with 50 µL of 10 
mM dithiothreitol (DTT) in 50 mM NH4HCO3 at 37˚C for 1 h, followed by alkylation in the dark 
with 50 µL of 50 mM iodoacetamide in 50 mM NH4HCO3 at room temperature for 1 h. The 
samples were then briefly washed with 100 mM NH4HCO3, 200 µL ACN (50%, v/v) in 100 mM 
NH4HCO3 for 10 min, dehydrated with 100% ACN and then air dried. Finally, samples were 
digested using trypsin (Promega, Madison, WI, USA) at a trypsin to protein ratio of 1:10 for 30 
min on ice and then overnight at 37˚C. Peptides resulting from the tryptic digestion were 
extracted twice with 30 µL of ACN (50%, v/v) in 2% formic acid, dried by vacuum 
centrifugation and reconstituted to 10 µL with 2% formic acid in H2O. 
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2.6.4 Nanoflow liquid chromatography-tandem mass spectrometry 
As previously described [170], peptides were analyzed by nanoLC-MS/MS using a LTQ-XL ion-
trap mass spectrometer (Thermo, CA, USA) [171]. Reverse phase columns were packed in-house 
to approximately 7 cm (100 µm i.d.) using 100 Å, 5 µm Zorbax C18 resin (Agilent Technologies, 
CA, USA) in a fused silica capillary with an integrated electrospray tip. A 1.8 kV electrospray 
voltage was applied via a liquid junction up-stream of the C18 column. One tenth of the digested 
peptides in each gel piece (about 1.25 µg) was injected onto the C18 column using a Surveyor 
autosampler (Thermo, CA, USA), followed by an initial wash with buffer A (5% (v/v) ACN, 
0.1% (v/v) formic acid) for 10 min at 1 µL/min. Peptides were eluted from the C18 column with 
0%-50% Buffer B (95% (v/v) ACN, 0.1% (v/v) formic acid) over 58 min at 500 nL/min followed 
by 50-95% Buffer B over 5 min at 500 nL/min. The eluted solution was directed into a nanospray 
ionization source of the mass spectrometer. Spectra were scanned over the range 400-1500 amu, 
with automated peak recognition, dynamic exclusion window set to 90 s [172], and tandem MS 
of the top 6 most intense precursor ions at 35% normalization collision energy was performed 
using the Xcalibur software (version 2.06; Thermo, CA, USA).  
 
2.6.5 Protein identification and data processing 
To identify proteins, raw files acquired from mass spectrometry were converted to mzXML 
format and processed through the global proteome machine (GPM) software using version 2.1.1 
of the X!Tandem algorithm  (http://www.thegpm.org) [173, 174]. For each experiment, the 16 
fractions were processed sequentially with output files for each fraction, and a merged, non-
redundant output file was generated for protein identifications with log(e) values less than -1 
[175]. Tandem mass spectra were searched against the NCBI human protein database in GPM 
containing 513,692 protein sequences as of August 2010. The database also incorporated 
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common human and trypsin peptide contaminants. Search parameters included MS and MS/MS 
tolerances of ± 2 Da and ± 0.2 Da, up to 3 missed tryptic cleavages and K/R-P cleavages. Fixed 
modifications were set for carbamidomethylation of cysteine and variable modifications were set 
for oxidation of methionine. Each condition had 3 replicate samples. The 3 protein identification 
GPM output files from each of the replicates were combined into one joint dataset to produce a 
single shotgun proteomic analysis for each condition. Only proteins identified in all 3 replicates 
were retained in the final dataset for each condition. An additional requirement was imposed of 
having a total spectral count of at least 6 within at least one condition [176, 177].  
 
2.6.6 Quantitative proteomic and statistical analyses 
Protein abundance data were calculated based on normal spectral abundance factor (NSAF) 
values as described previously [178]. For each sample, i, the number of spectral counts (SpC) 
identifying a protein, k, was divided by the molecular weight of the protein in kDa. (SpC/MW) k 
values were then divided by the sum of (SpC/MW) for all (N) proteins in the experiments to give 
the NSAFi values. For each protein k, the sum S of all spectral counts obtained from the 3 
replicates was calculated, and the corresponding NSAFs were deduced and used as a measure of 
protein abundance. A spectral fraction of 0.5 was added to the spectral counts of each protein, to 
compensate for null values [179] and enable log-transformation for subsequent statistical 
analyses. The t-test evaluation was carried out using Microsoft Excel and Shapiro-Wilk tests for 
normality, and Gaussian fittings were carried out using Origin 7 (OriginLab Corporation, 
Northampton, MA). The 2-sample paired t-tests were performed on log-transformed NSAF data 
to find the proteins that increased and decreased in abundance for each treatment condition. 
Proteins with a p < 0.05 were regarded as differentially expressed. The resulting sets of up- and 
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down-regulated proteins were then functionally annotated using the Ingenuity Pathway 
Analysis (IPA) software (section 2.2.11). 
 
2.6.7 Western blotting  
Triplicate MEC1 protein samples (15 µg) from control, 2-FaraA (10 µM, 48 h), SNX-7081 (100 
nM, 48 h) treated, 100 nM SNX-7081 + 10µM 2-FaraA (48 h) treated were separated by 10% 
SDS-PAGE, and transferred to a PVDF membrane (Immun-Blot™, Bio-Rad Laboratories, 
Hercules, CA, USA). After blocking with 5% skim milk, the membranes were incubated (4°C, 16 
h) with the pH2AX primary antibody (Cell Signaling, Danvers, MA, USA), followed by 
incubation (1 h, room temperature) with a horse radish peroxidase (HRP)-conjugated secondary 
antibody: donkey anti-rabbit-HRP (Abcam, Cambridge, MA, USA). Proteins were visualized 
using Rapid Step ECL Reagent (Merck, Kilsyth, VIC, Australia) and ECL chemiluminescence 
film (GE Healthcare, Little Chalfont, Buckinghamshire, UK). Films were scanned on a Molecular 
Imager GS-800™ densitometer (Bio-Rad, Hercules, CA, USA). Bands were quantified using 
ImageQuantTL density analysis software (GE Healthcare, Little Chalfont, Buckinghamshire, 
UK). 
 
2.6.8 Flow cytometry 
The level of protein pH2AX was determined using a FACScalibur flow cytometer (FACSCalibur; 
Becton Dickinson, Franklin Lakes, NJ) with a 488 nm argon laser, running CellQuest Pro 
software version 5.2 (Becton Dickinson). The triplicate MEC1, MEC2 and U266 cell samples 
were treated with 2-FaraA (10 µM, 48 h), SNX7081 (100 nM, 48 h), and 100 nM SNX7081 + 10 
µM FdA (48 h) and labeled with pH2AX antibody conjugated to Alexa-488 (Abcam, Cambridge, 
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MA, USA) using standard procedures. Flow cytometry with fluorescence detection used 
logarithmic amplification; data were the averages of three biological replicates. 
  
 
 
 
Chapter Three 
 
Hsp90 Inhibitors Disrupt Lyn Kinase 
Signaling Pathways to Overcome Imatinib 
Resistance in Human MYLR Chronic 
Myeloid Leukemia Cells  
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3.1 Introduction 
Chronic myeloid leukemia (CML) occurs most commonly in later life.  The annual incidence of 
CML in Western countries is 1–2 individuals per 100,000, representing 15–20% of adult 
leukemias [180]. CML is a myeloproliferative disease usually involving reciprocal translocation 
of chromosomes 9 and 22 forming the Philadelphia chromosome [181], that encodes the chimeric 
BCR-ABL protein (p210), a constitutively-active protein tyrosine kinase that stimulates cell 
proliferation [182]. Standard treatment for CML is imatinib (STI571, Glivec), an ATP-
competitive inhibitor of BCR-ABL [183]. However, patients often develop secondary resistance 
to imatinib [49]. Therefore, novel treatment strategies to overcome imatinib resistance are needed. 
Over-expression of the BCR-ABL gene and acquisition of mutations that interfere with imatinib 
binding (e.g. T315I) are common mechanisms of resistance [184]. In addition, Lyn kinase up-
regulation has been associated with imatinib resistance in human K562 CML cells and CML 
patient samples [53, 185]. Lyn kinase is a member of the Src family of pro-survival non-receptor 
tyrosine kinases [53]. BCR-ABL activates Lyn in myeloid cells [53], and small interfering RNA 
(siRNA)-mediated knock-down of Lyn induces apoptosis in BCR-ABL(+) imatinib-resistant 
CML cells [186]. This evidence suggests that Lyn is a potential therapeutic target in imatinib-
resistant CML. 
 
MYL cells were isolated from a patient with chronic phase CML; MYLR cells are a drug-
resistant sub-clone derived by step-wise selection in medium containing imatinib [29]. MYLR 
cells do not express secondary mutations or over-express BCR-ABL (p210), but have elevated 
Lyn relative to MYL cells [187]. SiRNA-mediated knock-down of Lyn in MYLR cells inhibited 
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growth with partial loss of imatinib resistance, indicating that Lyn contributes to drug resistance 
[29].   
 
Hsp90 is an abundant ATP-dependent chaperone that promotes the folding, stability and 
localization of more than 200 ‘client’ proteins, many of which are oncoproteins [188]. Hsp90 
inhibition can simultaneously disrupt multiple signaling pathways critical to tumor cell growth 
and survival, which makes Hsp90 inhibitors effective in blocking the proliferation of cancer cells  
and overcoming drug resistance [105, 189]. It is proposed that high levels of Hsp90 stabilize Lyn 
[190]. Inhibition of Hsp90 reduces the growth of imatinib-resistant human KBM5-T315I CML 
cells (BCR-ABL-mutant) and CML stem cells, and prolongs the survival of imatinib-resistant 
leukemia in mice [191, 192]. The mechanism by which Hsp90 inhibition overcomes Lyn-
dependent imatinib resistance is not clear.  
 
There are 18 Hsp90 inhibitors in clinical trials [193]. A phase II/III clinical trial of 17-AAG, a 
‘first generation’ Hsp90 inhibitor, was terminated due to poor solubility and formulation 
difficulties. SNX-7081 and its glycyl ester derivative, SNX-5422, are novel Hsp90 inhibitors; 
SNX-5422 is currently in phase I by Pfizer [193]. SNX-5422 and SNX-7081 have similar 
chemical structures, binding as competitive inhibitors to the N-terminal ATP pocket of Hsp90 
[194]. We have determined the proteomic effects of 17-AAG, SNX-7081 and SNX-5422 on 
imatinib-resistant MYLR cells and parental imatinib-sensitive MYL cells using two-dimensional 
fluorescence difference gel electrophoresis (DIGE) and Proteome Profiler human phospho-
RTK (receptor tyrosine kinase) arrays. These analyses enabled the evaluation of multiple Hsp90 
isoforms and fragments, other chaperones and ‘client’ proteins. These complementary proteomic 
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techniques have provided further understanding of the mechanism of Lyn-dependent imatinib 
resistance in MYLR cells and determined how Hsp90 inhibition overcomes this resistance. 
 
3.2 Materials and methods 
As described in section 2.3 in Chapter 2. 
 
3.3 Results 
3.3.1 Differentially abundant proteins in imatinib-resistant MYLR versus MYL cell lines 
Receptor tyrosine kinases (RTKs) mediate cell signaling and when dysregulated drive the 
proliferation of many cancers [195]. Due to their low abundance, RTKs and their phospho-forms 
are often not detected by classical proteomics analyses, so Phospho-RTK antibody arrays were 
used to detect these proteins. The Proteome Profiler Human Phospho-RTK Array System 
measures the tyrosine phosphorylation of 42 RTKs. Differentially phosphorylated RTKs between 
MYL and MYLR are shown in Figure 3.1. The levels of three phosphorylated RTKs were 
reduced in MYLR cells relative to MYL, i.e., p-TrkA (2.12-fold), p-VEGFR2 (10.0-fold), and p-
FGFR3 (1.31-fold). In contrast, increases in p-Mer (1.75-fold), p-MSPR (1.44-fold), p-c-Ret 
(1.32-fold), p-Axl (1.26-fold), and p-EphA4 (2.38-fold) were observed in MYLR cells.  
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Figure 3.1. Phosphorylation of receptor tyrosine kinases (RTK). The phosphorylation states of 42 RTK in lysates 
from MYL and MYLR cells were analyzed with the phospho-RTK Array system. Differentially abundant 
phosphorylated RTK are shown with pixel intensities, error bars represent the mean ± standard deviation (p < 0.05, n 
= 2). 
 
Differentially abundant proteins from the soluble proteome of MYL and MYLR cells were 
identified by DIGE analysis. Here, 28 proteins were differentially abundant between MYL and 
MYLR by more than 1.30-fold (p < 0.05) and were subjected to electrospray ionization and 
tandem mass spectrometry (ESI-MS/MS) for protein identification (Table 3.1). Representative 
MYL and MYLR soluble proteome maps are presented in Figures 3.2A and B, and differentially 
abundant proteins are labeled in the MYLR map. Western blot analysis showed that Lyn kinase 
was 8.73-fold higher in MYLR cells compared with MYL, confirming a previous report [29], 
GAPDH was 2.41-fold higher, and Rho-GDI beta was 2.03-fold lower (Figure 3.3). The fold-
changes of Western blots were higher than DIGE, due to variation between different techniques, 
but the direction of change was constistent. 
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Figure 3.2.  Protein maps for MYL and MYLR cells. (A) MYL cells control, (B) MYLR cells control, labeled 
proteins are differentially abundant compared with MYL cells; spot numbers correspond to Table 3.1. (C) SNX-7081 
treated (50 nM, 48 h) MYL cells, labeled protein spots are differentially abundant compared with the MYL untreated 
control; spot numbers correspond to Table 3.2. (D) SNX-7081 treated (50 nM, 48 h) MYLR cells, labeled protein 
spots are differentially abundant compared with the MYLR untreated control; spot numbers correspond to Table 3.2. 
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Figure 3.3.  Western blot analyses of glyceraldehyde 3-phosphate dehydrogenase (GAPDH), RhoGDI2 and Lyn 
kinase. Actin was used as a loading control to quantify band intensities. A negative fold-change indicates a higher 
abundance of the protein in MYL rather than MYLR cells (p < 0.05, n = 3). 
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Table 3.1. Differentially abundant proteins between MYLR and MYL cells. 
Spot 
no.
a
 
Acc. no.
b
 Protein name Gene symbol 
MYLR/MYL Matched 
peptides 
(SC%)
d
 
Mowse 
score
e
 
Theoret. 
MW/pI
f
 
Biological 
function
g
 p‐value 
Fold‐
change
c
 
410 
692 
693 
P04406  Glyceraldehyde‐3‐phosphate 
dehydrogenase (GAPDH) 
GAPDH 0.0004 
0.0003 
0.0012 
1.60 
1.70 
1.50 
17 (46) 
17 (52) 
16 (55) 
534 
571 
563 
36030/8.57 
Metabolism, 
energy pathways 
687 P32119  Peroxiredoxin‐2 PRDX2 0.0058 -1.50 21 (50) 575 21878/5.66 
469 P40926  Malate dehydrogenase, 
mitochondrial 
MDH2 0.0204 -1.40 17 (43) 744 35481/8.92 
442 P00491  Purine nucleoside 
phosphorylase 
PNP 0.0145 -1.60 23 (61) 1043 32097/6.45 
492 
501 
P30048  Thioredoxin‐dependent 
peroxide reductase, 
mitochondrial 
PRDX3 0.0099 
0.0360 
 -1.40 
 -1.30 
13 (28) 
20 (32) 
504 
724 
27675/7.67 
464 
384 
P60174  Triosephosphate isomerase 
(TPI) 
TPI1 0.0024 1.40 
1.60 
14 (52) 
15 (61) 
382 
669 
30772/5.65 
349 P06132  Uroporphyrinogen 
decarboxylase 
UROD 0.0017 -1.30 11 (35) 405 40761/5.77 
391 P04083  Annexin A1 ANXA1 0.0359 -1.30 10 (38) 748 38690/6.57 
Cell 
communication, 
signal transduction 
485 P62826  GTP‐binding nuclear protein 
Ran 
RAN 0.0384 -1.50 7 (33) 258 24408/7.01 
445 P35232  Prohibitin PHB 0.0019 1.30 12 (58) 819 29786/5.57 
697 P52566  Rho GDP‐dissociation inhibitor 
2 (Rho‐GDI beta) 
ARHGDIB 0.0005 -1.40 11 (58) 316 22974/5.10 
498 O95816  BAG family molecular 
chaperone regulator 2 
BAG2 0.0003 1.80 6 (27) 246 23757/6.25 
Apoptosis 
488 Q9BUL8  Programmed cell death 
protein 10 
PDCD10 0.0353 1.40 8 (37) 235 24686/7.79 
429 P47756  F‐actin‐capping protein 
subunit beta 
CAPZB 0.0157 1.30 6 (18) 307 31331/5.36  
Cell growth and/or 
maintenance 642 P07737  Profilin‐1 PFN1 0.0264 -1.60 9 (47) 490 15045/8.44 
559 P16949  Stathmin STMN1 0.0132 -1.50 15 (32) 705 17292/5.76 
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Spot 
no.
a
 
Acc. no.
b
 Protein name Gene symbol 
MYLR/MYL Matched 
peptides 
(SC%)
d
 
Mowse 
score
e
 
Theoret. 
MW/pI
f
 
Biological 
function
g
 p‐value 
Fold‐
change
c
 
303 P28838  Cytosol aminopeptidase LAP3 0.0007 -2.10 18 (37) 571 56131/8.03 
Protein 
metabolism 
511 Q9HAV7  GrpE protein homolog 1, 
mitochondrial 
GRPEL1 0.0395 -1.50 7 (29) 287 24264/8.24 
494 P25787  Proteasome subunit alpha 
type‐2 
PSMA2 0.0257 1.50 2 (11) 135 25882/6.92 
266 P17987  T‐complex protein 1 subunit 
alpha 
TCP1 0.0377 1.30 25 (48) 1127 60306/5.80 
179 
181 
O00571  ATP‐dependent RNA helicase 
DDX3X (DDX3X) 
DDX3X 0.0282 
0.0092 
 -1.30 
 -1.30 
5 (9) 
7 (12) 
253 
392 
73198/6.73 
Regulation of 
nucleobase, 
nucleoside, 
nucleotide and 
nucleic acid 
metabolism 
546 P62805  Histone H4 HIST4H4 0.0247 -1.30 2 (21) 128 11360/11.36 
177 Q8TCS8  Polyribonucleotide 
nucleotidyltransferase 1, 
mitochondrial 
PNPT1 0.0120 -1.40 3 (5) 140 85897/7.87 
356 Q9BWF3  RNA‐binding protein 4 RBM4 0.0088 -1.30 10 (43) 741 40289/6.61 
698 O00299  Chloride intracellular channel 
protein 1 
CLIC1 0.0250 1.30 5 (24) 274 26906/5.09 
Transport 
645 P69892  Hemoglobin subunit gamma‐2 HBG2 0.0005 1.60 5 (47) 280 16116/6.64 
545    
554 
P07741  Adenine 
phosphoribosyltransferase 
APRT 0.004    
0.031 
 -1.50      
 -1.50 
7 (36)  
5 (36) 
362 
188 
19595/5.78 Purine salvage 
630 Q9P1F3  Costars family protein ABRACL ABRACL 0.0012 -1.60 9 (70) 319 9051/5.86 Biological process 
unknown 
a
Spot number as depicted in Figure 3.2B. 
b
Accession numbers of proteins were derived from the Swiss‐Prot database. 
c
Fold‐change of protein abundance in 
MYLR versus MYL, minus '‐' fold change indicates the protein has higher abundance in MYL than in MYLR. 
d
Number of peptides matched to identified 
protein using ESI‐MS/MS (electrospray ionization‐tandem mass spectrometry), with percentage sequence coverage (SC%) of matched protein in brackets. 
e
Mowse score indicating the confidence of protein identification. 
f
Theoretical molecular weight and isoelectric point obtained using the Mascot search 
engine against the Swiss‐Prot database. 
g
Primary biological function obtained from the Human Protein Reference Database (www.hprd.org).   
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Table 3.2. Differentially abundant proteins between MYLR-SNX-7081(50 nM, 48 h)-treated and MYLR, and MYL-SNX-7081(50 nM, 48 h)-treated and MYL 
cells. 
Spot 
no.
a
 
Acc. 
no.
b
 
Protein name 
Gene 
symbol 
MYL‐
treated/MYL 
MYLR‐
treated/MYLR 
Matched 
peptides 
(SC%)
d
 
Mowse 
score
e
 
Theoret. 
MW/pI
f
 
Biological function
g
 
p‐
value 
Fold 
change
c
 
 p‐
value 
Fold‐
change
c
 
Proteins changed abundance in both MYL and MYLR cells after SNX-7081 (50 nM, 48 h)   
195 
219 
220 
216 
222 
519 
P11142  Heat heat shock 70kDa 
protein 8 
HSPA8 0.0068 
0.0219 
0.0004 
0.0264 
0.0012 
0.0078 
1.30 
1.40 
1.40 
1.60 
1.70 
1.30 
0.0013 
0.0145 
0.0043 
0.0057 
0.0056 
‐ 
1.30 
1.40 
1.50 
1.60 
1.60 
- 
49 (54) 
29 (41) 
42 (58) 
26 (41) 
49 (64) 
14 (17) 
1324 
1368 
1531 
1396 
1947 
703 
70854/5.37 
Protein metabolism 212 
223 
P38646  Heat shock 70 kDa 
protein 9 
HSPA9 0.0344 
0.0038 
1.50 
3.40 
0.0429 
0.0001 
1.50 
4.20 
19 (34) 
23 (36) 
1010 
1316 
73635/5.87 
227 P50990  T‐complex protein 1 
subunit theta 
CCT8 0.0018 1.30 0.0011 1.30 31 (42) 1318 59583/5.42 
363 P51665  26S proteasome non‐
ATPase regulatory subunit 
7 
PSMD7 0.0153 1.30 0.0077 1.50 12 (38) 529 37002/6.29 
167 
142 
P08238  Heat shock protein 
HSP90‐beta 
HSP90AB1 0.0322 
‐ 
1.30 
- 
 ‐ 
0.0216 
 - 
1.50 
24 (31) 
24 (29) 
952 
953 
83212/4.97 Cell 
communication, 
Signal transduction 
389 
387 
P22626  Heterogeneous nuclear 
ribonucleoproteins A2/B1 
HNRNPA2
B1 
0.0169 
‐ 
1.30 
- 
 ‐ 
0.0004 
 - 
1.60 
20 (49) 
15 (28) 
755 
579 
37407/8.97 Regulation of 
nucleobase, 
nucleoside, 
nucleotide and 
nucleic acid 
metabolism 
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Spot 
no.
a
 
Acc. 
no.
b
 
Protein name 
Gene 
symbol 
MYL‐
treated/MYL 
MYLR‐
treated/MYLR 
Matched 
peptides 
(SC%)
d
 
Mowse 
score
e
 
Theoret. 
MW/pI
f
 
Biological function
g
 
p‐
value 
Fold 
change
c
 
 p‐
value 
Fold‐
change
c
 
Proteins only changed abundance in MYL cells after SNX-7081 (50 nM, 48 h)   
471 O75489  NADH dehydrogenase 
[ubiquinone] iron‐sulfur 
protein 3, mitochondrial 
NDUFS3 0.0372 -1.30     7 (35) 393 30223/6.99 
Metabolism ; 
Energy pathways 
475 P30041  Peroxiredoxin‐6 PRDX6 0.0452 1.30   4 (18) 170 25019/6.00 
532 P30043  Flavin reductase (NADPH) BLVRB 0.0049 1.60     5 (37) 342 22105/7.13 
303 P28838  Cytosol aminopeptidase LAP3 0.0389 1.30   18 (37) 571 56131/8.03 Protein metabolism 
Proteins only changed abundance in MYLR cells after SNX-7081 (50 nM, 48 h) 
179 
188 
O00571  ATP‐dependent RNA 
helicase DDX3X 
DDX3X   0.0279 
0.0482 
 -1.30 
-1.40 
5 (9) 
16 (27) 
253 
800 
73198/6.73 
Regulation of 
nucleobase, 
nucleoside, 
nucleotide and 
nucleic acid 
metabolism 
208 Q96AE4  Far upstream element‐
binding protein 1 (FBP1) 
FUBP1   0.0019 -1.30 6 (9) 290 67518/7.18 
546 P62805  Histone H4 HIST4H4   0.0167 1.40 2 (21) 128 11360/11.3
6 
311 P31943  Heterogeneous nuclear 
ribonucleoprotein H 
HNRNPH1     0.0334 1.30 5 (14) 277 49198/5.89 
346 Q9BWD1  Acetyl‐CoA 
acetyltransferase, 
cytosolic 
ACAT2     0.0300 -1.40 7 (24) 303 41324/6.47 
Metabolism ; 
Energy pathways 
691 Q13907  Isopentenyl‐diphosphate 
Delta‐isomerase 1 
IDI1   0.0250 1.30 5 (24) 200 26302/5.93 
257 P04040  Catalase CAT   0.0164 1.40 12 (30) 528 59719/6.90 
459 O95336  6‐
phosphogluconolactonase 
PGLS     0.0454 1.50 13 (50) 713 27530/5.70 
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Spot 
no.
a
 
Acc. 
no.
b
 
Protein name 
Gene 
symbol 
MYL‐
treated/MYL 
MYLR‐
treated/MYLR 
Matched 
peptides 
(SC%)
d
 
Mowse 
score
e
 
Theoret. 
MW/pI
f
 
Biological function
g
 
p‐
value 
Fold 
change
c
 
 p‐
value 
Fold‐
change
c
 
304 P60842  Eukaryotic initiation 
factor 4A‐I 
EIF4A1     0.0102 -1.30 19 (42) 868 46125/5.32 
Protein metabolism 
298 P26641  Elongation factor 1‐
gamma 
EEF1G   0.0357 1.30 10 (21) 364 50087/6.25 
421 P61289  Proteasome activator 
complex subunit 3 
PSME3   0.0405 1.30 4 (29) 347 29488/5.69 
436 Q06323  Proteasome activator 
complex subunit 1 
PSME1     0.0093 1.30 15 (38) 554 28705/5.78 
535 P33316  Deoxyuridine 5'‐
triphosphate 
nucleotidohydrolase, 
mitochondrial (dUTPase) 
DUT     0.0396 -1.30 13 (33) 646 26547/9.46 DNA replication 
668 P26447  Protein S100‐A4 S100A4     0.0389 1.30 5 (27) 97 11721/5.85 Cell growth and/or 
maintenance 
307 P00352  Retinal dehydrogenase 1 ALDH1A1     0.0064 2.00 27 (40) 1403 54827/6.30 Aldehyde 
metabolism 
694 Q96CN7  Isochorismatase domain‐
containing protein 1 
ISOC1     0.0231 -1.30 7 (36) 322 32216/6.96 Biological process 
unknown 
a
Spot number as depicted in Figure 3.2C, D. 
b
Accession numbers of proteins were derived from the Swiss‐Prot database. 
c
Fold‐change of protein abundance in 
treated cells versus control cells, minus '‐' fold change indicates the protein decreased abundance after SNX‐7081 (50 nM, 48 h) 
d
Number of peptides matched 
to identified protein using ESI‐MS/MS (electrospray ionization‐tandem mass spectrometry), with percentage sequence coverage (SC%) of matched protein in 
brackets. 
e
Mowse score indicating the confidence of protein identification. 
f
Theoretical molecular weight and isoelectric point obtained using the Mascot 
search engine against the Swiss‐Prot database. 
g
Primary biological function obtained from the Human Protein Reference Database (www.hprd.org).   
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3.3.2 MYLR cells are sensitive to Hsp90 inhibitors  
MYLR cells were tested for resistance to other cytotoxic drugs. MYL and MYLR were 
incubated for 48 h with increasing concentrations of imatinib, gemcitabine, Ara-C or 
DADMe-Immucillin-H and cell viability was determined by the MTS assay (Figure 3.4). The 
EC50 of imatinib for MYL was 0.25 µM compared to 4.0 µM for MYLR, consistent with 
previous reports [29]. While MYL cells were sensitive to each drug, MYLR cells were 
coordinately resistant to gemcitabine, Ara-C and DADMe-Immucillin-H. However, MYLR 
and MYL cells were equally sensitive to SNX-7081 and 17-AAG (Figure 3.5), and SNX-
5422 had similar effects to SNX-7081 (data not shown). After a 48 h treatment, the respective 
EC50 values for MYLR and MYL are, for SNX-7081, 53 nM and 48 nM; for SNX-5422, 51 
nM and 55 nM; for 17-AAG, 860 µM and 980 µM.  
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Figure 3.4. Dose-viability curves for MYL and MYLR cells in response to imatinib, gemcitabine, Ara-C 
and DADMe-Immucillin-H. Cells were grown with the indicated concentrations of drugs, imatinib (500 nM, 1 
µM, 5 µM, 10 µM, 48 h), Gemcitabine, Ara-C and DADMe-Immucillin-H (0.5 nM, 5 nM, 50 nM, 500 nM, 5 
µM, 50 µM, 48 h) and viability was determined by the MTS assay. Viability was calculated as a percentage 
compared with the vehicle control that was set as 100%. Error bars represent the mean ± standard deviation (p < 
0.05, n = 3), *** p < 0.001.   
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Figure 3.5. Effects of Hsp90 inhibitors on MYL and MYLR cell viability and growth. (A) Cells were 
cultured with the indicated concentrations of SNX-7081 (25 nM, 50 nM, 100 nM, 500 nM, 1 µM, 48 h) and 
viability was determined by the MTS assay.  (B) Cells were cultured with the indicated concentrations of 17-
AAG (50 nM, 100 nM, 500 nM, 1 µM, 5 µM, 10 µM, 48 h) and viability was determined by the MTS assay. (C) 
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(D) Densities of MYL or MYLR cells were determined by cell counting using a hemocytometer at the indicated 
times and concentrations of SNX-7081. Error bars represent the mean ± standard deviation (p < 0.05, n = 3), * p 
< 0.01.  
 
3.3.3 Decreased pro-survival signaling with Hsp90 inhibitors  
Western blot analysis was performed to investigate Hsp90 inhibitor-induced apoptosis in 
imatinib-resistant MYLR. Incubation of MYL and MYLR cells with increasing 
concentrations of SNX-7081 for 24 h decreased the levels of Lyn, pLyn, BCR-ABL, and Akt 
(Figure 3.6A). The level of Lyn protein was decreased by SNX-5422 or 17-AAG treatment, 
similar to SNX-7081 (Figure 3.6B). MYL cells express two splice variants of Lyn, that 
appear as a doublet in Western blots; MYLR preferentially expresses Lyn kinase B (lower 
band) [196]. Phosphorylation of the signaling protein Stat5 was high in MYLR cells, and 
reduced by SNX-7081 in a dose-dependent manner (Figure 3.6C). Transfection of MYLR 
cells with Lyn siRNA significantly reduced expression of Lyn kinase and phosphorylated 
Stat5 (Figure 3.6D). Transfection of MYLR with a scrambled control siRNA was very 
similar to the untransfected control, which means the introduction of target siRNA did not 
cause non-specific toxic effects during the transfection procedure or during the introduction 
of nucleotides to the cells. 
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Figure 3.6 Effects of Hsp90 inhibitors on pro-survival signaling proteins. (A) Western blots showing levels 
of Lyn kinase, pLyn kinase, BCR-ABL and Akt in MYL and MYLR cells treated with SNX-7081 (24 h). (B) 
Western blots showing levels of Lyn kinase in MYL and MYLR cells treated with SNX-5422 and 17-AAG (24 
h). (C) Western blots showing levels of pStat5 and Stat5 in MYL, MYLR, as well as MYLR treated with SNX-
7081 (24 h). (D) Effects of siRNA-silenced Lyn kinase on pStat5 in MYLR cells. Actin was used as a loading 
control, (p < 0.05, n = 3). 
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3.3.4 Hsp90 inhibition affects both imatinib-sensitive and resistant CML cells 
MYLR cells treated with SNX-5422 (100 nM, 24 h) displayed reduced phosphorylation of 
TrkA (4.32-fold), MSPR (2.61-fold), VEGFR2 (2.72-fold), FGFR3 (3.13-fold), and EphA4 
(4.45-fold) as shown in Figure 3.7. DIGE analysis identified differentially abundant proteins 
in SNX-7081-treated MYL and MYLR cells relative to untreated control cultures. Following 
SNX-7081 exposure (50 nM, 48 h), changes in 6 proteins were common to drug-treated MYL 
and MYLR cells. Four proteins were differentially abundant in drug-treated MYL cells and 
16 proteins changed in treated MYLR cells relative to untreated controls (fold-change >1.30; 
p < 0.05; Table 3.2). Representative proteome maps of SNX-7081-treated MYL and MYLR 
cells are presented in Figure 3.2 C and D. 
 
 
 
Figure 3.7. Effects of SNX-5422 (100 nM, 24 h) on levels of phosphorylated RTK in MYLR cells. Levels of 
42 phosphorylated-RTK were determined and differentially abundant RTK are shown with pixel intensities, 
error bars represent the mean ± standard deviation (p < 0.05, n = 2). 
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3.3.5 Ingenuity pathway analysis  
IPA software was used to investigate the signalling pathways affected by SNX-7081 in MYL 
and MYLR cells based on the differentially abundant proteins identified by DIGE (Table 3.2). 
The top network (score of 30) based on proteins whose abundance changed in MYL cells 
after SNX-7081 are shown in Figure 3.8A; the 2 top scoring networks (scores of 30 and 21) 
for proteins that changed in abundance in MYLR cells after SNX-7081 were merged and 
shown in Figure 3.8B.  These two networks both converge to Ubiquitin C, a precursor protein 
for ubiquitination.  
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Figure 3.8. Protein functional network analysis based on DIGE data generated by IPA software. (A) Top 
network based on proteins differentially abundant between MYL SNX-7081-treated versus MYL control (Table 
3.2). (B) Merged top 2 scoring networks based on differentially abundant proteins between MYLR SNX-7081-
treated versus MYLR control (Table 3.2). Proteins with grey-shaded icons were detected in this study; other 
interacting proteins were identified in the IPA database. Interactional proteins are connected by single lines; 
proteins that affect another protein (by controlling expression) are indicated by arrows. Dashed lines indicate 
indirect interactions. Proteins are indicated by their gene names. 
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3.4 Discussion 
3.4.1 Proteome analysis of imatinib resistance  
Levels of several proteins previously shown to respond to imatinib, changed in MYLR cells 
treated with imatinib. For example, decreased levels in MYLR of ATP-dependent RNA 
helicase DDX3X (1.30-fold, Table 3.1) was suggested as a potential marker for response to 
imatinib by CML [197]. Uroporphyrinogen decarboxylase (UROD) deficiency is a 
documented side-effect of imatinib treatment [198], and depleted UROD in MYLR cells 
(1.30-fold, Table 3.1) was observed here. The signaling molecule Rho-GDI beta, a GTPase 
regulator that controls gene transcription, cell cycle progression, cell morphology, and tumor 
progression [199], decreased in MYLR cells as shown by DIGE analysis (1.40-fold, Table 3.1) 
and Western blot analysis (2.03-fold, Figure 3.3). Imatinib treatment may reduce Rho-GDI 
expression [200], as the Rho pathway is a target of BCR-ABL [201]. Decreased Rho-GDI 
beta levels in MYLR might result from the step-wise increase in imatinib when imatinib-
resistant MYLR was selected from MYL.  
 
Mitochondrial dysfunction plays a role in the development of imatinib resistance via the 
production of mitochondrial ROS, and mitochondrial dysfunction has been observed in both 
BCR-ABL-dependent and independent imatinib resistant cells [202]. Thioredoxin reductase 
deficiency potentiates mitochondrial dysfunction [203], the decreased thioredoxin-dependent 
peroxide reductase (1.40-fold) in MYLR might lead to mitochondrial dysfunction and 
contributed to the development of imatinib resistance in MYLR cells. Imatinib-resistant cells 
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have the TCA (citric acid cycle) cycle inhibition [202], which might explain the TCA enzyme 
malate dehydrogenase is in 1.40-fold lower abundance in MYLR cells. 
 
Several proteins found to be differentially abundant between MYL and MYLR cells are 
important for energy metabolism (Table 3.1). Cancer cells use an up-regulated glycolytic 
pathway for ATP production (Warburg effect) [204], and recent clinical reports suggest that a 
hyperactive glycolytic pathway may correlate with development of imatinib resistance [205]. 
The glycolytic enzymes, glyceraldehyde 3-phosphate dehydrogenase (GAPDH), and 
triosephosphate isomerase (TPI) were both increased 1.60-fold in MYLR cells (Table 3.1). 
Western blot analysis confirmed higher levels of GAPDH (2.41-fold) in MYLR cells (Figure 
3.3). High glycolysis plays a key role in resistance to imatinib via p53 inactivation [206]. 
Previously, siRNA knock-down of GAPDH was shown to re-sensitize resistant cells to 
imatinib [207]. Observations here support the notion that disrupting cancer cell dependence 
on glucose metabolism may enhance the efficacy of and/or overcome resistance to targeted 
molecular therapies [206].  
 
Prohibitin increased by 1.30-fold in MYLR compared with MYL cells (Table 3.1). Prohibitin 
interacts with Rb family proteins to repress E2F-mediated transcription, inducing a block in 
G0/G1 phase of the cell cycle and promoting cancer cells survival [208], making it a 
promising therapeutic target. The anti-cancer drug Rocaglamides targets prohibitin and was 
shown to induce apoptosis in various cancer cells by inhibiting the Raf-MEK-ERK pathway 
[209]. Lentiviral vector-mediated RNA interference (RNAi) of prohibitin inhibits the 
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induction of apoptosis in the acute promyelocytic leukemia cell line, NB4-R1 [210]. 
Inhibitors targeting prohibitin may overcome imatinib resistance. 
 
Several protein changes observed in MYLR cells relative to MYL may be related to enhanced 
Lyn kinase signaling. Peroxiredoxin-2 and thioredoxin-dependent peroxide reductase are 
redox regulating proteins that reduce H2O2 [211, 212], and were decreased in MYLR 
compared with MYL (1.50- and 1.40-fold respectively; Table 3.1). A reduction in these 
antioxidant enzymes may result in higher H2O2 levels in MYLR cells. Lyn kinase activity is 
proportional to the level of H2O2 to mediate leukocyte wound attraction [213], thus increased 
H2O2 may activate Lyn kinase in MYLR cells. Hemoglobin subunit gamma-2 is 1.60-fold 
higher in MYLR cells (Table 3.1). Lyn kinase association with the erythropoietin receptor is 
essential for hemoglobin synthesis in erythro-leukemic cells [214], and high levels of Lyn 
kinase might contribute to the increased level of hemoglobin subunit gamma-2 in MYLR 
cells.  
 
3.4.2 MYLR cells are sensitive to Hsp90 inhibition 
MYLR cells were tested for resistance to other cytotoxic drugs. Gemcitabine and Ara-C are 
nucleoside analogs used to treat acute myeloid leukemia and non-Hodgkin’s lymphoma by 
interfering with DNA synthesis [215]. DADMe-Immucillin-H is an inhibitor of purine 
nucleoside phosphorylase in clinical trial for treatment of T-cell leukemia [216]. MYLR cells 
are resistant to these anti-cancer drugs (Figure 3.4), probably indicating that the differences 
between MYL and MYLR represent a general Lyn kinase-related anti-cancer mechanism. 
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Despite their multi-drug resistance, MYLR cells were sensitive to Hsp90 inhibitors, and the 
novel Hsp90 inhibitors SNX-7081 and SNX-5422 were more effective than 17-AAG (Figure 
3.5). 
 
3.4.3 Decreased pro-survival signaling in response to Hsp90 inhibitors  
Hsp90 inhibitors overcome multi-drug resistance in MYLR cells by inhibiting multiple 
‘client’ proteins including Lyn kinase, pLyn kinase, BCR-ABL, Akt, Stat5 and pStat5. Lyn 
kinase is an up-regulated oncoprotein in MYLR cells that is activated by phosphorylation at 
Tyr397 [14]. BCR-ABL is a major oncoprotein in CML [217], and Akt signaling plays an 
important role in cancer survival. The Stat5 pathway is constitutively activated in many 
hematological cancers [218]. Knocking down Lyn kinase with siRNA reduced 
phosphorylated Stat5 (Figure 3.6D), suggesting that Stat5 is a Lyn substrate affected by 
Hsp90 inhibition in MYLR cells. Similar to Lyn kinase, phosphorylated Stat5 was elevated in 
MYLR cells and reduced by SNX-7081 in a dose-dependent manner (Figure 3.6C). 
Individual cancers may have mutations in more than 90 genes; drugs with specific targets can 
be by-passed by compensatory pathways, leading to drug resistance [219]. Targeting multiple 
signaling pathways has been used to overcome drug resistance in various cancers [220].  
 
3.4.4 Effects of Hsp90 inhibition on proteins in MYL and MYLR cells 
The Hsp90 inhibitor SNX-7081, reduced the phosphorylation of 5 RTKs, TrkA (4.32-fold), 
MSP R (2.61-fold), VEGFR2 (2.72-fold), FGFR3 (3.13-fold), and EphA4 (4.45-fold; Figure 
3.7). Hsp90 inhibition blocks RTK signaling pathways by destabilizing and inactivating 
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RTKs and their downstream nodal effector kinases including Src, Raf-1 and Akt [221]. TrkA 
and FGF R3 are known Hsp90 client proteins [222, 223], and Hsp90 inhibition by 
geldanamycin inactivates VEGFR2 and its downstream signaling partners [224]. EphA4 
forms signaling complexes with two non-RTKs, Lyn kinase and the related tyrosine kinase 
Fyn, in human platelets [225]. Over-expression of EphA4 promotes cancer cell proliferation, 
making it a potential anticancer target [226]. Similar to Lyn kinase, pEphA4 was over-
expressed (2.38-fold, Figure 3.1) in MYLR and depleted (4.45-fold, Figure 3.7) by Hsp90 
inhibition. 
 
Of the SNX-7081-induced protein changes common to both MYL and MYLR cells, several 
chaperone proteins were increased, i.e., heat shock 70 kDa protein 8, heat shock 70 kDa 
protein 9, Hsp 90β, T-complex protein 1 subunit theta (Table 3.2). Increased Hsp90β is 
consistent with gene expression studies showing that cancer cells up-regulate Hsp90β 
expression following Hsp90 inhibition [227]; the binding of an inhibitor to the N-terminal 
ATP pocket of Hsp90 decreases Hsp90 activity [194], and may trigger cells to produce more 
Hsp90. This compensatory response may contribute to cellular resistance to Hsp90 inhibition 
[227], and SNX-7081 may be more effective if cells are repeatedly dosed with the drug to 
overcome this compensatory mechanism. Heat shock 70 kDa protein 8 and heat shock 70 
protein 9 increased in both MYL and MYLR cells after SNX-7081 (Table 3.2). These two 
proteins both belong to the Hsp70 family; protein 8 locates in the nucleus and cytoplasm, 
while protein 9 is mitochondrial [228]. The induction of Hsp70 is the most sensitive marker 
of response to an Hsp90 inhibitor, and induction has been demonstrated at the protein and 
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mRNA level [227, 229]. Like Hsp90, Hsp70 is an ATP-driven molecular chaperone, and 
facilitates Hsp90 recruitment to proteins [230]. Inactivation of Hsp90 may also leave Hsp90 
client proteins in a partially-folded Hsp70-bound state. In this circumstance, Hsp70 facilitates 
ubiquitination of the Hsp90 client proteins, targeting them for proteasomal degradation [231]. 
Hence the increase of Hsp70 may play an important role in preventing the accumulation of 
mis-folded Hsp90 clients. The Hsp70 induction following Hsp90 inhibition is usually 
mediated by the transcription factor, heat shock factor-1 (HSF1) [232]. Under normal 
conditions, HSF1 is held in an inactive state in the cytoplasm bound primarily to Hsp90. 
When cells are treated with an Hsp90 inhibitor, Hsp90 proteins release HSF1; HSF1 
trimerises, and is then phosphorylated and translocated to the nucleus where it induces heat 
shock genes, leading to the increase of Hsp70 [233]. Inhibition of Hsp70 is a potential 
approach for cancer therapeutics, and co-inhibition of Hsp70 and Hsp90 has a synergistic 
anti-cancer effect [234].   
 
SNX-7081 increased levels of the proteasome-related proteins, 26S proteasome non-ATPase 
regulatory subunit 7 (1.30-fold in MYL and 1.50-fold in MYLR) and proteasome activator 
complex subunits 1 and 3 (both 1.30-fold in MYLR, Table 3.2). Proteasomes are part of a 
major mechanism by which cells regulate levels of particular proteins and degrade mis-folded 
proteins. Hsp90 plays a role in maintaining the functional integrity and the ATP-dependent 
assembly of the 26S proteasome [235], and Hsp90 inhibition increases proteasomal 
degradation [236]. Inhibition of Hsp90 causes mis-folding of its client proteins, and triggers 
increases of proteosome proteins to degrade these mis-folded proteins [237]. In CML cells, 
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Lyn kinase is degraded via the proteasome after polyubiquitination mediated by SOCS1 
(suppressor of cytokine signaling 1) [238]. The increase of these proteasome proteins after 
SNX-7081 (Table 3.2) might promote depletion of Lyn kinase.  
 
IPA analysis produced networks based on proteins that changed in abundance after SNX-
7081 treatment of MYL (Figure 3.8A) or MYLR (Figure 3.8B) cells. Both networks 
converged on a common molecule, ubiquitin C (UBC). The UBC gene encodes a protein that 
is a polyubiquitin precursor. Ubiquitin binds to proteins and tags them for degradation [239]. 
The ubiquitin/proteasome system is the major proteolytic system involved in selective 
degradation of short-lived regulatory proteins in eukaryotic cells [240]. Hsp90 inhibitors 
increase ubiquitination [241], and promote the degradation of Hsp90 client proteins via the 
ubiquitin-proteasome pathway [236, 237]. Hsp70 facilitates ubiquitination of the Hsp90 client 
proteins for proteasomal degradation [236], and the increase of Hsp70 promotes substrate 
ubiquitination [236]. Levels of Lyn are reduced by increased ubiquitination with translocation 
of ubiquitin ligase c-Cbl into lipid rafts [242]. E3 ubiquitin ligase c-Cbl, negatively regulates 
Lyn in mast cells [243] and B-cells [244]. The activity of Src kinases is also partly regulated 
by ubiquitination [245, 246]. While not excluding other mechanisms for Lyn reduction, an 
alteration in Lyn expression in B-cells may be partly due to increased ubiquitination and 
degradation [242]. Hsp90 inhibitors may overcome imatinib resistance, down-regulating Lyn 
kinase by increasing ubiquitin-proteasome pathway. 
 
After SNX-7081 treatment, the antioxidant proteins peroxiredoxin-6 and flavin reductase, 
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increased 1.30-fold and 1.60-fold in MYL cells respectively, and catalase increased by 1.40-
fold in MYLR cells (Table 3.2). Similar to other Hsp90 inhibitors such as 17-AAG and 17-
DMAG, SNX-7081 has a benzoquinone structure that may increase the production of ROS 
[237]. Consistent with this, increased levels of antioxidants have been associated with Hsp90 
inhibitor treatment [247]. Oxidative stress induced by Hsp90 inhibition may contribute to the 
drug’s anti-tumor effects, and increases of these antioxidant proteins may limit the 
effectiveness of Hsp90 inhibitors [248]. Synergistic treatment with an antioxidant inhibitor 
might induce more apoptosis. As previously noted, Lyn kinase activity is proportional to 
H2O2 levels [213], and increased levels of antioxidant proteins identified here i.e. catalase, 
peroxiredoxin-6 and flavin reductase, may be related to reduced H2O2 [249, 250] and 
therefore reduced activated Lyn. Catalase can inhibit the phosphorylation of Lyn kinase in 
human neutrophils [251]. The increased levels of these antioxidant proteins induced by SNX-
7081 might contribute to the decreased levels of activated Lyn kinase. 
 
DIGE analysis identified 16 proteins whose levels changed only in SNX-7081-treated MYLR 
cells (Table 3.2). These results provide some insight as to how Hsp90 inhibition overcomes 
imatinib resistance in MYLR cells. Far upstream element binding protein 1 (FBP1) activates 
transcription of the proto-oncogene c-myc, a protein that can induce growth of leukemia cells 
[252]. Over-expression of FBP1 was shown to promote tumor growth, while FBP1 
knockdown reduced cell proliferation [253]. FBP1 was previously identified in the BCR-
ABL over-expressed human CML cell line LAMA 84 R (imatinib-resistant) but not in the 
BCR-ABL wild-type CML cell line LAMA 84 S (imatinib-sensitive) [184]. Although FBP1 
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levels were not significantly different between MYL and MYLR cells, SNX-7081 treatment 
decreased FBP1 by 1.30-fold in MYLR cells (Table 3.2). Thus Hsp90 inhibition by SNX-
7081 might overcome imatinib resistance by reducing FBP1 in MYLR cells. SNX-7081 also 
depleted deoxyuridine 5'-triphosphate nucleotidohydrolase (dUTPase) by 1.30-fold in MYLR 
cells (Table 3.2), also identified in LAM84R but not LAMA84S cells [184]. dUTPase is 
located in mitochondria and catalyzes the hydrolysis of dUTP to dUMP, preventing 
incorporation of dUTP into DNA and providing dUMP for synthesis of thymidylate. dUTPase 
is required for efficient DNA replication and repair [254], and several studies have reported a 
down-regulation of dUTPase during apoptosis [255, 256]. Reduced levels of dUTPase 
observed here might be related to a decrease in DNA replication and repair proteins following 
Hsp90 inhibition [257].  
 
Eukaryotic initiation factor 4A-I (EIF4A1) decreased 1.30-fold in Hsp90-inhibited MYLR 
cells. The eukaryotic translation initiation factor complex eIF4F, comprises 3 proteins in 
mammalian systems: the cap-binding protein eIF4E, the scaffold protein eIF4G, and the ATP-
dependent RNA helicase eIF4A [258]. As we found in Chapter 4, SNX-7081 decreases 
EIF4G in chronic lymphocytic leukemia MEC1 cells [259], and Suzuki et al. reported that the 
Hsp90 inhibition in HeLa cells abrogates co-localization of eIF4E and eIF4E-transporter into 
stress granules, and the association of eIF4E with eIF4G [258]. eIF4F is involved in the 
initiation phase of eukaryotic translation and enhances translational efficiency [260]. 
Inhibition of EIF4F suppresses expression of oncogenes and induces apoptosis in cancer cells 
[261]. When mis-folded proteins accumulate after Hsp90 inhibition, the cell may slow 
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translation by decreasing EIF4F, and thus induce apoptosis. Retinal dehydrogenase increased 
by 2.00-fold in MYLR cells after SNX-7081 (Table 3.2). Retinal dehydrogenase converts 
retinal to retinoic acid that may force differentiation and prevent proliferation [262]. 
Increasing retinal dehydrogenase 1 could reduce cell proliferation after SNX-7081 treatment.  
 
3.5 Conclusions 
A number of differentially abundant proteins related to Lyn kinase-dependent imatinib 
resistance have been identified. For MYLR cells compared with MYL, phosphorylated TrkA, 
VEGF R2, and FGF R3 decreased, while Mer, MSP R, c-Ret, Axl, and EphA4 increased. 
DIGE analysis identified 28 proteins that were differentially abundant by more than 1.30-fold 
(p < 0.05) between MYL and MYLR. DIGE didn’t detect cell signaling proteins due to their 
low abundance, so we used Western blotting and Phospho-RTK antibody arrays for further 
analysis of some specific proteins (Figure 3.1, 3.6, 3.7). MYLR cells are cross-resistant to 
gemcitabine, Ara-C and DADMe-Immucillin-H, consistent with MYLR having acquired a 
general Lyn kinase-dependent survival response. The Hsp90 inhibitor SNX-7081 and its 
glycyl ester, SNX-5422, are toxic to MYL and MYLR cells, and more effective than 17-
AAG. Decreases in pro-survival proteins including Lyn kinase, phosphorylated-Lyn kinase, 
BCR-ABL and Akt induced by Hsp90 inhibitors, may explain how Hsp90 inhibitors 
overcome imatinib resistance. Similar to Lyn kinase, pStat5 and Stat5 were over-expressed in 
MYLR compared with MYL. Silencing of Lyn kinase in MYLR cells with siRNA decreased 
pStat5 demonstrating that the activation of Stat5 is Lyn kinase-dependent in MYLR cells. 
Phosphorylated TrkA, MSP R, VEGF R2, FGF R3, and EphA4 were reduced by Hsp90 
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inhibitor treatment. Similar to Lyn kinase, pEphA4 was over-expressed in MYLR and down-
regulated by an Hsp90 inhibitor. DIGE analysis of SNX-7081 treated MYL and MYLR cells 
(50 nM, 48 h), identified 6 proteins with increased levels in both cell lines, 4 differentially 
abundant proteins in MYL and 16 in MYLR cells alone (Table 3.2). IPA network analysis 
suggests that these protein changes might be related to increased ubiquitination induced by 
SNX-7081 treatment. Therefore Hsp90 inhibitors may overcome Lyn-related imatinib 
resistance in MYLR cells by decreasing over-expressed Lyn kinase and its substrate protein 
pStat5 via increasing ubiquitin/proteasome proteins and antioxidant proteins.  
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4.1 Introduction 
B-cell chronic lymphocytic leukemia (CLL) is the most common adult leukemia in Western 
countries [263]. CLL is characterized by the accumulation of clonal B-lymphocytes in the 
peripheral circulation, bone marrow, lymph nodes and spleen. In later stages of the disease, 
up to 99% of the circulating peripheral blood leukocytes may be leukemic [264]. The 
incidence of CLL increases with age, averaging 72 years at diagnosis [265]. CLL is 
predominantly a result  of a decrease in the rate of apoptosis of B-lymphocytes rather than 
increased proliferation, with cells surviving in vivo for several months compared to a few 
days for normal B-lymphocytes [266]. Enhanced cell survival may be the result of multiple 
mutations in proteins involved in signalling pathways that normally lead to cell death, such as 
p53, PKR (protein kinase R) and DAPK1 (death associated protein kinase 1), and activation 
of survival pathways by up-regulation of BCR (B-cell receptor), Syk (spleen tyrosine kinase), 
PI3K (phosphoinositide 3-kinase), Akt (protein kinase B), and NFkB (nuclear factor-kappaB) 
[264]. 
 
Despite the high efficacy of FCR (fludarabine, cyclophosphamide, and rituximab), the front-
line chemo-immunotherapy regimen, a significant proportion of CLL patients eventually 
relapse and develop drug-resistance [267]. Patients with mutated p53 respond poorly to FCR 
[268]. p53 is the most documented oncogene, mutated in more than 50% of cancers and 10–
15% of CLL [32]. p53 may be subject to point mutations or deletion of the gene on 
chromosome 17p [269]. p53 is a transcription factor that is phosphorylated and accumulates 
following DNA damage, coordinating the cellular response, and triggering  cell-cycle arrest 
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or apoptosis [270]. Loss of p53 function results in decreased activation of p53 target genes 
[271], and decreased levels of death effectors such as Bax [272], the BH3-only proteins Noxa 
or Puma [273], and APAF-1 [274]. In CLL, p53 mutation is linked to resistance to alkylating 
agents and purine analogs, i.e., cyclophosphamide and 2-FaraA, in vitro [75, 275] and in vivo 
[263, 276]. Given the poor prognosis for CLL patients with 2-FaraA-refractory CLL as a 
result of mutated p53 [277], new therapeutic options  are  required.   
 
Heat shock protein 90 (Hsp90) is a molecular chaperone that ensures the correct folding and 
stability of more than 200 ‘client’ proteins, many of which are oncoproteins including Src, 
PI3K, Akt, BCR-ABL, c-Kit, and mutant p53 [83, 86, 192, 278-283]. Hsp90 is highly 
expressed by a variety of cancers, including CLL, and stabilises mutant or abundant 
oncoproteins, leading to inhibition of apoptosis and enhanced cell proliferation [284-286]. 
Hsp90 has been proposed as a molecular target for therapy [86]. Geldanamycin, a naturally 
occurring Hsp90 inhibitor, induces apoptosis in lymphoma [287] and leukemia cells [102] in 
a p53-independent manner. The mechanisms underlying Hsp90 inhibitor-induced p53-
independent apoptosis are still undefined but will likely vary with cell type and mutational 
status. Derivatives of geldanamycin, including 17-AAG (17-N-allylamino-17-
demethoxygeldanamycin) have had limited success in clinical trials due to their poor 
solubility and toxicity [91]. Several companies have developed synthetic Hsp90 inhibitors 
including a family of compounds developed by Serenex (now Pfizer, New York, NY, USA). 
One of these compounds, SNX-7081, is significantly more potent than 17-AAG, against CLL 
cell lines and primary cells [102]. Studies in rats demonstrate that this family of compounds 
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is orally bio-available with good pharmacokinetic properties [104].  
 
In this chapter, we investigate the effects of SNX-7081 on the proteome of the human CLL 
cell line, MEC1. MEC1 cells have a deletion in the short arm of chromosome 17 (17p-), the 
locus for p53, and a mutation in the remaining allele, which most likely explains their 
resistance to 2-FaraA [30, 32]. MEC1 represents a good model for investigating the potential 
of drugs for the treatment of p53-mutated CLL. To confirm the p53-independent mechanism 
of action of SNX-7081, we assessed the effects of the Hsp90 inhibitor on the p53 wild-type 
Raji (B-cell Burkitt's lymphoma), p53-mutated U266 (myeloma cells) [42], and p53-null 
HL60 (acute myeloid leukemia) [40] cell lines. Both alleles of the p53 gene in Raji cell have 
point mutations, but neither of the alleles is inactivated by the mutation [37]. p53 in Raji 
responses to 2-FaraA treatment [32], and Raji has always been used as a p53 wild-type cell 
[38]. Sub-cellular fractionation of MEC1 reduced proteomic complexity and provided 
information on the cellular localization of differentially-abundant proteins. Peptides were 
labelled with isobaric tags for relative and absolute quantitation (iTRAQ) before analysis by 
2D liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS) to identify 
and quantify protein changes in cells induced by SNX-7081. The data obtained further our 
understanding of the mechanisms by which Hsp90 inhibitors induce apoptosis in CLL cells 
with mutated p53. Furthermore, the differentially abundant proteins identified may be 
therapeutic targets and may provide rationales for development of combination therapies for 
management of CLL.  
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4.2 Materials and Methods 
As described in section 2.4 in Chapter 2. 
 
4.3 Results 
4.3.1 SNX-7081 induces apoptosis in MEC1 cells  
MEC1 cells were treated with SNX-7081 (0.01, 0.05, 0.1, 0.5 and 1 µM) for 24, 48 and 72 h, 
and the proportions of viable cells were determined by the MTT assay relative to a control 
culture at the same time points (Figure 4.1). SNX-7081 reduced MEC1 cell viability in a 
concentration and time-dependent manner. Further studies were conducted using 500 nM 
SNX-7081 for 24 h, a dose that was found to reduce cell viability by 60% compared to a 
control. 
 
 
 
 
 
 
 
 
Figure 4.1. Viability of MEC1 cells as a function of SNX-7081 concentration. Cells were treated for the 
indicated times and concentrations of SNX-7081. Results were calculated from biological triplicates relative to 
controls using the MTT assay for cell viability. Error bars show standard deviations.  
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4.3.2 The effect of SNX-7081 on the cell cycle of MEC1  
The effect of SNX-7081 (500 nM, 24 h) on the MEC1 cell cycle was determined by flow 
cytometry (Figure 4.2). Following SNX-7081 treatment, the proportion of cells in S-phase 
decreased (41% to 11%), with a concomitant accumulation of cells in G0/G1 (from 45% to 
54%) and G2/M phase (from 14 to 35%). During apoptosis, DNA is cleaved into small 
fragments that can be liberated from permeabilised cells by washing, resulting in an 
accumulation of cells in a sub-G1 phase. Figure 4.2 depicts the increased proportion of cells 
with a sub-G1 DNA content (8 to 36%) following SNX-7081, consistent with the increase in 
cell death observed in Figure 4.1.           
          
Figure 4.2. Effects of SNX-7081 on the distribution of MEC1 cells in the cell cycle. Relative proportions of 
cells are shown for control and SNX-7081-treated cells (500 nM, 24 h) in sub-G1, G0/G1, S, and G2/M phases. 
Sub-G1 cells contain less DNA than G0/G1 due to leakage of fragmented DNA, providing a measure of the 
proportion of apoptotic cells. Results were acquired as biological triplicates, values and error bars represent the 
mean ± standard deviation, p < 0.01. 
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4.3.3 Effect of SNX-7081 on sub-cellular proteomes of MEC1  
Differentially abundant proteins were identified from MEC1 cells treated with SNX-7081 
(500 nM, 24 h) relative to control cultures. Totals of 835, 811 and 839 proteins were detected 
in the nuclear, cytosolic and mitochondrial fractions, respectively (>95% confidence). 
Nuclear (31), cytosolic (16) and mitochondrial (4) proteins were identified with a differential 
abundance greater than 2-fold (p < 0.05, Table 4.1), and classified into functional groups 
according to the UniProtKB/Swiss-Prot database (http://www.uniprot.org; Figure 4.3). The 
nuclear proteins identified have roles in DNA replication and repair (29%), RNA processing 
(23%), nuclear transport (16%) and transcriptional regulation (13%). Of the cytosolic 
proteins identified, most are chaperones (69%), comprised of 38% cytosolic and 31% 
endoplasmic reticulum chaperones. The majority of the differentially abundant mitochondrial 
proteins have roles as transporters for iron, ADP, ATP and dicarboxylic acids.   
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Table 4.1. Differentially abundant proteins (p < 0.05) in MEC1 cells treated with SNX-7081 (500 nM, 24 h). 
Accession no.
a
 Protein name
b
 Gene name Function
c
 
Ratio 
treated/control
d
 
p‐value
e
 
Nuclear proteins 
P63208 S‐phase kinase‐associated protein 1 (p19A) SKP1 Cell cycle 0.40 0.0034 
Q07666 Src‐associated in mitosis 68 kDa protein (Sam68) SAM68 Cell cycle 2.01 0.0209 
Q16531 DNA damage‐binding protein 1 (DDB1) DDB1 DNA replication and repair 0.34 0.0003 
B5BUB1 RuvB‐like 1  RUVBL1 DNA replication and repair 0.48 0.0026 
Q9Y230 RuvB‐like 2  RUVBL2 DNA replication and repair 0.50 0.0196 
Q09028 Histone‐binding protein RBBP4 (RBBP4) RBBP4 DNA replication and repair 0.49 0.0065 
P12004 Proliferating cell nuclear antigen (PCNA) PCNA DNA replication and repair 0.25 0.0003 
B7Z8Z6 DNA replication licensing factor MCM2 (MCM2) MCM2 DNA replication and repair 0.34 0.0008 
B4DWW4 DNA replication licensing factor MCM3 (MCM3) MCM3 DNA replication and repair 0.35 0.0006 
B4DLA6 DNA replication licensing factor MCM4 (MCM4) MCM4 DNA replication and repair 0.33 0.0001 
Q14566 DNA replication licensing factor MCM6 (MCM6) MCM6 DNA replication and repair 0.31 0.0001 
P02545 Lamin‐A/C  LMNA Nuclear assembly 0.48 0.0195 
P20700 Lamin‐B1  LMNB1 Nuclear assembly 0.43 0.0000 
P12270 Nucleoprotein TPR  TPR Nuclear transport 0.40 0.0018 
Q8N6V5 NUP50 protein (Nup50) NUP50 Nuclear transport 0.46 0.0021 
O75694 Nuclear pore complex protein Nup155 (Nup155) NUP155 Nuclear transport 0.44 0.0017 
Q8N1F7 Nuclear pore complex protein Nup93 (Nup93) NUP93 Nuclear transport 0.44 0.0002 
B2RBR9 Homo sapiens karyopherin (importin) beta 1 (KPNB1) KPNB1 Nuclear transport 0.39 0.0006 
O00566 U3 small nucleolar ribonucleoprotein protein MPP10 
(MPP10) 
MPP10  RNA processing 0.39 0.0014 
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Accession no.
a
 Protein name
b
 Gene name Function
c
 
Ratio 
treated/control
d
 
p‐value
e
 
P17844 Probable ATP‐dependent RNA helicase DDX5 (DDX5) DDX5 RNA processing 0.42 0.0069 
B2R6L4 RNA polymerase IIA 25 kd subunit (XAP4) POLR2E RNA processing 0.42 0.0090 
Q59EL4 PRPF4 protein variant (PRPF4) PRPF4 RNA processing 0.47 0.0082 
Q9BWF3 RNA‐binding protein 4  RBM4 RNA processing 0.46 0.0092 
B2RWN5 HEAT repeat containing 1 HEATR1 RNA processing 0.45 0.0031 
O75643 U5 small nuclear ribonucleoprotein 200 kDa helicase 
(U5‐200KD) 
SNRNP200 RNA processing 0.47 0.0061 
O14497 AT‐rich interactive domain‐containing protein 1A (B120) ARID1A Transcription factor 0.50 0.0009 
Q58EY4 SWI/SNF related, matrix associated, actin dependent 
regulator of chromatin, subfamily c, member 1  
SMARCC1  Transcription factor 0.50 0.0228 
Q9UKT9 Zinc finger protein Aiolos  IKZF3 Transcription factor 0.50 0.0010 
Q13951 Core‐binding factor subunit beta (CBF‐beta) CBFB Transcription factor 0.49 0.0129 
Q9H8H0 Nucleolar protein 11  NOL11  – 0.45 0.0009 
A8MXW4 CDW3/SMU1  SMU1  – 0.49 0.0000 
Cytosolic proteins 
Q92598 Heat shock protein 105 kDa (Hsp105) HSPH1 Cytosolic chaperone 2.03 0.0020 
Q6FI51 DNAJB1 protein  DNAJB1 Cytosolic chaperone 3.10 0.0001 
P11142 Heat shock cognate 71 kDa protein (Hsp71) HSPA8 Cytosolic chaperone 3.47 0.0001 
P04792 Heat shock protein beta‐1 (HspB1) HSPB1 Cytosolic chaperone 3.50 0.0263 
P08107 Heat shock 70 kDa protein 1 (Hsp70) HSPA1A Cytosolic chaperone 6.10 0.0002 
P07900 Heat shock protein HSP 90‐alpha (Hsp90) HSP90AA1 Cytosolic chaperone 2.26 0.0025 
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Accession no.
a
 Protein name
b
 Gene name Function
c
 
Ratio 
treated/control
d
 
p‐value
e
 
P11021 78 kDa glucose‐regulated protein (GRP78) GRP78 Endoplasmic reticulum chaperone 0.38 0.0066 
Q5CAQ5 Tumor rejection antigen (Gp96) 1 (TRA1) TRA1 Endoplasmic reticulum chaperone 0.49 0.0218 
B3KY95  Protein disulfide‐isomerase A6 (PDIA6) PDIA6 Endoplasmic reticulum chaperone 0.50 0.0108 
P07237 Protein disulfide‐isomerase (PDI) P4HB Endoplasmic reticulum chaperone 0.40 0.0017 
Q53G71 Calreticulin variant (ERp60) CALR Endoplasmic reticulum chaperone 0.48 0.0008 
P13639 Elongation factor 2 (EF‐2) EEF2 Translation 0.33 0.0000 
Q4LE58 EIF4G1 variant protein (EIF4G1) EIF4G1  Translation 0.41 0.0007 
Q4LE83 Fatty acid synthase FASN Fatty acid biosynthesis 0.40 0.0001 
B2RDA5 Homo sapiens myxovirus (influenza virus) resistance 1, 
interferon‐inducible protein p7  
MX1 GTP binding 0.49 0.0110 
Q5SP06 Major histocompatibility complex, class II, DR alpha 
(HLA‐DR) 
HLA‐DRA Immune response 0.44 0.0032 
Mitochondrial proteins 
P04181 Ornithine aminotransferase, mitochondrial  OAT Amino acid biosynthesis 0.42 0.0005 
Q02978 Mitochondrial 2‐oxoglutarate/malate carrier protein 
(OGCP) 
SLC25A11 Transport (dicarboxylic acids) 0.47 0.0416 
P05141 ADP/ATP translocase 2 (ANT 2) SLC25A5 Transport (ADP and ATP) 0.48 0.0106 
Q96NB2 Sideroflexin‐2  SFXN2 Transport (iron) 0.46 0.0038 
a
Accession numbers are from the UniProtKB/Swiss‐Prot database. 
b
Protein name with short name in bracket derived from  UniProtKB/Swiss‐Prot database. 
c
The 
molecular functions were assigned using the latest version of the UniProtKB/Swiss‐Prot database, – function not available. 
d
The ratio is calculated by ProteinPilot 
software based on biological triplicates of MEC1 control and SNX‐7081‐treated (500 nM, 24 h). 
e
Student t‐test assuming equal variance set at 95% significance level. 
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Figure 4.3. Biological functions of differentially abundant proteins in MEC1 cells treated with SNX-
7081 (500 nM, 24 h) from the nuclear, cytoplasmic and mitochondrial fractions. The Uniprot database 
(www.uniprot.org) was used to group the proteins according to their functions. 
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IPA software was used to investigate the signalling pathways affected by SNX-7081 
based on the differentially abundant cytosolic, nuclear and mitochondrial proteins with 
fold-changes of at least 1.25 (p < 0.05). The IPA knowledgebase was restricted to human 
immune, leukemia and lymphoma cells. The 2 top scoring networks showed overlap of 
transcriptional regulation or binding to c-Myc (Hsp beta-1, HSPB1; histone H4, 
HIST1H4A; exosome complex component RRP43, EXOSC8; and peroxiredoxin-1, 
PRDX1). These networks had independent scores of 16 and 11, with 15 and 13 focus 
molecules, and are involved in ‘cancer, haematological disease and cell death’ and ‘cell 
cycle, cellular assembly and organisation, and DNA replication, recombination and 
repair’, respectively. Of the 58 proteins in the merged network, 44 are involved in 
apoptosis, 43 in cancer, 34 in the cell cycle and 33 in DNA replication, recombination 
and repair. A simplified merged network showing a convergence on c-Myc, as well as 
cyclin D1 (CCND1) and retinoblastoma protein 1 (pRb) is depicted in Figure 4.4. 
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Figure 4.4. Merged protein functional network generated by IPA software. Proteins with grey shaded 
icons were detected in this study, other interacting proteins were identified in the IPA database. Protein-
protein interactions are indicated by edges with single lines, proteins that affect another protein (by 
controlling expression) are indicated by arrows. Dashed lines indicate indirect interactions. Proteins are 
indicated by their gene names. The corresponding protein names are: CCND1, cyclin D1; CCT2, 
chaperonin containing TCP1, subunit 2 (beta); CCT8, chaperonin containing TCP1, subunit 8 (theta); 
CDK1, cyclin-dependent kinase 1; CDK11A, cyclin-dependent kinase 11A; CDK11B, cyclin-dependent 
kinase 11B; CPSF3, cleavage and polyadenylation specific factor 3; DNAJA1, DnaJ homolog subfamily A 
member 1; DNAJB1, DnaJ homolog subfamily B member 1; EXOSC8, exosome component RRP43; 
FASN, fatty acid synthase; HIST1H4A, histone H4; HSP90AB1, heat shock protein 90 kDa-beta; HSPB1, 
heat shock protein beta-1; IKZF3, IKAROS family zinc finger 3 (Aiolos); ITGB2, integrin beta 2; MCM7, 
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mini-chromosome maintenance complex component 7; MYC, c-Myc; MAT2A, methionine 
adenosyltransferase II, alpha; MZB1, marginal zone B and B1 cell-specific protein; PCNA, proliferating 
cell nuclear antigen; PRDX1, peroxiredoxin-1; RB1, retinoblastoma protein (pRb); RBBP4, retinoblastoma 
binding protein 4; RFC2, replication factor C (activator 1) 2; SAFB, scaffold attachment factor B; 
SMARCC1, SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily c, 
member 1.  
 
 4.3.4. Validation of differentially abundant proteins  
The relative abundances of key proteins identified by LC-MS/MS and predicted by IPA 
software were confirmed by Western blotting of sub-cellular fractions of MEC1 (Figure 
4.5A, B). In the cytosolic fraction, Western blotting confirmed increases in Hsp90 (2.21-
fold, p=0.0253) and Hsp70 (4.10-fold, p=0.0072) following SNX-7081 (500 nM, 24 h).  
Significant decreases in GRP78 (16.7-fold, p=0.0354), PDIA6 (1.85-fold, p=0.0372), and 
HLA-DR (1.67-fold, p=0.0441) were all confirmed. In the MEC1 nuclear fraction, DDB1 
(2.04-fold, p=0.0213), PCNA (2.33-fold, p=0.0385), and MCM2 (2.63-fold, p=0.0052) 
decreased. Changes in the levels of 3 key proteins predicted by IPA software were 
confirmed by Western blotting of the MEC1 nuclear fraction; the abundances of cyclin 
D1 (1.57-fold, p=0.0384) and pRb (1.53-fold, p=0.0192) were increased, while c-Myc 
(2.08-fold, p=0.0062) decreased after SNX-7081. p53 protein levels did not change in the 
MEC1 nuclear fraction following drug exposure, supporting the hypothesis that apoptosis 
induced by SNX-7081 in p53-mutated MEC1 is independent of p53.  
 
Quantitative RT-PCR was used to detect changes in mRNA levels for the genes encoding 
the differentially abundant proteins identified by iTRAQ analysis in MEC1 cells (Figure 
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4.5C). Hsp70 mRNA increased (8.63-fold, p=0.0001) following SNX-7081 (500 nM, 24 
h), while there were decreases in the levels of mRNAs for GRP78 (2.38-fold, p=0.0024), 
PDIA6 (1.79-fold, p=0.0069), HLA-DR (5.56-fold, p=0.0009), PCNA (4.76-fold, 
p=0.0002), MCM2  (2.22-fold, p=0.0033), and Nup155 (2.63-fold, p=0.0237). These 
changes are consistent with changes in protein levels observed by LC-MS/MS and 
Western blotting (Figure 4.5A,B, Table 4.1). 
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Figure 4.5. Levels of MEC1 protein in nuclear and cytosolic fractions and mRNAs affected by SNX-
7081 (500 nM, 24 h). (A) Western blots of the indicated proteins in MEC1 nuclear or cytosolic fractions 
with actin as internal control (n = 3). (B) Relative protein levels in MEC1 nuclear or cytosolic fractions 
based on Western blotting. Results are expressed as ratio from biological triplicates relative to controls 
(actin). (C) Relative levels of indicated mRNAs in MEC1 cells determined by RT-PCR. Results are shown 
as ratios of biological triplicates relative to control (18S mRNA), error bars represent mean ± standard 
deviation (n = 3), significant changes (p < 0.05) are indicated by (*) relative to the control (n = 3). 
 
To confirm that SNX-7081 induces cell cycle arrest and inhibition of DNA replication 
and repair irrespective of p53 status, p53, DDB1, MCM2, pRb, c-Myc, Cyclin D1 and 
PCNA levels were measured before and after SNX-7081 treatment (500 nM, 24 h) in a 
panel of cell lines with different p53 mutational states (p53 wild-type Raji, p53-mutant 
MEC1 and U266, and p53-null HL60). As shown in figure 4.6, p53 was not detected in 
p53-null HL60 cells, and levels remained unchanged in MEC1, U266, and Raji cells 
following SNX-7081 treatment. After SNX-7081 exposure, however, levels of DDB1, 
MCM2, c-Myc, and PCNA decreased, while pRb and cyclin D1 increased. These results 
are consistent with the LC-MS/MS and Western blotting analyses on MEC1 sub-cellular 
fractions.  
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Figure 4.6. Levels of key proteins in whole cell lysates of MEC1, U266, Raji and HL60 cells treated 
with SNX-7081 (500 nM, 24 h). (A) Western blots of the indicated proteins in MEC1, U266, Raji and 
HL60 whole cell lysates with actin as internal control (n = 3). (B) Relative protein levels in MEC1, U266, 
Raji and HL60 whole cell lysates based on Western blotting. Results are shown as ratios of biological 
triplicates relative to controls (actin), error bars represent mean ± standard deviation (n = 3), significant 
changes (p < 0.05) are indicated by (*) relative to the control (n = 3). 
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4.4 Disccussion 
Drug resistance is a major challenge for the clinical management of CLL. Recent trials of 
the FCR regimen have shown high response rates, however the success of therapies for 
patients with p53-mutated CLL is extremely limited [288]. In a recent study, we showed 
that inhibition of Hsp90 may overcome resistance to 2-FaraA in the p53-mutated cell line, 
MEC1, and in CLL patient samples [102]. However, the mechanisms by which Hsp90 
inhibition induces p53-independent apoptosis are largely unknown. To elucidate the 
cytotoxic mechanisms of SNX-7081 against MEC1 cells, iTRAQ labelling coupled with 
LC-MS/MS was used to identify changes in protein abundance following exposure to the 
drug (Table 4.1). Functional associations between the differentially abundant proteins 
identified networks important in apoptosis, cancer, cell cycle and DNA replication, 
recombination and repair. Results of Western blotting and RT-PCR were consistent with 
the results of our LC-MS/MS analysis, suggesting that SNX-7081 induces changes in 
protein stability and transcription. Previous reports indicate that Hsp90 inhibitors affect 
the mRNA and protein levels of BIM, Mcl-1, Nox1 and Noxo1 [289, 290]. The Hsp90 
inhibitor geldanamycin, was reported to up-regulate Hsp70 through mRNA stabilization 
[291]. Here, we demonstrate that Hsp90 inhibition down-regulates mRNA and protein for 
GRP78, PDIA6, HLA-DR, PCNA, MCM2, and Nup155 in MEC1 cells. SNX-7081 
decreased 4 transcription factors (AT-rich interactive domain-containing protein 1A, 
SWI/SNF-related matrix-associated actin-dependent regulator of chromatin sub-family c 
member 1, zinc finger protein Aiolos and core-binding factor subunit beta; Table 4.1), 
that may account for the decreases in the mRNAs observed. Further investigations of the 
effects of Hsp90 inhibitors on mRNA levels are warranted.  
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 4.4.1 Effects of SNX-7081 on cell cycle proteins 
Levels of several proteins known to regulate the cell cycle were also changed by SNX-
7081 in MEC1 cells. Inhibition of Hsp90 induces cell cycle arrest in cancer cells [292, 
293], but the underlying mechanisms are not clear. Analysis of MEC1 cells treated with 
SNX-7081 showed blockade of the cell cycle in S-phase, with accumulation of cells in 
the G0/G1 and G2/M phases (Figure 4.2). LC-MS/MS analysis of SNX-7081-treated 
cells identified S-phase kinase-associated protein 1, an important signal transduction 
protein in the transition between G1 and S phases [294], been recorded as a depletion in 
the treated cells compared to untreated of 2.50-fold. Decreased levels of this protein may 
contribute to the blockade of entry into S-phase observed in Figure 4.2. Similarly Src-
associated in mitosis 68 kDa protein which is involved in G2/M progression [295], 
increased by 2.01-fold following SNX-7081  possibly contributing to the increased 
proportion of MEC1 cells in G2/M phases (Figure 4.2). 
 
IPA software was used to map a network of interacting proteins whose levels changed 
following SNX-7081 treatment (Figure 4.4). The interaction network converged on 3 key 
proteins, cyclin D1, pRb and c-Myc, all of which displayed significant differential 
abundance in the nuclear fraction of MEC1 (increased 1.57, 1.53, and decreased 2.08-
fold, respectively). Changes in these protein levels might be direct effects from Hsp90 
inhibition or a result of changing activity of transcription factors or kinases. Cyclin D1 is 
a key regulator of G1 phase; increased levels of cyclin D1 accelerate the transition 
through G1 phase, but prevent entry to S phase [296], causing G2/M phase arrest [102]. 
After SNX-7081, the proportion of MEC1 cells in G0/G1 phase increased from 45 to 
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54%, cells in S phase decreased from 41 to 11%, and cells in G2/M phase increased from 
14 to 35% (Figure 4.2). It is conceivable that the changes observed in the distribution of 
MEC1 cells in the cell cycle may be related to the increased abundance of cyclin D1 
(Figure 4.4). Western blotting analysis further confirmed increases of cyclin D1 in U266, 
Raji and HL60 cells following SNX-7081 treatment. 
 
4.4.2 SNX-7081 compromises DNA replication and repair 
Cyclin D1 also plays a role in DNA repair [297]. Although reduced level of cyclin D1 in 
cancer cells can compromise DNA repair [297, 298], its over-expression can also prevent 
DNA repair and enhance DNA damage-induced apoptosis [102, 296]. Cyclin D1 binds to 
PCNA, enhancing the ability of cells to repair DNA [296]. PCNA could hasten DNA 
replication and repair by promoting the recruitment of DNA polymerase to DNA strand 
breaks [299]. Here, PCNA levels were decreased in MEC1, U266, Raji and HL60 cells 
after SNX-7081, consistent with a reduced capacity for DNA repair and with previous 
findings [300]. Cyclin D1 over-expression has also been reported to decrease fatty acid 
synthase (FASN) protein in lymphoma cells [301]. We observed a 2.50-fold decrease of 
FASN following SNX-7081, which may be related to the increase of cyclin D1. A recent 
study of breast cancer cells indicated that FASN over-expression might regulate the DNA 
damage/repair pathway and provide resistance to DNA-damaging drugs [302, 303]. 
Together, these results suggest that an increase in cyclin D1 following Hsp90 inhibition 
may be an important component in a network of proteins involved in DNA repair.  
 
The oncogene c-Myc is involved in cell proliferation and apoptosis and plays a direct role 
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in the control of DNA replication. The decrease of c-Myc observed in all cell lines tested, 
might contribute to a decrease in the DNA repair and replication capacity of Hsp90-
inhibited cells. Interestingly, it was recently reported that c-Myc suppresses cyclin D1 
levels [304]. Thus the elevated cyclin D1 observed here might be related to a depletion of 
c-Myc. pRb is a tumour suppressor protein that prevents cells transitioning into the S 
phase of the cell cycle [305]. Western blotting analysis confirmed an increase of pRb in 
MEC1, Raji and HL60 cells, but was undetected in U266 cells, perhaps due to a 
dysfunctional pRb as seen in some cancers [306]. pRb also interacts with cyclin D1 to 
regulate the cell cycle [305, 307] (Figure 4.4). The increase in pRB in response to SNX-
7081 may also explain the decreased proportion of MEC1 cells in S phase (from 41 to 
11%) after SNX-7081. Furthermore, pRb inhibits DNA replication through association 
with DNA replication licensing factor MCM7 [308], an association that is supported by 
our data showing that MCM7 levels were decreased by 1.85-fold after SNX-7081. pRb 
also interacts with other DNA replication and repair proteins, i.e., SAFB (scaffold 
attachment factor B) and RBBP4 (retinoblastoma-binding protein 4), that we found 
decreased following SNX-7081 by 1.45-fold and 2.04-fold, respectively.  
 
This project is the first to discover decreases in DNA repair proteins in response to Hsp90 
inhibition, namely DNA damage-binding protein 1 (DDB1), RuvB-like 1 and RuvB-like 
2. DNA damage-binding protein 1 (DDB1) plays a role in the detection and repair of UV-
induced DNA damage [309], while RuvB-like 1 and 2, are found in several high-
molecular-weight chromatin-remodelling complexes that maintain DNA repair and 
transcription [310, 311]. We report here for the first time decreased levels of several 
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mini-chromosome maintenance (MCM) proteins and the histone-binding protein RBBP4 
in response to Hsp90 inhibition. Decreases in DDB1 and MCM2 were also observed in 
U266, Raji and HL60 cell lines after SNX-7081.  
 
p53 levels did not change upon SNX-7081 treatment in p53-mutated MEC1, U266 cells 
and p53 wild-type Raji cells, which is consistent with the previous reports and 
implicating Hsp90 inhibitors has a p53-independent mechanism of action [102, 312, 313]. 
The decreases of DDB1, MCM2, c-Myc, and PCNA, and increases of pRb and cyclin D1 
were confirmed in MEC1, U266, Raji, and HL60 cells by Western blotting, indicating 
SNX-7081 arrests cell cycle and inhibits DNA replication and repair, and provide a 
rationale for synergistic combinations of Hsp90 inhibitors and DNA damaging agents 
such as fludarabine [314], radiation [315, 316], or topoisomerase II inhibitors [317].  
 
4.4.3 SNX-7081 decreases RNA processing proteins, transcription factors and 
nuclear transport proteins  
In addition to the effects of SNX-7081 on DNA repair and replication, 7 proteins 
involved in RNA processing were decreased by more than 2-fold in MEC1 cells. Six of 
these (U3 small nucleolar ribonucleoprotein protein MPP10, probable ATP-dependent 
RNA helicase DDX5, PRPF4 protein variant, RNA-binding protein 4, HEAT repeat 
containing 1, U5 small nuclear ribonucleoprotein 200 kDa helicase) have not been 
previously attributed to Hsp90 regulation. In agreement with these findings, Connor et al. 
reported Hsp90 inhibitor-induced depletion of RNA polymerase [318]. RNA processing 
is critical for the proliferation of tumour cells and RNAi knock-down of RNA processing 
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proteins in human ovarian cancer cells induces apoptosis [319]. The current study 
implicates inhibition of RNA processing as a mechanism underlying the anti-proliferative 
effects of SNX-7081 on MEC1 CLL cells. 
 
Four transcription factors were decreased by more than 2-fold by SNX-7081 in MEC1 
cells (Table 4.1). The SWI/SNF chromatin remodelling complexes regulate transcription 
of certain genes by altering chromatin structure. These complexes may have roles as 
tumour suppressors or be required for the activity of other tumour-suppressor genes [320, 
321]. Core-binding factor subunit beta is a non-DNA-binding sub-unit of the Cbf family 
of hetero-dimeric transcription factors, that is important in hematopoietic maturation, 
bone formation and normal differentiation of lymphoid and myeloid lineage cells [322]. 
Several nuclear pore complex (NPC) proteins including Nup50, Nup155, Nup93 and 
Nucleoprotein TPR, decreased more than 2-fold after SNX-7081 in MEC1 cells. The 
NPC is the ‘gateway’ between the nucleus and cytoplasm. Hsp90 is an essential 
molecular chaperone for nuclear transport [323], and SNX-7081-induced depletion of 
these proteins would likely reduce translocation of proteins through the nuclear pore. 
 
4.4.4 SNX-7081 increases cytosolic chaperones but decreases endoplasmic reticulum 
chaperones 
SNX-7081 has differential effects on cytosolic and ER chaperones in MEC1 cells. We 
observed increases in the cytosolic chaperones, heat shock protein 105 kDa (Hsp105, 
2.03-fold), DNAJB1 protein (3.10-fold), heat shock cognate 71 kDa protein (Hsp71, 
3.47-fold), heat shock protein beta-1 (HspB1, 3.50-fold), heat shock 70 kDa protein 1 
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(Hsp70, 6.10-fold), and Hsp90 (2.26-fold). By contrast, SNX-7081 decreased the 
expression of the ER chaperones 78 kDa glucose-regulated protein (GRP78, 2.63-fold), 
tumour rejection antigen (Gp96) 1 (TRA1, 2.04-fold), protein disulfide-isomerase A6 
(PDIA6, 2.00-fold), protein disulfide-isomerase (PDI, 2.50-fold), and calreticulin variant 
(ERp60, 2.08-fold). Increases in the expression of cytosolic chaperones may be indicative 
of a stress response to drug treatment, or compensation for Hsp90 inhibition, e.g., Hsp70 
is a complementary chaperone to Hsp90 and increases upon Hsp90 inhibition [229]. The 
ER chaperone, GRP78 was reported to protect cells from apoptosis [324], and depleted 
levels have been linked with the induction of p53-independent apoptosis [325]. The ER 
chaperones identified in our study may well contribute to the induction of apoptosis in 
MEC1 cells. 
 
4.4.5 Other protein changes 
Hsp90 is required for the expression of elongation factor 2 (EF-2), a target for anticancer 
drugs [326]. Hsp90 inhibitors disrupt formation of the EF-2/Hsp90 protein complex [327]. 
SNX-7081 decreased EF-2 by 3.03-fold in MEC1 cells. EIF4G variant protein is a 
component of the eukaryotic initiation factor 4F (EIF4F) protein complex involved in 
enhanced translational efficiency, mRNA splicing and stability, and RNA nuclear export 
[260]. Inhibition of EIF4F selectively suppresses the expression of oncogenes and 
induces apoptosis in cancer cells [328]. Depleted EIF4G may contribute to the anti-
proliferative effects of SNX-7081 on MEC1 cells. 
 
The major histocompatibility complex (MHC) class II family protein (HLA-DR) is 
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depleted 2.27-fold by SNX-7081 in MEC1 cells. HLA-DR is synthesized in the ER, 
exported to the Golgi, and presented on the cell surface as a peptide binding protein 
important for eliciting an immune response [329]. CLL cells develop various mechanisms 
to escape immune surveillance [330, 331]. Therefore, the decrease in HLA-DR 
expression induced by SNX-7081 suggests that Hsp90 inhibitors may also influence the 
mechanisms of immune evasion employed by CLL cells [332]. 
  
4.5 Conclusions 
Hsp90 plays a critical role in regulating the expression and function of proteins involved 
in cell survival and proliferation. Using the p53-mutated CLL cell line MEC1, we have 
demonstrated that SNX-7081-induced apoptosis occurs as a result of depleting proteins 
that depend on the chaperone function of Hsp90. Inhibition of Hsp90 by SNX-7081 
reduces the levels of a number of cell cycle proteins and proteins involved in DNA 
replication and repair, RNA processing and regulation of transcription and translation as 
shown in Figure 4.7. This investigation identified a number of novel proteins decreased 
by SNX-7081 (e.g., DDB1, RuvB-like1, RuvB-like 2, MCM2, MCM3, MCM4, MCM6, 
RBBP4, MPP10, DDX5, PRPF4, RNA-binding protein 4, HEAT repeat containing 1, and 
U5-200KD). Employing additional protein fractionation steps, including phospho-
enrichment and further analysis using mass spectrometers with higher resolving power 
would improve the detection of important signalling kinases.  
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Figure 4.7. Proteins decreased in MEC1 cells by SNX-7081 (500 nM, 24 h) identified by iTRAQ LC-
MS/MS with roles in DNA replication and repair, RNA processing, and regulation of transcription 
and translation. Proteins are indicated by their gene names as for Table 4.1.  
 
p53 levels were unaffected following SNX-7081 treatment of p53-mutated MEC1, U266 
cells and p53 wild-type Raji cells. Furthermore, decreased levels of DDB1, MCM2, c-
Myc, PCNA and increased pRb and cyclin D1 levels were detected across all cell lines, 
despite their different p53 mutational states. Changes in protein abundance identified here 
may contribute to a better understanding of the mechanisms of p53-independent 
apoptosis and may aid the development of more targeted therapies for p53-mutated CLL 
and other cancers. Hsp90 inhibition by SNX-7081 induces cell cycle arrest and inhibition 
of DNA replication and repair, providing a rational mechanism for the synergism we have 
reported between SNX-7081 and 2-FaraA [314].  
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5.1 Introduction 
The mainstay of treatment of chronic lymphocytic leukemia (CLL) is cytotoxic 
chemotherapy; however, CLL remains an incurable disease with resistance to drugs 
developing in the majority of patients. CD (cluster of differentiation) antigen and B-cell 
receptor (BCR) signaling are important in the pathophysiology [333]. There are emerging 
anti-CD therapeutic antibodies under clinical trials [333]. CD antigens are potential 
targets for treatment of B-cell Lymphoproliferative Disease (B-LPD) with therapeutic 
antibodies. For example, antibodies against CD20 (rituximab, mabthera), CD52 
(alemtuzumab, campath-1H), and CD80 (galiximab) are effective for treatment of some 
B-LPDs such as CLL and NHL (non-Hodgkin lymphoma) [334, 335]. Immunotoxins 
such as BL22 directed against CD22, may be useful in the treatment of CLL, NHL and 
HCL (hairy cell leukemia) [336]. Radio-immuno-conjugates, such as 131I-tositumomab 
(Bexxar) and 90Y-ibritumomab tiuxetan (zevalin), both directed against CD20, are 
effective for treatment of NHL [337]. The success of rituximab and other monoclonal 
antibodies has demonstrated that B-cell malignancies may be particularly suitable for 
immunotherapy.  
 
Heat shock proteins interact with antigen presenting cells, and play fundamental 
immunological roles such as activation of antigen presenting cells, indirect presentation 
(or cross-priming), and chaperoning of peptides during antigen presentation [338]. There 
is hypothesis that heat shock proteins associate with various cellular antigens, they appear 
to be involved in innate immune responses and are commandeered for adaptive immune 
responses [339-342].  
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A CD antibody microarray (DotScanTM) has been developed in our laboratory, that 
captures live cells expressing antigens corresponding to immobilised antibodies on the 
microarray [153, 343], providing an extensive immunophenotype (surface profile or 
disease signature), that is a facile method in the field of proteomics. Surface profiles of 
untreated and drug-treated cancer cells can be compared to identify differentially 
abundant proteins as potential drug targets as well as elucidate mechanisms of action of 
drugs [156-158]. 
 
Recent studies indicate that an Hsp90 inhibitor in combination with therapeutic 
antibodies may produce higher response rates. Hsp90 inhibitor 17-AAG and rituximab, a 
chimeric monoclonal antibody against the protein CD20, induce synergistic apoptosis of 
B-cell CLL [344]. 17-AAG combined with trastuzumab, the humanized antibody against 
the receptor tyrosine kinase ErbB2, inhibits proliferation of trastuzumab-resistant breast 
cancer cells [345, 346]. The Hsp90 inhibitor geldanamycin has synergistic effects with 
TRAIL (tumor necrosis factor related apoptosis-inducing ligand) receptor antibody [347], 
and overcomes TRAIL resistance of colon cancer cell lines [348]. 
 
In this chapter, we used CD antibody microarrays to determine changes in surface 
molecule expression on MEC1 cells treated with the Hsp90 inhibitor, SNX-7081. 
Differentially abundant surface molecules may provide further insight into the 
mechanism of action of SNX-7081. In addition, increases in the expression of CD 
antigens after SNX-7081 treatment may provide additional targets for increased binding 
of therapeutic antibodies with enhanced cell killing. Identification of surface molecules 
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induced by SNX-7081 on CLL may enable rational development of synergistic chemo-
immunotherapy strategies.  
 
 
5.2 Materials and Methods  
As described in section 2.5 in Chaper 2. 
 
5.3 Results 
5.3.1 Differentially abundant CD antigens induced by the Hsp90 inhibitor SNX-7081 
MEC1 cells treated with SNX-7081 (500 nM, 48 h) were immunophenotyped using the 
CD antibody microarray. Representative dot patterns for SNX-7081-treated and control 
cells are shown in Figure 5.1. Figure 5.2 lists all the CD antigens expressed on control or 
treated samples. The average normalized binding densities for CD antigens for control 
and drug-treated samples are summarized in Figure 5.2a. The average binding densities 
for each antigen for the control cultures were then subtracted from the corresponding 
densities from SNX-7081-treated cultures, and the differences were sorted in ascending 
order as shown in Figure 5.2b. Antigens above the x-axis were induced on SNX-7081-
treated MEC1 cells while those below were repressed. SNX-7081 induced significant 
increases (p < 0.05) in descending order of CD69, CD53, CD27, CD20, CD262, kappa, 
CD80, CD19, CD319, CD98, and CD47, with repression of CD22, CD150, and CD212. 
Induction of CD antigens by SNX-7081 was also calculated as a ratio with the 
corresponding average density for the control cultures. SNX-7081 increased the 
following antigens significantly (p < 0.05) with the ratio indicated in brackets: CD69 
(10.0-fold), CD262 (5.59-fold), CD27 (4.85-fold), CD20 (2.73-fold), CD53 (2.09-fold), 
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kappa (1.95-fold), CD19 (1.55-fold), CD80 (1.54-fold), CD98 (1.47-fold), CD319 (1.34-
fold), CD47 (1.24-fold), and decreased CD212 (14.3-fold), CD22 (2.44-fold), CD150 
(1.45-fold) as listed in Table 5.1. A number of other antigens on MEC1 cells were 
different between control and treated samples as shown in Figures 5.1 and 5.2, but the 
levels of changes for these antigens were not significant. 
 
 
Figure 5.1. Capture of MEC1 cells on a DotScan antibody microarray. Cells were treated with SNX-
7081 (500 nM, 48 h). (A) Key to antibodies, which contains 195 antibodies dots including 182 specific CD 
antibodies plus 13 isotype controls for testing non-specific binding, and alignment dots around the border 
consisting of a 1:1 mixture of CD44 and CD29 antibodies that are positive controls for cell binding. 
Triangles pointing up indicate significant increases (p < 0.05) in expression of antigens for the SNX-7081-
treated culture relative to the control, while triangles pointing down indicate significant decreases (p < 
0.05). (B) Control culture. (C) SNX-7081-treated culture. The dot patterns (B) and (C) are representative of 
three separate cultures with antibody positions corresponding to (A).  
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Figure 5.2.  Differentially abundant CD antigens on MEC1 cells induced by SNX-7081 (500 nM, 48 h). (a) 
Normalized average densities of cell binding (n = 3). Error bars represent standard deviations. Antigens significantly 
up- or down-regulated are indicated by asterisks (p < 0.05). (b) The average binding densities for control cultures 
were then subtracted from the values for SNX-7081-treated cultures and the differences sorted in ascending order. 
Antigens above the x-axis were induced by SNX-7081 and those below were repressed.  
 
 
Table 5.1. MEC1 cell CD antigens that significantly differentially abundant after SNX-
7081 (500 nM, 48 h) treatment (p < 0.05). 
CD antigen Ratio
1
 p‐value
2
 
69 10.0 0.0266 
262 5.59 0.0353 
27 4.85 0.0022 
20 2.73 0.0035 
53 2.09 0.0140 
kappa 1.95 0.0446 
19 1.55 0.0059 
80 1.54 0.0452 
98 1.47 0.0475 
319 1.34 0.0065 
47 1.24 0.0124 
212 0.07 0.0257 
22 0.41 0.0062 
150 0.69 0.0170 
1
Ratio calculated by dividing the average cell binding density of MEC1‐SNX‐7081 (500 
nM, 48 h)‐treated by those of MEC1 control. 
2
p‐value calculated using the students’ t‐
test (n = 3). 
 
 
 
5.4. Discussion 
 
In the previous chapter, iTRAQ and LC-MS/MS were used to identify the differentially abundant 
proteins induced by SNX-7081 in nuclear, cytoplasmic and mitochondrial fractions. These 
proteins provide further insight into the mechanisms of action of SNX-7081 and may be new 
therapeutic targets. Antibody microarray-based technology is a promising tool in the field of 
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proteomics. One of the important applications is to compare proteomic profiles of untreated and 
drug-treated cancer cells to identify potential drug targets as well as further elucidate 
mechanisms of drug action. In the present study, we have used an antibody microarray to identify 
CD antigens whose levels change on the human B-lymphoid cell line MEC1 treated with Hsp90 
inhibitor. CD antigen changes induced by SNX-7081 could define aspects of the drug mechanism 
and provide targets for combined treatment with therapeutic antibodies or cytotoxic drugs. 
 
CD20 was induced 2.73-fold on MEC1 cells treated with SNX-7081 (Table 5.1). CD20, a B-cell 
antigen, is a calcium channel that regulates cell-cycle progression and proliferation. CD20 is 
expressed at lower levels on B-CLL compared with normal B-cells [349]. Rituximab (trade 
names rituxan and mabThera) is a chimeric monoclonal antibody. The Fc portion of rituximab 
mediates antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent 
cytotoxicity (CDC). Rituximab induces apoptosis of cells expressing CD20. Combination 
therapy using the Hsp90 inhibitor 17-AAG, with rituximab is synergistic against CLL [344]. The 
up-regulation of CD20 observed may provide an explanation for this synergy, SNX-7081 
increases CD20, and rituximab destroys malignant B-cells that have up-regulated CD20 on their 
surface. Previous results from our lab support combination therapy using cladribine or 
fludarabine that is clinically synergistic with rituximab against CLL and lymphomas [350-352], 
because cladribine or fludarabine can elevate CD20 level in CLL and lymphoma cells [156]. 
Another mechanism that may contribute to the synergistic drug effect is that rituximab increases 
phosphorylation of Akt [353], which negatively regulates apoptosis [354]. As we found in 
chapter 3, Hsp90 inhibitor SNX-7081 and 17-AAG cause Akt depletion, so combining Hsp90 
inhibitor with rituximab is able to diminish the increase of phosphorylation of Akt and enhance 
the effectiveness of rituximab [344]. 
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Since CD19 is a marker of B-cells, the protein has been used to diagnose B-cell related cancers 
like CLL and B-cell lymphomas [355, 356]. It is now emerging that CD19 plays a  role in driving 
the growth of these cancers, most intriguingly by stabilizing the level of the MYC oncoprotein 
[357]. This suggests that CD19 is a potential target for antibody-based therapy [356, 358]. There 
are anti-CD19 therapeutic antibodies targeting B-cell malignancies. For example, a novel 
humanized antibody SAR3419 for the treatment of B-cell non-Hodgkins lymphoma (NHL) [359, 
360], a novel Fc-domain-engineered CD19 monoclonal antibody XmAb5574 for the treatment of 
CLL [356], and a humanized anti-CD19 antibody hBU12 for the treatment of non-Hodgkin 
lymphoma (NHL). Anti-CD19 based therapy also been used in conjuction with cytotoxic drugs 
such as fludarabine [361, 362]. The therapeutic antibody binds to CD19 on the surface of normal 
and transformed B cells and kills them. Compared with CD20 antibodies, CD19 antibodies are 
more targeted to early lymphoblastic leukemias and lymphomas. CD19 is expressed early in B-
cell development [363], but both CD19 and CD20 antibodies have little toxicity because they are 
very specific for the targeted antigen. Our results show that SNX-7081 increased CD19 by 1.55-
fold in MEC1 cells (Table 5.1), suggesting that SNX-7081 might have a synergistic effect with 
CD19 therapeutic antibodies.    
 
Similar to CD19 and CD20, CD22 is a B-cell specific membrane-bound protein [364], so it is 
also a potential target for CLL, and is under investigation for therapy with antibody-drug 
conjugates. CD22 is a regulatory molecule that prevents the overactivation of the immune system 
[365]. In Chapter 4, we found SNX-7081 decreased the immune response protein HLA-DR by 
2.27-fold. CLL cells develop various mechanisms to escape immune surveillance [330, 331]. The 
depletion of both CD22 and HLA-DR by the SNX-7081 may inhibit the immune response to 
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MEC1 cells.  Anti-CD22 antibodies show great promise in the treatment of B-cell malignancies, 
such as non-Hodgkin's lymphoma, Burkitt's lymphoma, multiple myeloma, CLL, hairy cell 
leukemia and prolymphocytic leukemia [366-368]. Epratuzumab is an anti-CD22 monoclonal 
antibody under clinical trial as a single agent and in combination with rituximab in patients with 
non-Hodgkin’s lymphoma [369], A recombinant immunotoxin against CD22 (called CAT-8015 
or HA22) has induced complete remission in relapsed/refractory hairy cell leukemia [370]. The 
Hsp90 inhibitor SNX-7081, inhibits levels of CD22 (2.44-fold) in MEC1 cells, so synergy would 
not be expected for SNX-7081 with such an antibody. CD22 is a negative regulator of the BCR 
(B-cell receptor) signaling, involved in regulation of cell adhesion, B-cell survival, and BCR-
induced cell death [366, 371]. A decrease of CD22 promotes apoptosis in human B-lymphocytes 
[372]. The down-regulation of CD22 (2.44-fold) induced by SNX-7081 might contribute to the 
apoptosis of MEC1 cells. 
 
CD262, also known as death receptor 5 (DR5), increased 5.59-fold after SNX-7081. DR5 is a 
receptor for TRAIL (TNF-related apoptosis-inducing ligand) which is a promising candidate for 
treatment of cancer [373]. The anti-leukemic drugs etoposide, Ara-C, and doxorubicin induce 
apoptosis in leukemia cells by up-regulating DR5 levels [374]. Ligation of DR5 plays a 
significant role in the apoptosis observed which is independent of p53, and may act through a 
NF-κB related pathway [374]. Silencing DR5 expression using siRNA suppressed apoptosis, 
indicating that DR5 is required for induction of apoptosis [375]. Drugs that up-regulate 
expression of the TRAIL receptors DR4 and/or DR5 may synergize in combination with TRAIL 
through augmentation of TRAIL-induced apoptosis [375]. Our results show that SNX-7081 
increased DR5 in p53-mutated MEC1 cells to induce apoptosis, providing a rationale for 
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combination treatment of Hsp90 inhibitor SNX-7081 with TRAIL. This is consistent with the 
previous reports that combination of geldanamycin and TRAIL induced highly significant 
apoptosis in TRAIL-resistant prostate carcinoma LNCaP cells [347], and Hsp90 inhibitor 17-
AAG have synergistic effect with TRAIL in colon cancer cell lines [348], and glioblastoma cells 
[376]. 
 
The cell surface antigen CD53 has been proposed to play a role in regulation of cell development, 
activation, growth and motility [377]. CD53 is over-expressed in B-cell lymphoma, and protects 
against programmed cell death mediated by phosphorylation and activation of Akt, increases 
levels of Bcl-XL, decreases Bax, and reduces caspase activation [378]. CD53 increased 2.09-fold 
after SNX-7081, cells might increase CD53 to protect against apoptosis induced by SNX-7081.  
 
CD27, also known as TNFRSF7, is a member of the tumor necrosis factor (TNF) receptor family. 
CD27 exists as a dimeric glycoprotein on the cell surface, and as a soluble protein in serum, it 
plays roles in lymphoid proliferation, differentiation, and apoptosis. CD27 induces apoptosis in 
B-cells when bound to its ligand CD70 [379] or pro-apoptotic protein Siva [380]. The CD27-
CD70 interaction plays a key role in regulating B-cell differentiation, activation and 
immunoglobulin synthesis [379]. CD27 increased 4.85-fold after SNX-7081, suggesting that 
increased CD27 might be part of the mechanism for SNX-7081 induced apoptosis in MEC1 cells.  
 
The Hsp90 inhibitor SNX-7081 increased CD69 by 10.0-fold. CD69 level correlate with poor 
prognosis and is an independent disease prognosticator for CLL [381]. CD69 appears to have 
dual roles in cellular function. As a complex on NK cells, CD69 can stimulate activating 
Chapter 5: Hsp90 Inhibitor SNX-7081 Induces Immunophenotypic Changes on MEC1 Cells 
 
144 
 
responses (cytokine secretion, proliferation enhanced cytotoxicity), or with additional signals, 
CD69 can induce apoptosis when bound to LPS [382]. CD69 levels show a proportional 
relationship with apoptotic cell number in human leukemia K652 and HL-60 cell lines [383]. 
Consistent with a previous report that the Hsp90 inhibitor 17-DMAG, increases CD69 [286], our 
data suggest that SNX-7081 might induce apoptosis in MEC1 cells by increasing CD69 (Figure 
5.2). 
 
5.5. Conclusions 
 
Dotscan microarray analysis of MEC1 cells treated with the Hsp90 inhibitor SNX-7081 (500 nM, 
48 h) revealed significant changes (p < 0 .05) in levels of several cell surface antigens. Some of 
these CD antigens are potential targets [333]. CD20 (increased 2.73-fold), CD19 (increased 1.55-
fold), and CD262 (DR5, increased 5.59-fold) provide rationales for synergy of SNX-7081 with 
antibodies against CD20 (rutuximab) and CD19 (XmAb5574), and TRAIL receptor. CD antigens 
often act as receptors or ligands important to the cell, initiating a signal cascade and altering the 
behavior of the cell. Several CD antigen changes after SNX-7081 are involved with apoptosis, 
including CD27 (increased 4.85-fold), CD262 (increased 5.59-fold), and CD69 (increased 10.0-
fold) (Table 5.1), indicating that the mechanism of SNX-7081 may involve these CD antigens 
linked signaling pathways. 
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6.1 Introduction 
 
Fludarabine-based regimens (2-FaraA) have become the mainstay in the first-line treatment of 
CLL, with high partial and complete response rates [384, 385]. In recent clinical trials of CLL, 
drug resistance due to mutations in the p53 pathway was a major challenge to clinical 
management, especially for 2-FaraA based treatment [268]. 2-FaraA is dephosphorylated then 
transported into the cell via several nucleoside-specific membrane transporters, and converted to 
the cytotoxic triphosphate derivative. Fludarabine triphosphate (2-FaraATP) is incorporated into 
elongating DNA chains, and terminates chain synthesis [166], causing double strand breaks in 
DNA. The cellular response to this DNA damage relies on networks of proteins that induce 
apoptosis or DNA damage repair. p53 plays a pivotal role in the response of a cell to DNA 
damage regulating the checkpoint between apoptosis and DNA repair [386]. In response to DNA 
damage, p53 is phosphorylated and accumulates inducing cell cycle arrest, down-regulating 
DNA repair proteins [387, 388], and inducing apoptosis, thus preventing propagation of damaged  
cells [389]. The CLL cell lines, MEC1 and MEC2, have a deletion in the short arm of 
chromosome 17 (17p-), the locus for p53, and a mutation in the remaining allele, that makes 
them good models for testing drugs for the treatment of p53-mutated CLL [30]. The human 
U266 myeloma cell line has a codon 161 mutation in p53 [42]. p53-mutated cells (e.g., MEC1), 
tend to be resistant to DNA damaging agents such as 2-FaraA [74, 75], due to their inability to 
induce apoptosis and down-regulate DNA repair proteins [390]. Our previous study showed that 
the Hsp90 inhibitor SNX-7081 synergises with and restores sensitivity to fludarabine in CLL 
cells with lesions in the p53 pathway [169]. 
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The results in Chapter 4 has shown that the Hsp90 inhibitor SNX-7081 can induce apoptosis in 
p53-mutated MEC1 CLL cells [259]. However, despite promising data from Hsp90 inhibitor 
clinical trials, toxicity has limited the efficacy of Hsp90 inhibitors [391]. Combinations of Hsp90 
inhibitors with more conventional therapies may be synergistic and reduce the effective dose of 
the Hsp90 inhibitor required, thereby overcoming the toxicity. Together with Dr. Giles Best at 
the North Blood Center, the Kolling Institute, we found that the Hsp90 inhibitor SNX-7081 and 
2-FaraA have synergistic effects in 3 p53-mutated cell lines, MEC1, MEC2 and U266, and 23 
CLL patient samples [169]. However, the mechanism of this drug synergy was not determined. 
In this Chapter, we have used label-free quantitative shotgun proteomics [144] to obtain a 
comprehensive analysis of protein changes induced by SNX-7081, 2-FaraA, and the combination 
of 2-FaraA and SNX-7081. The results obtained provide insights into the mechanism of this drug 
synergy. 
 
 
6.2 Materials and Methods 
As described in section 2.6 in Chapter 2. 
 
6.3 Results 
6.3.1 Analysis of label-free shotgun proteomics data 
In total, 1596 non-redundant proteins (when one protein showed up in more than one condition, 
we only counteded it once) were identified in the lysates from control and drug-treated cells. The 
number of proteins reproducibly identified was 1050 in the control, 1076 following SNX-7081, 
1163 following 2-FaraA, and 1221 after SNX-7081+2-FaraA (Table 6.1). Variation of the 
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numbers of proteins identified between the 3 replicates was minimal. The number of peptides in 
each LC-MS/MS run was highly consistent between both replicates and treatments. Calculated 
levels of peptide FDR (false discovery rate) and protein FDR were less than 0.1% for all groups.  
 
Table 6.1. Numbers of identified proteins and peptides in MEC1 samples 
Condition 
Number of identified 
proteins 
CV%
b
 Redundant count of peptides CV%
c
 
Number of 
proteins 
found in all 
3 replicates 
  R1
a
 R2 R3   R1
a
 R2 R3     
Control 1637 1907 1791 0.0762 39609 34407 33224 0.0950 1050 
SNX‐7081‐treated 1769 1626 1772 0.0484 35223 35651 34067 0.0234 1076 
FdA treated 1811 2178 1840 0.1050 35704 38078 34300 0.0530 1163 
FdA + SNX‐7081 treated 1843 1965 2211 0.0934 35410 38181 41135 0.0749 1221 
a
R1, R2 and R3 are replicate 1, replicate 2 and replicate 3, respectively. 
b
CV% is
 
coefficient of variation of protein 
numbers between replicates,  
c
CV% is coefficient of variation of peptide numbers between replicates. 
 
 
6.3.2 Differentially abundant proteins after single and drug synergy treatments 
Protein abundances were compared between control and treated cells to determine changes 
induced by exposure to either single or combination drug treatments. The numbers of proteins 
identified with abundance increased or decreased more than 2-fold after single or synergistic 
drug treatment (p < 0.05) are illustrated in Figure 6.1. Combination drug treatment increased the 
abundance of 193 proteins, 83 of them also increased after SNX-7081 treatment, and 66 of them 
also increased after 2-FaraA. There were 97 proteins decreased after combination drug treatment, 
73 of them also decreased after SNX-7081, and 22 of them also decreased after 2-FaraA. The 
biological functions of these proteins were identified using the Uniprot database and allocated to 
16 biological process groups (Appendix Table A1-A6, Figure 6.2). DNA damage, replication and 
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repair related protein changes after single and combination are the most interesting results, and 
we listed these changes in Table 6.2. 
 
 
 
 
Figure 6.1. Pie charts of numbers of identified proteins that increased (A) or decreased (B) by more than 2-fold 
(p<0.05) after SNX-7081 (100 nM, 48 h), 2-FaraA (10 µM, 48 h) and SNX-7081 (100 nM) + 2-FaraA (10 µM) (48 h) 
treatments. Numbers on the overlapping area indicate the number of proteins that changed abundance after more 
than one treatment conditions.  
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Table 6.2. DNA damage, replication and repair related protein changes after drug treatment (n=3, p<0.05) in MEC1 cell 
accession 
number
a
 
protein names
b
 Gene name
c
  Biological processes
d
  Ratio treated/control
e
 
Proteins increased after SNX-7081 (100nM, 48h) 
P28072  Proteasome subunit beta type‐6 PSMB6 DNA damage 5.66 
P35244  Replication protein A 14 kDa subunit RPA3 DNA damage 3.94 
P35998  26S protease regulatory subunit 7 PSMC2 DNA damage 3.17 
Proteins decreased after SNX-7081 (100nM, 48h) 
Q8TCT9 Minor histocompatibility antigen H13 HM13 DNA damage 0.05 
Q9H4A4  Aminopeptidase B RNPEP DNA damage 0.25 
Q99460  26S proteasome non‐ATPase regulatory subunit 1 PSMD1 DNA damage 0.35 
Q14566  DNA replication licensing factor MCM6 MCM6 DNA replication and repair 0.17 
P33993  DNA replication licensing factor MCM7 MCM7 DNA replication and repair 0.20 
P49736  DNA replication licensing factor MCM2 MCM2 DNA replication and repair 0.41 
P33992  DNA replication licensing factor MCM5 MCM5 DNA replication and repair 0.42 
P78527 DNA‐dependent protein kinase catalytic subunit DNA‐PK, PRKDC DNA replication and repair 0.00 
Q08945  FACT complex subunit SSRP1 SSRP1 DNA replication and repair 0.15 
P31350  Ribonucleoside‐diphosphate reductase subunit M2 RRM2 DNA replication and repair 0.29 
P27708  CAD protein CAD  DNA replication and repair 0.33 
P35637  RNA‐binding protein FUS FUS DNA replication and repair 0.49 
O15067  Phosphoribosylformylglycinamidine synthase PFAS DNA replication and repair 0.49 
Q15233  Non‐POU domain‐containing octamer‐binding 
protein 
NONO DNA replication and repair 0.50 
P13010  X‐ray repair cross‐complementing protein 5 XRCC5 (Ku80) DNA replication and repair 0.50 
P39748  Flap endonuclease 1 FEN1 DNA replication and repair 0.50 
Proteins increased after 2-FaraA (10µM, 48h) 
Q8NFC6  Biorientation of chromosomes in cell division 
protein 1‐like 
BOD1L DNA damage 9.87 
C9J5P2  DNA topoisomerase 2  TOP2A  DNA damage 12.5 
Q96K76  Ubiquitin carboxyl‐terminal hydrolase 47 USP47 DNA damage 9.87 
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P20618  Proteasome subunit beta type‐1 PSMB1 DNA damage 7.39 
A6NP15  Proteasome (Prosome, macropain) 26S subunit, 
non‐ATPase, 12, isoform CRA_c 
PSMD12  DNA damage 6.47 
Q9ULC4  Malignant T cell‐amplified sequence 1 MCTS1 DNA damage 5.18 
P25789  Proteasome subunit alpha type‐4 PSMA4 DNA damage 4.76 
Q9NY33  Dipeptidyl peptidase 3 DPP3 DNA damage 3.03 
P27348  14‐3‐3 protein theta YWHAQ DNA damage 2.60 
Q04837  Single‐stranded DNA‐binding protein, 
mitochondrial 
SSBP1 DNA replication and repair 21.0 
Q01105  Protein SET SET DNA replication and repair 2.46 
E7EVW0  DNA polymerase POLD1  DNA replication and repair 2.27 
Q9Y230  RuvB‐like 2 RUVBL2 DNA replication and repair 2.03 
Proteins decreased after 2-FaraA (10µM, 48h) 
P51665  26S proteasome non‐ATPase regulatory subunit 7 PSMD7 DNA damage 0.19 
P62333  26S protease regulatory subunit 10B PSMC6 DNA damage  0.47 
Proteins increased after 100nM SNX-7081+ 10µM 2-FaraA (48h) 
P29590  Protein PML PML DNA damage 65.5 
Q71UI9  Histone H2A.V H2AFV DNA damage 52.7 
P20618  Proteasome subunit beta type‐1 PSMB1 DNA damage 10.2 
P28072  Proteasome subunit beta type‐6 PSMB6 DNA damage 10.2 
P49721  Proteasome subunit beta type‐2 PSMB2 DNA damage 9.11 
C9J5P2  DNA topoisomerase 2  TOP2A  DNA damage 6.51 
Q9ULC4  Malignant T cell‐amplified sequence 1 MCTS1 DNA damage 6.51 
Q02880  DNA topoisomerase 2‐beta TOP2B DNA damage 5.98 
P49720  Proteasome subunit beta type‐3 PSMB3 DNA damage 3.95 
Q9NY33  Bardet‐Biedl syndrome 1  DPP3 DNA damage 3.38 
Q96CS3  FAS‐associated factor 2 FAF2 DNA damage 3.07 
P63104  14‐3‐3 protein zeta/delta YWHAZ DNA damage 2.43 
P31946  14‐3‐3 protein beta/alpha YWHAB DNA damage 2.12 
P27348  14‐3‐3 protein theta YWHAQ DNA damage 2.60 
Q04837  Single‐stranded DNA‐binding protein, 
mitochondrial 
SSBP1 DNA replication and repair 20.4 
Q9UKK3  Poly [ADP‐ribose] polymerase 4 PARP4 DNA replication and repair 6.83 
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Proteins decreased after 100nM SNX-7081+ 10µM 2-FaraA (48h) 
Q14566  DNA replication licensing factor MCM6 MCM6 DNA replication and repair 0.30 
E9PBA2  replication factor C 5, 36.5kDa  RFC5  DNA replication and repair 0.06 
Q06203  Amidophosphoribosyltransferase PPAT DNA replication and repair 0.10 
Q9NS87  Kinesin‐like protein KIF15 KIF15 DNA replication and repair 0.12 
P35249  Replication factor C subunit 4 RFC4 DNA replication and repair 0.15 
P52701  DNA mismatch repair protein Msh6 MSH6 DNA replication and repair 0.22 
P33993  DNA replication licensing factor MCM7 MCM7 DNA replication and repair 0.40 
Q12888  Tumor suppressor p53‐binding protein 1 TP53BP1 DNA replication and repair 0.50 
P13010  X‐ray repair cross‐complementing protein 5 XRCC5 (KU80) DNA replication and repair 0.50 
a
Accession numbers were derived from the 2012_03 version of UniProtKB/Swiss‐Prot database. 
b
Protein names were protein names as in the  2012_03 
version UniProtKB/Swiss‐Prot database. 
c
Gene names were gene names as in the 2012_03 version UniProtKB/Swiss‐Prot database. 
d
Biological 
processes were assigned using the 2012_03 version UniProtKB/Swiss‐Prot database. 
e
Ratios were calculated based on NSAF value of triplicate treated 
and control samples (p value<0.05). 
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Figure 6.2. Comparison and classification of proteins that changed more than 2-fold (p < 0.05) after t-test 
analysis of control samples versus different drug-treated samples. According to the biological process in the 
UniProt database (www.uniprot.org), proteins with increased or decreased abundance after treatment with different 
drugs were classified into 16 different biological process categories, with the absolute numbers of proteins indicated 
as bar charts. The bars on the negative side of x-axis indicate number of proteins decreased after drug treatment; the 
bars on the positive side of x-axis indicate numbers of proteins increased after drug treatment.  
 
6.3.2.1 Control MEC1 cells compared with SNX-7081 treatment (100 nM, 24 h) 
In paired comparisons of control MEC1 cells with 100 nM SNX-7081 treated (p < 0.05), with 
fold-changes greater than 2, 144 proteins increased and 186 decreased after SNX-7081 (100 nM, 
24 h, Figure 6.1). Proteins found in each biological process are listed in Appendix Tables A1 and 
A2, the number of proteins are summarized in Figure 6.2. After SNX-7081 (100 nM, 24 h), 13 
proteins that decreased have functions in DNA repair and replication as listed in Table 6.2, 
suggesting that reducing DNA repair may be a major mechanism of action for SNX-7081. There 
were 8 chaperone proteins increased following treatment, 13 electron transport proteins increased, 
and 4 immunity-associated proteins decreased. Hsp90 inhibition may affect the immune response, 
consistent with iTRAQ results from the last chapter [259]. Two tumour suppressors, fumarate 
hydratase and cytosolic non-specific dipeptidase, increased in abundance after SNX-7081 by 
2.69-fold and 2.63-fold, respectively. Protein biosynthesis was inhibited by SNX-7081, 16 
proteins in this functional group decreased while only 4 increased. Hsp90 inhibition caused 
accumulation of multiple unfolded Hsp90 client proteins, that likely slows protein synthesis. 
Thirteen ribosomal proteins increased after SNX-7081, while only 2 decreased. SNX-7081 
increased 11 apoptosis-related proteins, consistent with the induction of apoptosis observed. Six 
proteins with roles in apoptosis decreased in abundance after SNX-7081, including 2 anti-
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apoptotic proteins, baculoviral IAP repeat-containing protein 6 (3.70-fold) and the 
serine/threonine-protein kinase mTOR (6.67-fold).  
 
6.3.2.2 Control MEC1 cells compared with 2-FaraA treatment (10 µM, 48 h)  
2-FaraA induced the fewest protein changes of the 3 treatments, consistent with MEC1 resistance 
to 2-FaraA. In paired comparisons of the protein changes between control and 2-FaraA (10 µM, 
48 h) treated cells, 52 proteins decreased and 127 proteins increased after 2-FaraA (p < 0.05 and 
fold-change > 2, Figure 6.1). The Uniprot analysis of these proteins is listed in Appendix Table 
A3 and A4, and summarized in Figure 6.2. After 2-FaraA (10 µM, 48 h) treatment, 9 DNA 
damage proteins increased in abundance, and 4 DNA replication and repair proteins increased as 
listed in Table 6.2. These data suggest that 2-FaraA induces DNA damage and stimulates the 
initiation of DNA repair. Five chaperone proteins increased in abundance in response to 2-FaraA 
treatment.  
 
6.3.2.3 Control MEC1 cells compared with 100 nM SNX-7081 + 10 µM 2-FaraA (48 h) 
treatment 
Comparison of untreated MEC1 cells with 100 nM SNX-7081 + 10 µM 2-FaraA (48 h) (p < 0.05, 
fold-change > 2), identified 193 proteins that increased and 97 proteins that decreased following 
the combined drug treatment (Figure 6.1). The drug combination increased 14 DNA damage 
proteins and decreased 9 DNA replication and repair proteins as listed in Table 6.2, consistent 
with the single drug treatments with 2-FaraA and SNX-7081, respectively. Nine chaperone 
proteins increased after drug combination treatment, none decreased. Many of these chaperones 
were also increased after single drug treatment with SNX-7081 or 2-FaraA, a similar stress 
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response maybe initiated by either drug. Nine electron transport proteins increased in abundance 
after SNX-7081+2-FaraA, while none decreased. This is similar to the effect of SNX-7081 as a 
single agent. Two tumor suppressor proteins increased after combination drug treatment, 
including cytosolic non-specific dipeptidase (3.59-fold), and pinin (2.87-fold). Similar to SNX-
7081 alone, 9 ribosomal proteins increased after drug combination treatment and 2 decreased. 
The drug combination increased 7 apoptosis-related proteins and decreased 4. Among the 4 
decreased apoptosis-related proteins, an anti-apoptotic protein, baculoviral IAP repeat-containing 
protein 6, was identified after treatment with SNX-7081 alone.  
 
6.3.3 IPA analysis 
The lists containing proteins changed in abundance after single or combination drug treatment 
(p<0.05, fold change>2) were analyzed by the IPA software. IPA identifies protein networks with 
distinct biological functions that contain significant numbers of proteins identified in the data set. 
There were many proteins having functions in DNA damage and repair changed abundance after 
single and combination drug treatment identified by IPA software. DNA damage and repair 
related networks were generated after 10 µM 2-FaraA (48 h) (Figure 6.3A), SNX-7081 (100 nM, 
48 h) (Figure 6.3B) and 100 nM SNX-7081 + 10 µM 2-FaraA (48 h) (Figure 6.3C) treatments. 
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Figure 6.3 DNA damage and repair related networks generated by IPA software. (A) IPA network generated 
based on proteins changed abundance after 2-FaraA (10 µM, 48 h) treatment, score 39; (B) IPA network generated 
based on proteins changed abundance after SNX-7081 (100 nM, 48 h) treatment, score 50; (C) Merged two IPA 
networks generated based on proteins changed abundance after 100 nM SNX-7081 + 10 µM 2-FaraA (48 h) 
treatments, score 60 and 42. Interacting proteins with a clear background were added by IPA software. Interactional 
proteins are connected by single lines; proteins that affect another protein (by controlling expression) are indicated 
by arrows. Dashed lines indicate indirect interactions. Proteins are indicated by their gene names. 
 
C 
Chapter 6: The Hsp90 Inhibitor SNX-7081 is Synergistic with Fludarabine via DNA Damage and Repair 
Mechanisms 
 
159 
 
The IPA identified a pathway named ‘cell cycle: G2/M DNA damage checkpoint regulation’ in 
two lists containing proteins increased following 2-FaraA (10 µM, 48 h) and proteins increased 
following 100 nM SNX-7081 + 10 µM 2-FaraA (48 h); with a -log10 (p-value)>1.3 indicating 
95% confidence (Figure 6.4). The IPA pathway ‘cell cycle: G2/M DNA damage checkpoint 
regulation’ generated after 2-FaraA (10 µM, 48 h) includes the protein 14-3-3 theta (YWHAQ), 
14-3-3 protein zeta/delta (YWHAZ), DNA topoisomerase 2 (TOP2A), S-phase kinase-associated 
protein 1 (LOC728622/SKP1). The ‘cell cycle: G2/M DNA damage checkpoint regulation’ 
pathway generated after 100 nM SNX-7081 + 10 µM FdA (48 h) treatment includes 14-3-3 
protein theta (YWHAQ), 14-3-3 protein beta/alpha (YWHAB), DNA topoisomerase 2 (TOP2B), 
14-3-3 protein zeta/delta (YWHAZ), DNA topoisomerase 2 (TOP2A), and S-phase kinase-
associated protein 1 (LOC728622/SKP1).  
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Pathways Proteins contained in the pathway 
 Aminoacyl‐tRNA Biosynthesis  YARS2, LARS2, HARS, SARS2, EPRS 
 Protein Ubiquitination Pathway  B2M, USP15, DNAJB11, USP47, PSMD12, UBE2V1, PSMB1, 
PSMA4, ANAPC5, TCEB1, LOC728622/SKP1 
 Cell Cycle: G2/M DNA Damage 
Checkpoint Regulation 
 YWHAQ, YWHAZ, TOP2A, LOC728622/SKP1 
 IGF‐1 Signaling  YWHAQ, MAP2K2, YWHAZ, PRKAR2A, MAP2K1 
 Citrate Cycle  SDHA, DLD, IDH1 
 PI3K/AKT Signaling  YWHAQ, MAP2K2, YWHAZ, INPPL1, MAP2K1 
 Protein Kinase A Signaling  YWHAQ, MAP2K2, PDE12, YWHAZ, PRKAR2A, ANAPC5, 
MAP2K1, VASP 
 NRF2‐mediated Oxidative Stress 
Response 
 MAP2K2, DNAJB11, CAT, DNAJA2, TXN, MAP2K1 
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Pathways  Proteins contained in the pathway 
 Cell Cycle: G2/M DNA Damage 
Checkpoint Regulation 
 YWHAQ, YWHAB, TOP2B, YWHAZ, TOP2A, LOC728622/SKP1 
 ERK/MAPK Signaling  YWHAQ, PPP2R1A, MAP2K2, PPP1R7, YWHAB, YWHAZ, 
PRKAR2A, PRKACA, MAP2K1, HSPB1, PRKAR1A 
 IGF‐1 Signaling  YWHAQ, MAP2K2, YWHAB, YWHAZ, PRKAR2A, PRKACA, 
MAP2K1, PRKAR1A 
 Dopamine Receptor Signaling  PPP2R1A, PPP1R7, PRKAR2A, PRKACA, SPR, PCBD1, 
PRKAR1A 
 CDK5 Signaling  PPP2R1A, MAP2K2, PPP1R7, PRKAR2A, PRKACA, MAP2K1, 
PRKAR1A 
 Biosynthesis of Steroids  MVD, DHCR7, IDI1, LSS 
 BMP signaling pathway  MAP2K2, PRKAR2A, PRKACA, NFKB2, MAP2K1, PRKAR1A 
 Oxidative Phosphorylation  SDHA, NDUFA10, ATP6V1H, ATP5D, UQCRFS1, MT‐CO2, 
ATP6V1B2, COX4I1 
 Protein Kinase A Signaling  YWHAQ, MAP2K2, PPP1R7, YWHAB, PDE12, YWHAZ, 
PRKAR2A, PRKACA, NFKB2, MAP2K1, VASP, PRKAR1A 
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Figure 6.4 IPA pathways. (A) Top IPA pathways generated based on proteins increased in abundance after 2-FaraA 
(10 µM, 48 h) treatment. The table under the graph listed proteins contained in the corresponding pathways.  (B) Top 
IPA pathways generated based on proteins increased in abundance after 100 nM SNX-7081+ 10 µM 2-FaraA (48h) 
treatment. The table under the graph listed proteins contained in the corresponding pathways. Significance threshold 
was set at –log (0.05)=1.3, which indicating 95% confidence of not being generated by chance. Proteins are indicated 
by their gene names. 
 
6.3.4 Increases of DNA damage marker pH2AX 
Western blotting and flow cytometry were used to assess levels of the phosphorylated form of the 
histone H2AX (pH2AX) following exposure to 2-FaraA (10 µM, 48 h), SNX-7081 (100 nM, 48 
h), or 100 nM SNX-7081 + 10 µM 2-FaraA (48 h). Phosphorylated H2AX is a marker of double-
stranded DNA breaks [392]. As shown in Figure 6.5A, Western blot analysis showed that 
following treatment with 2-FaraA, the levels of phosphorylated H2AX in MEC1 cells increased 
by 1.25-fold; SNX-7081 induced a 1.10-fold increase, while the combination of the two drugs 
resulted in a synergistic increase of 4.10-fold. Figure 6.5B Flow cytometry showed that for 
MEC1 cells treated with 2-FaraA (10 µM, 48 h), pH2AX increased by 1.79-fold, SNX-7081 (100 
nM, 48 h) increased pH2AX by 1.48-fold, while 100 nM SNX-7081 + 10 µM 2-FaraA (48 h)  
increased pH2AX by 4.82-fold. Similar effects were seen in the other two p53-mutated cell lines, 
MEC2 and U266. In MEC2 cells, 2-FaraA increased pH2AX by 3.21-fold, SNX-7081 induced 
pH2AX by 1.10-fold, while the combination treatment induced pH2AX by 6.75-fold. In U266 
cells, 2-FaraA increased pH2AX by 4.49-fold, SNX-7081 did not change pH2AX level, while the 
combination treatment induced pH2AX by 8.25-fold.  
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Figure 6.5 Changed levels of the DNA damage marker pH2AX in response to drug treatments. (A) Western blot 
analysis of pH2AX changes induced by 2-FaraA (10 µM, 48 h), SNX7081 (100 nM, 48 h), and 2-FaraA (10 µM) + 
SNX7081 (100 nM) (48 h) compared with control MEC1 cells. (B) Flow cytometry analysis of pH2AX levels 
compared with controls on 3 p53-mutated cell lines, MEC1, MEC2 and U266 after 2-FaraA (10 µM, 48 h), SNX-
7081 (100 nM, 48 h), and SNX-7081 (100 nM) + FdA (10 µM) (48 h). The level of actin was used to normalize 
values for control and treated cells. Fold induction indicates the intensity of the indicated treated sample divided by 
the intensity of the control sample treated with DMSO. Error bars show mean ± standard deviation. The figure is 
representative of three independent experiments. 
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6.4 Discussion 
6.4.1 SNX-7081 down-regulates DNA replication and repair proteins in MEC1 cells when 
used as singly or in combination with 2-FaraA  
DNA replication and repair related proteins (13) decreased after SNX-7081 (100 nM, 48 h), an 
effect also seen after 100 nM SNX-7081+10 µM FdA (48 h) with 9 DNA replication and repair 
related proteins decreased. This conclusion is supported by the DNA replication and repair 
related networks generated by the IPA software as shown in Figure 6.3.  
   
Double-stranded DNA breaks (DSBs) are processed by two major repair pathways, namely non-
homologous end joining (NHEJ) and homologous recombination (HR) [393, 394]. NHEJ is 
active in all phases of the cell cycle, but HR is most effective in late S and G2 phases [395, 396]. 
The key proteins associated with NHEJ include XRCC6/XRCC5, DNA-PKcs, Artemis, 
XRCC4/LigaseIV, and MSH6 [397, 398]. HR requires a large number of proteins including RPA, 
Rad51, Rad52, Rad54, BRCA1, BRCA2, and the Rad51 paralogs (XRCC2, XRCC3, Rad51C, 
and Rad51D) [399]. Very recently, another Hsp90 inhibitor 17-DMAG, was reported to inhibit 
repair of radiation-induced DSBs and reduce the phosphorylation of DNA-PK through 
diminished interaction with ErbB1 [316]. 17-AAG also inhibited DNA repair of radiation-
induced DSBs via degrading BRCA2 in the HR pathway [400]. Our data show that SNX-7081 
inhibits DNA repair via the NHEJ repair pathway, by acting upon the DNA-PK, XRCC5 and 
MSH6 proteins.  
 
The assembly of the DNA-PK complex at DNA ends is required for the NHEJ ligation step. 
DNA-PK is a serine/threonine-protein kinase that acts as a molecular sensor of DNA damage. 
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Our results show that DNA-PK was down-regulated by 333-fold after SNX-7081. The XRCC5/6 
dimer stabilizes broken DNA ends, an important step in DNA non-homologous end joining 
(NHEJ) and V(D)J recombination [401-403]. Our data show a 2.00-fold decrease in XRCC5 
following both SNX-7081, and the combination treatment. The decrease of X-ray repair cross-
complementing protein 5 (XRCC5) after Hsp90 inhibitor treatment consistent with the fact that 
17-DMAG is synergistic with X-ray treatment [404]. MSH6 is a component of the post-
replicative DNA mismatch repair system (MMR), that heterodimerizes with MSH2 to form MutS 
alpha. This dimer then binds to DNA mismatches and initiates DNA repair. MSH6 also interacts 
with proliferating cell nuclear antigen (PCNA) [405-407], and is part of the BASC (BRCA1-
Associated Genome Surveillance Complex) [408]. Our data show that the MSH6 protein was 
decreased by drug combination treatment by 4.55-fold. RFC4 and RFC5 are two of the five-
subunit protein complexes RFC (replication factor C) used in eukaryotic replication as a clamp 
loader for loading PCNA onto DNA [409], required for DNA replication. Their abundances were 
decreased by 6.67-fold and 16.7-fold respectively after combination drug treatment. Several 
components of the MCM complex, the putative replicative helicase essential for 'once per cell 
cycle' DNA replication initiation and elongation in eukaryotic cells, decreased after SNX-7081 or 
combination drug treatment, as shown in Figure 6.3 IPA networks and Appendix Table A2 and 
A6.  
 
6.4.2 2-FaraA alone or with SNX-7081 induces DNA damage in MEC1 cells 
Nine DNA damage-related proteins increased in abundance after 2-FaraA; similar changes were 
seen after SNX-7081 + 2-FaraA combination treatment with 14 DNA damage-related proteins 
increased. This effect is further supported by identification of the G2/M DNA damage checkpoint 
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network by the IPA software, with p<0.05, -log10 (p-value)>1.3, greater than 95% confidence 
(Figure 6.4).  
 
Promyelocytic leukemia protein (PML) is a dynamic sensor of DNA damage [410]. The 
significant increase in PML following SNX-7081+2-FaraA (65.5-fold) indicates significant DNA 
damage. The abundance of H2AFV (Histone H2A.V) belonging to the histone H2A family, 
increased by 52.7-fold after combination drug treatment. The enzyme TOP2A is involved in 
double-stranded DNA break formation [411]. The increase of TOP2A after 2-FaraA (12.5-fold) 
and with the drug combination (6.51-fold) suggests that 2-FaraA also causes double-stranded 
breaks through up-regulating the expression of proteins involved in the formation of DNA breaks 
such as TOP2A, apart from its incorporation into nucleic acid chains as fludarabine triphosphate 
(FdATP) [166]. A functional proteasome is also required in the response to DNA damage [412]. 
We have found that several proteasome subunit types of DNA damage proteins increased in 
abundance after 2-FaraA or combination treatment. The increase in DNA damage may have 
induced the cell cycle regulatory protein, S-phase kinase-associated protein 1 (SKP1), this cell 
cycle protein plays an important role at the DNA damage checkpoint [413]. SKP1 increased by 
14.3-fold after 2-FaraA treatment, and 11.1-fold after combination drug treatment. The increase 
is less for SNX-7081 + 2-FaraA than 2-FaraA alone, which might due to SNX-7081 alone 
decreased SKP1. We found in Chapter 4 (Table 4.1) that SKP1 decreased by 2.50-fold after 
SNX-7081 (500 nM, 24h) treatment. SKP1 did not decrease significantly (p<0.05) in chapter 6, 
perhaps due to reduced SNX-7081 used (500 nM in chapter 4 versus 100nM in chapter 6).  
However, the minor inhibitory effect of SNX-7081 on SKP1 might still exist, which could cause 
the depression of the increase fold-change from 14.3-fold after 2-FaraA, to 11.1-fold after SNX-
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7081+2-FaraA. The increase of SKP1 indicates DNA damage has occurred and has triggered 
mechanisms that regulate the cell cycle, as indicated by the cell cycle and G2/M DNA damage 
checkpoint regulation pathway increase after 2-FaraA or drug synergy treatment identified by 
IPA analysis. Although most DNA damage proteins increased after 2-FaraA treatment, two DNA 
damage  proteins, 26S proteasome non-ATPase regulatory subunit 7, and 26S protease regulatory 
subunit 10B, decreased by 5.26-fold and 2.13-fold after 2-FaraA (10 µM, 48 h). Apart from DNA 
damage response, these two proteins also play roles in the cell cycle and apoptosis [414-416]. 
  
Different DNA repair and DNA damage proteins were identified between single agent and 
combination drug treatment. In shotgun proteomics experiments, the precursor ions are selected 
randomly and therefore the proteins detected in each run may differ. Although the proteins are 
different, there is a trend that the DNA replication and repair proteins decreased after SNX-7081 
or SNX-7081 + 2-FaraA treatment, while the DNA damage proteins increased after 2-FaraA or 
SNX-7081 + 2-FaraA treatment. 
 
6.4.3 Drug synergy mechanism 
Based on our findings, we propose a mechanism for the synergy between SNX-7081 and 2-FaraA. 
2-FaraA induced DNA damage not only by incorporation into nucleic acid chains as 2-FaraATP 
as known before [417], but also by up-regulating DNA damage proteins including TOP2A. In 
response to this DNA damage, the MEC1 cells up-regulated proteins involved in DNA damage 
checkpoints. However, despite the regulation of some checkpoint and apoptosis-related proteins 
in the MEC1 cells, the lack of any apoptosis induction or cell cycle arrest by 2-FaraA is likely 
related to the absence of a functional p53 protein [76]. p53 is critical in preventing tumor 
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development and maintaining genomic integrity through inhibition of cell replication following 
DNA damage. In response to DNA damage, p53 wild-type cells induce G1 cell cycle arrest and 
subsequently apoptosis [70]. As our previous study demonstrated, this is not the case for MEC1 
cells [169]. In the absence of functional p53, 2-FaraA increased the DNA repair proteins Single-
stranded DNA-binding protein by 21.0-fold, Protein SET by 2.46-fold, DNA polymerase by 2.27-
fold and RuvB-like 2 by 2.03-fold in MEC1 cells. These increases are likely to contribute to the 
ability of the MEC1 cells to repair 2-FaraA-induced DNA damage and resist apoptosis. Our data 
suggest that the combination of 2-FaraA with the Hsp90 inhibitor SNX-7081 in MEC1 cells 
induces DNA damage which is accentuated by SNX-7081-mediated inhibition of DNA repair, 
resulting in the synergy for apoptosis previously reported [169].  
 
 
This mechanism for drug synergy was further supported by our observations concerning the 
phosphorylation of the histone H2AX. Phosphorylation of H2AX on serine 139 is a marker of 
double-stranded DNA breaks [418]. By Western blotting, we demonstrated a significant increase 
in phosphorylated H2AX in response to treatment with SNX-7081+2-FaraA, over levels induced 
by exposure to either agent alone in MEC1 cells (Figure 6.5A). Our proteomic data for MEC1 
suggest that DNA damage does occur following exposure to 2-FaraA, the low levels of pH2AX 
in the 2-FaraA-treated cells may be explained by DNA repair having occurred. The high 
expression of pH2AX in the SNX-7081+2-FaraA treated cells supports the hypothesis that SNX-
7081 restricts the repair of DNA breaks induced by 2-FaraA thus prolonging phosphorylation of 
H2AX. Flow cytometry showed another two p53-mutated cell lines MEC2 and U266, have 
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similar changes in pH2AX (Figure 6.5B), suggesting that this is a general drug synergy 
mechanism in p53-mutated cell lines [169].  
 
6.4.4 Other protein changes 
Apart from the proteins from DNA damage and DNA repair mechanisms, we found some other 
interesting changes. Our results show that 13 and 9 electron transport proteins increased in 
abundance after SNX-7081 and the combination drug treatment, respectively. Mitochondria play 
an important role in apoptosis, mediated by electron transport protein cytochrome c [419]. 
Inhibition of the electron transport chain, results in increased reactive oxygen species (ROS) 
production, that may increase apoptosis [420]. On the other hand, down-regulating electron 
transport has an anti-apoptosis effect [386]. Our results showed that increasing electron transport 
protein abundances is part of the SNX-7081 drug mechanism. 
 
There were 13 and 9 ribosomal proteins increased after SNX-7081 and SNX-7081+2-FaraA 
treatment, while only 2 proteins decreased.  Ribosomal proteins may coordinate protein 
biosynthesis, but recent evidence suggests that a number of ribosomal proteins have secondary 
functions independent of their involvement in protein biosynthesis. Many ribosomal proteins 
function as cell proliferation regulators and sometimes as inducers of cell death [398]. Ribosomal 
protein L13a has been shown to induce apoptosis by arresting the cell cycle in G2/M phase [421]. 
SNX-7081 and SNX-7081+2-FaraA can arrest MEC1 cell growth in G2/M phase [169], that 
might be related to the increased ribosomal proteins. 
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6.5 Conclusions 
Quantitative label-free shotgun proteomics, employing spectral counting with normalized spectral 
abundance factors (NSAFs), has been used to investigate changes in protein expression in MEC1 
cells following exposure to the Hsp90 inhibitor SNX-7081, 2-FaraA, and a combination. The 
mechanism of drug synergy between the Hsp90 inhibitor SNX-7081, and 2-FaraA is as follows, 
2-FaraA induce DNA damage, SNX-7081 down-regulates DNA repair proteins with 
accumulation of damaged cells that undergo apoptosis. As indicated by the confirmatory flow 
cytometry result on the DNA damage marker pH2AX, the drug synergy mechanism may also 
operate in the other two p53-mutated cell lines, MEC2 and U266. Our data provide a valuable 
insight into the mechanisms of synergy between SNX-7081 and 2-FaraA, a potential alternative 
treatment for p53-mutated chronic lymphocytic leukemia (CLL), where treatment options are 
limited [169]. The combination drug treatment also reduces the effective dose of the Hsp90 
inhibitor required, thereby overcoming the toxicity problem now facing Hsp90 inhibitor clinical 
trials [391].  
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The general purpose of this study was to gain a better understanding of the mechanisms of action 
of the Hsp90 inhibitor SNX-7081 by proteomic techniques. Treatment of leukemia cells with an 
Hsp90 inhibitor, with subsequent analysis by DIGE, iTRAQ, label-free, and antibody 
microarrays proteomic techniques identified proteins differentially expressed between control 
and drug-treated cultures. The results obtained (1) further elucidated the mechanisms of action of 
Hsp90 inhibitors, (2) discovered new capability of Hsp90 inhibitors in overcoming drug 
resistance, (3) lead to new potential combination therapies between Hsp90 inhibitors and drugs 
that damage DNA. 
 
7.1 The growing list of Hsp90-regulated proteins 
Hsp90 inhibitors are ‘hot’ anti-cancer topic. It is of fundamental biological and medical 
importance to identify all Hsp90 client and regulated proteins. More than 200 Hsp90 clients have 
been identified by classical biochemical techniques including signaling proteins in human cancer 
pathways. A current list of Hsp90-interacting proteins was compiled by Didier Picard [422]. This 
list includes both Hsp90 clients, dependent on Hsp90 for folding, stability and/or activity, as well 
as co-chaperones, that regulate Hsp90 and/or client function. Proteomic techniques enable 
identification of proteins regulated by Hsp90 inhibitors [423]. We have discovered many 
proteins that change in abundance after Hsp90 inhibitor treatment, as shown in Tables 3.1 and 
3.2 in Chapter 3, Table 4.1 in Chapter 4, Table 5.1 in Chapter 5, Table 6.2 in Chapter 6, and 
Table A1-A6 in Appendix. These protein lists extend the list of known Hsp90-regulated proteins.  
 
7.2 Hsp90 inhibitors can overcome drug resistances 
Chemotherapy and radiation therapy remain the most commonly used treatments for cancer, with 
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new and more specific anti-cancer drugs emerging. However, due to the rapid genetic and 
epigenetic changes in adaptation to stress induced by anti-cancer drugs, cancer cells can become 
resistant to single or multiple drugs. As for other cancers, drug resistance is a problem for 
treating leukemia; for example, imatinib resistance in CML and 2-FaraA resistance in CLL. 
Experiments with fungi have demonstrated a crucial role for the chaperone Hsp90 is buffering 
genetic variation and enabling evolution of drug resistance [424].  Hsp90 could have a similar 
effect in development of drug resistance in cancer cells [105, 189], so Hsp90 inhibitors might 
overcome drug resistance. Such resistance often arises through mutations such as amplifications 
in the genes encoding oncoproteins targeted by the drug. For example, amplification of the 
protein BCR-ABL, or Lyn kinase may cause resistance to imatinib in CML cells. The chaperone 
Hsp90 binds to a diverse set of client proteins involved in oncogenesis. Inhibiting Hsp90 can 
disrupt multiple signaling pathways required for tumor cell growth and survival. For example, 
Hsp90 inhibitors disrupt the cell signaling proteins Lyn kinase, BCR-ABL, Akt and Stat5 at the 
same time (Figure 3.6 in Chapter 3). Multiple knocking down of oncogenic clients of Hsp90 is a 
“rational approach” to address the heterogeneity and complexity of the numerous genetic defects 
characteristic of most clinical cancers [193]. On this basis, inhibition of Hsp90 levels should be 
effective agaist multiple forms of drug resistance [105, 189]. Hsp90 inhibitor XL888, overcomes 
BRAF inhibitor resistance in melanoma cell lines [289]; the Hsp90 inhibitor AUY922, 
overcomes resistance to JAK2 inhibitors in mice xenografted with human B-ALL [425]. The 
Hsp90 inhibitor 17-AAG, overcomes trastuzumab resistance in breast cancer patients [426].   
 
Imatinib, an ATP-competitive inhibitor of the oncogenic protein BCR-ABL, is the standard 
treatment for CML [183], but many patients develop resistance to imatinib [49]. In Chapter 3, we 
Chapter 7: General Discussion 
 
174 
 
found that imatinib-resistant MYLR cells are also resistant to gemcitabine, Ara-C and DADMe-
Immucillin-H, but sensitive to the Hsp90 inhibitors SNX-7081, SNX-5422, and 17-AAG. Using 
DIGE, Phospho-RTK antibody arrays, Western blotting and siRNA techniques, we showed that 
Hsp90 inhibitors overcome the coordinate drug resistance in MYLR cells by decreasing the over-
expressed Lyn kinase, and the down-stream pStat5, and increasing  ubiquitin/proteosome-related 
proteins and anti-oxidant proteins. 
 
2-FaraA based therapies are the front-line treatments for CLL patients, however, p53-mutated 
CLL responds poorly to 2-FaraA [267]. In Chapter 4, we found that the Hsp90 inhibitor SNX-
7081, can overcome 2-FaraA resistance and induce apoptosis in p53-mutated MEC1 CLL cells. 
iTRAQ analysis on nuclear, cytoplasmic, mitochondrial fractions, and antibody microarray 
profiling of cell surface CD (cluster of differentiation) antigens have been used to determine 
protein changes induced by SNX-7081. The results indicate that SNX-7081 overcomes 2-FaraA 
resistance in MEC1 cells by arresting the cell cycle and inhibiting DNA replication and repair 
via p53-independent mechanisms. 
 
7.3 Hsp90 inhibitors are synergistic with other anti-cancer drugs 
In the Phase I and Phase II clinical trials, single agent activity of Hsp90 inhibitors has been 
modest against recurrent, refractory cancers mainly due to high toxicity [391, 427]. Inhibition of 
Hsp90 can result in degradation of 200 client proteins. Hsp90 inhibitors as single agents have 
exerted predominantly cytostatic effects in most tumor models and clinical trials to date [193]. 
The concept of combination chemotherapy to increase the likelihood of curing cancer is well 
established [428]. In combination chemotherapy, drugs with different mechanisms of action are 
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used to decrease the likelihood that resistant cancer cells will develop. Each drug is used at its 
optimal dose, which can minimize the side-effects like toxicity.  
 
We found that the Hsp90 inhibitor SNX-7081, reduces the levels of DNA repair proteins in 
MEC1 CLL cells (Chapter 4), and we subsequently found that SNX-7081 synergistic with a 
DNA-damaging drug 2-FaraA [166]. In collaboration with Dr. Giles Best and Prof. Stephen 
mulligan (Kolling Institute, Royal North Shore Hospital), we found the drug synergy in three 
p53-mutated cell lines (MEC1, MEC2 and U266) and 23 CLL patient samples [314]. Using 
label-free quantitative shotgun proteomics, we determined the mechanism of synergy. 2-FaraA 
induces DNA damage, and SNX-7081 decreases levels of DNA repair proteins resulting in more 
rapid accumulation of DNA damage and more cells going into apoptosis as illustrated in Figure 
7.1. Combining with 2-FaraA can reduce the required amount of Hsp90 inhibitor, thus reducing 
toxicity. 
 
                           A                                      B                                                 C 
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Figure 7.1. Mechanism of drug synergy. (A) 2-FaraA as a purine analogue interferes with DNA synthesis and 
induces DNA damage [166]. (B) SNX-7081 as a single drug decreases DNA repair proteins (as found in chapter 4). 
(C) 2-FaraA + SNX-7081 combination, 2-FaraA induces DNA damage, SNX-7081 down-regulates DNA repair 
proteins and damage accumulates.     
 
In addition to 2-FaraA, Hsp90 inhibitors have additive or synergistic effects in killing solid 
tumors and leukemias when combined with cytotoxic agents such as cisplatin, gemcitabine and 
cytarabine, death receptor ligands tumor necrosis factor-related apoptosis-inducing ligand 
(TRAIL), proteasome inhibitors, histone deacetylase inhibitors, and protein kinase inhibitors 
(Table 7.1). There is a specific reason for each drug according to its mechanism to provide the 
synergistic effect with the Hsp90 inhibitor as listed in Table 7.1. The development of Hsp90 
inhibitors has been limited by toxicity as single agents [391, 427]; combination with other anti-
cancer drugs can reduce the required amount for each drug and reduce toxicity. 
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Table 7.1.  Additive/synergistic effects of Hsp90 inhibitors with other anti-cancer drugs. 
Hsp90 inhibitors Drugs in combination Interaction Cancer type Mechanism Reference 
SNX‐7081 2‐FaraA Synergistic Leukemia DNA damage, DNA repair [314] 
17‐AAG rituximab Synergistic Leukemia Depletion of Akt [344] 
17‐AAG TRAIL receptor antibody 
(HHGS‐ETR 1/2) 
Synergistic Hodgkin's 
lymphoma, colon, 
prostate 
Down‐regulate Akt, Erk, cell cycle arrest and 
death; suppression of NF‐kB pathway (RIP and 
IKK degradation) 
[348, 429‐432] 
GA/17‐AAG Cisplatin Synergistic Colon  Schedule‐dependent; p53, JNK pathway 
involved; phase 2 for solid tumors 
[433‐435] 
Radicicol Cisplatin, oxaliplatin Synergistic Colon, glioma MLH1 proficient/deficient; no change in 
apoptosis/cell cycle 
[436, 437] 
GA/17‐AAG Cisplatin Synergistic Pediatric solid tumor Depletion of Akt, IGF1R; cell cycle arrest; [438, 439] 
17‐AAG Taxol Synergistic Breast cancer Down‐regulate Akt and Her2 [440] 
17‐AAG Bortezomib (PS‐341, 
proteasome inhibitor) 
Synergistic Breast, leukemia, 
multiple myeloma 
Administration: simultaneously better than 
sequential addition; accumulation of 
aggregates 
[241, 441, 
442] 
17‐AAG UCN‐01 (7‐
hydroxystaurosporine), 
Chk1 inhibitor 
Synergistic Leukemia Interruption of RAF/MEK and Akt pathways [443] 
17‐AAG Imatinib 
mesylate/PD180970 
Enhancement Leukemia Decrease BCR‐ABL [442, 444, 
445] 
17‐AAG PKC412 (FLT3 tyrosiine 
kinase inhibitor) 
Synergistic AML Down regulate FLT3, Akt, Erk, STAT5; selective 
for AML with mutated FLT3 
[446] 
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Hsp90 inhibitors Drugs in combination Interaction Cancer type Mechanism Reference 
17‐AAG GTP14564 (FLT3 tyrosine 
kinase inhibitor against) 
Synergistic Leukemia Reduced level of FLT3, STAT5, enhanced 
G0/G1 arrest and apoptosis in leukemia with 
FLT mutations 
[447] 
17‐AAG LY294002 (PI3K inhibitor) Synergistic Malignant glioma Down regulate PI3K/Akt  [442, 448, 
449] 
17‐AAG Gemcitabine (only 
effective in S phase cells) 
Synergistic Ovarian tumor, 
myeloid leukemia 
cell line 
17‐AAG arrests cells in G1 and G2; deplete 
chk1; phase 1 for solid tumors 
[435] 
GA, radicicol Topoisomerase II poison 
(etoposide) (VP16) 
Synergistic Colon DNA damage; topoisomerase II activity 
increase 
[317, 450] 
17‐AAG LBH589 Synergistic CML, AML Attenuate levels of mutant BCR‐ABL [451] 
17‐AAG Histone deacetylase 
inhibitor (HDACls): 
suberoylanilide 
hydroxamic acid (SAHA) 
and sodium butyrate (SB) 
Synergistic Leukemia Multiple perturbations in signaling, cell cycle, 
and survival pathways that culminate in 
mitochondrial injury and apoptosis. Through 
ERK activation and p21CIP1, not Akt 
[452‐454] 
17‐AAG ATO (arsenic trioxide) Synergistic Leukemia Abrogate Akt activation, increased ROS 
generation 
[442, 455] 
17‐AAG Cytarabine Synergistic Leukemia (AML) Chk1 depletion [456, 457] 
17‐AAG Doxorubicin Synergistic Breast  RB and schedule dependent [458, 459] 
17‐AAG Trastuzumab (Herceptin) Enhancement Breast Reduce ErbB2 levels; phase 2 clinical trial for 
breast cancer 
[345, 426, 459] 
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Hsp90 inhibitors Drugs in combination Interaction Cancer type Mechanism Reference 
Radicicol Emunin, NZ28 (inhibit heat 
shock response) 
Sensitize Multiple myeloma Reduced Hsp70 level [460] 
17‐AAG X‐ray Synergistic Human oral 
squamous cell 
carcinoma 
DNA damage, DNA repair [404] 
17‐DMAG radiation Synergistic Human lung cancer 
cells 
ATM‐mediated DNA repair [315] 
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7.4 Conclusions 
In this project, we used comprehensive proteomics techniques to study the protein changes 
induced by Hsp90 inhibitors in B-lymphoid cancers. The results extend the list of Hsp90-
regulated proteins. Inhibitors down-regulate the Lyn kinase pathway, inhibit DNA repair and 
arrest cell cycle. Hsp90 inhibitors overcome various forms of drug resistance, such as imatinib 
resistance in MYLR CML cells, and 2-FaraA resistance in MEC1 CLL cells. Combining Hsp90 
inhibitors with other anti-cancer drugs, like 2-FaraA may provide more effective chemotherapy 
and reduce the toxicity found in Hsp90 inhibitor clinical trials. 
 
7.5 Future directions 
This project has identified novel proteins whose levels are modulated by the Hsp90 inhibitor 
SNX-7081, resulting in apoptosis. To further elucidate the roles of these proteins, transfection 
experiments with antisense oligonucleotides or expression vectors should be conducted. For 
example, the protein DDB1 decreased after SNX-7081 treatment of MEC1 cells. DDB1 has a 
role in DNA repair, so it would be interesting to see if knocking down DDB1 is sufficient to 
induce apoptosis, or whether high levels of DDB1 induced with a plasmid prevent apoptosis by 
SNX-7081. Similarly, it would be interesting to determine the effects of depletion and/or over-
expression of other DNA repair, cell cycle, RNA processing translation and transcription proteins 
we have identified, that changed abundance in response to SNX-7081. 
 
In addition, we identified protein changes in various B-lymphoid cancer cell lines. These cell 
lines are commonly used as models for malignancies. However, it is important that the findings 
generated here with cell lines are translated to leukaemia cells from patients. 
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For some of the proteins that changed abundance after SNX-7081 treatment of MEC1 cells, we 
found that their mRNA level also changed (Figure 4.5C in Chapter 4). The Hsp90 inhibitor 
increased the mRNA for Hsp70 and decreased mRNAs for GRP78, PDIA6, HLA-DR, PCNA, 
MCM2, and Nup155, suggesting that SNX-7081 induces changes in these proteins from the 
mRNA level. Since Hsp90 is a chaperone protein, inhibiting chaperones should only affect the 
stability and level of the client proteins [461], the mRNA level changes might be an indirect 
effect via the transcription factors whose levels changed after SNX-7081.  Our results showed 
that SNX-7081 decreased 4 transcription factors (AT-rich interactive domain-containing protein 
1A, SWI/SNF-related matrix-associated actin-dependent regulator of chromatin sub-family c 
member 1, zinc finger protein Aiolos and core-binding factor subunit beta; Table 4.1). Further 
investigation of how these mRNA level changes are connected with the transcription factor 
changes is warranted. One strategy could be testing whether the depletion and over-expression of 
the transcription factors could alter the mRNA levels of the proteins in Figure 4.5C. 
 
The future direction of the Hsp90 inhibitor research should be focused more on synergy with 
other drugs. Our result indicate potential drug combinations with Hsp90 inhibitor, some of these 
combination drug treatment have been tested, for example, we found the X-ray repair cross-
complementing protein 5 (XRCC5) decreased 2.00-fold after Hsp90 inhibitor treatment (Table 
6.2 in Chapter 6), consistent with the Hsp90 inhibitor 17-DMAG being synergistic with X-rays 
[404]. We propose that combination of SNX-7081 with an anti-CD19 therapeutic antibody (e.g., 
XmAb5574) should be synergistic because CD19 was increased by 1.55-fold after SNX-7081 
(Table 5.1 in Chapter 5). To determine which drugs will be more effective for combination 
treatment with Hsp90 inhibitors, more studies are required to understand the Hsp90 inhibitor 
mechanism and types of drug resistance. Some Hsp90 inhibitor-based combination treatments 
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should go to clinical trial following more in vitro experiments. However, there may be problems 
in performing trials that combine agents from highly competitive pharmaceutical companies [462, 
463]. Regulatory agencies, pharmaceutical firms and clinicians should cooperate because the 
rewards could be great in advancing our understanding of cancers and drug therapy for the 
benefit of cancer patients. 
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Table A1. Proteins increased in abundance after SNX-7081 (100nM, 48h) treatment (n = 3, p < 0.05) in MEC1 
cell. 
Gene identifier
a
 
Accession 
number
b
 
Protein names
c
 
Gene 
name
d
  
Biological 
processes
e
  
SNX‐
7081/Ctr 
ratio
f
 
ENSP00000368350 P13693  Translationally‐controlled 
tumor protein 
TPT1 apoptosis 17.3 
ENSP00000215909 P09382  Galectin‐1 LGALS1 apoptosis 13.8 
ENSP00000354201 Q9H832  Ubiquitin‐conjugating 
enzyme E2 Z 
UBE2Z apoptosis 8.15 
ENSP00000225402 Q9NY61  Protein AATF AATF apoptosis 6.34 
ENSP00000369081 Q8NBS9  Thioredoxin domain‐
containing protein 5 
TXNDC5 apoptosis 5.13 
ENSP00000343458 P51572  B‐cell receptor‐associated 
protein 31 
BCAP31 apoptosis 4.97 
ENSP00000361777 Q01105  Protein SET SET apoptosis 2.88 
ENSP00000261427 P61086  Ubiquitin‐conjugating 
enzyme E2 K 
UBE2K apoptosis 11.8 
ENSP00000348565 Q9GZZ9  Ubiquitin‐like modifier‐
activating enzyme 5 
UBA5 apoptosis 5.40 
ENSP00000253815 Q96RP6  Ubiquitin carrier protein  PUBC1  apoptosis 4.97 
ENSP00000330343 P55854  Small ubiquitin‐related 
modifier 3 
SUMO3 apoptosis 4.62 
ENSP00000360367 Q9ULC4  Malignant T cell‐amplified 
sequence 1 
MCTS1 cell cycle 3.55 
ENSP00000358921 P61163  Alpha‐centractin ACTR1A cell cycle 2.25 
ENSP00000264893 Q9NVA2  Septin‐11 Sep‐11 cell cycle 2.07 
ENSP00000360939 P30085  UMP‐CMP kinase CMPK1 cell metabolism 8.39 
ENSP00000246337 P06132  Uroporphyrinogen 
decarboxylase 
UROD cell metabolism 8.15 
ENSP00000310275 O75531  Barrier‐to‐autointegration 
factor 
BANF1 cell metabolism 5.66 
ENSP00000370748 Q13907  Isopentenyl‐diphosphate 
Delta‐isomerase 1 
IDI1 cell metabolism 5.09 
ENSP00000379037 P19971  Thymidine phosphorylase TYMP cell metabolism 4.97 
ENSP00000282272 Q8N8A2  Serine/threonine‐protein 
phosphatase 6 regulatory 
ankyrin repeat subunit B 
ANKRD44 cell metabolism 4.97 
ENSP00000277865 P00367  Glutamate dehydrogenase 
1, mitochondrial 
GLUD1 cell metabolism 4.42 
ENSP00000241052 P04040  Catalase CAT cell metabolism 3.07 
ENSP00000303147 P31153  S‐adenosylmethionine 
synthase isoform type‐2 
MAT2A cell metabolism 2.45 
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Gene identifier
a
 
Accession 
number
b
 
Protein names
c
 
Gene 
name
d
  
Biological 
processes
e
  
SNX‐
7081/Ctr 
ratio
f
 
ENSP00000284719 Q9NTK5  Obg‐like ATPase 1 OLA1 cell metabolism 2.45 
ENSP00000054950 Q15293  Reticulocalbin‐1 RCN1 cell metabolism 15.9 
ENSP00000297258 Q01469  Fatty acid‐binding protein, 
epidermal 
FABP5 cell metabolism 7.52 
ENSP00000320043 O75608  Acyl‐protein thioesterase 1 LYPLA1 cell metabolism 5.85 
ENSP00000325136 P55084  Trifunctional enzyme 
subunit beta, mitochondrial 
HADHB cell metabolism 4.89 
ENSP00000357873 P45954  Short/branched chain 
specific acyl‐CoA 
dehydrogenase, 
mitochondrial 
ACADSB cell metabolism 4.60 
ENSP00000359878 P11310  Medium‐chain specific acyl‐
CoA dehydrogenase, 
mitochondrial 
ACADM cell metabolism 3.87 
ENSP00000304006 P68402  Platelet‐activating factor 
acetylhydrolase IB subunit 
beta 
PAFAH1B2 cell metabolism 4.97 
ENSP00000352706 Q6NVY1  3‐hydroxyisobutyryl‐CoA 
hydrolase, mitochondrial 
HIBCH cell metabolism 6.73 
ENSP00000205402 P09622  Dihydrolipoyl 
dehydrogenase, 
mitochondrial 
DLD cell metabolism 2.39 
ENSP00000342026 P30041  Peroxiredoxin‐6 PRDX6 cell metabolism 5.67 
ENSP00000342564 Q02252  Methylmalonate‐
semialdehyde 
dehydrogenase [acylating], 
mitochondrial 
ALDH6A1 cell metabolism 5.13 
ENSP00000368646 Q13162  Peroxiredoxin‐4 PRDX4 cell metabolism 4.70 
ENSP00000216500 Q9Y394  Dehydrogenase/reductase 
SDR family member 7 
DHRS7 cell metabolism 4.70 
ENSP00000262746 Q06830  Peroxiredoxin‐1 PRDX1 cell metabolism 4.32 
ENSP00000249071 P15153  Ras‐related C3 botulinum 
toxin substrate 2 
RAC2 cell signaling 13.9 
ENSP00000262948 P36507  Dual specificity mitogen‐
activated protein kinase 
kinase 2 
MAP2K2 cell signaling   5.87 
ENSP00000344742 O95630  STAM‐binding protein STAMBP cell signaling   4.86 
ENSP00000296446 Q9BUB1  PRKAR2A protein  PRKAR2A  cell signaling   4.16 
ENSP00000291295 P62158  Calmodulin CALM1 cell signaling   4.07 
ENSP00000339467 P84095  Rho‐related GTP‐binding 
protein RhoG 
RHOG cell signling 8.39 
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ENSP00000228945 P52566  Rho GDP‐dissociation 
inhibitor 2 
ARHGDIB cell signling 4.35 
ENSP00000302486 Q02750  Dual specificity mitogen‐
activated protein kinase 
kinase 1 
MAP2K1 cell signling 2.08 
ENSP00000318687 Q92598  Heat shock protein 105 kDa HSPH1 chaperone 343 
ENSP00000248553 P04792  Heat shock protein beta‐1 HSPB1 chaperone 16.2 
ENSP00000350894 P50454  Serpin H1 SERPINH1 chaperone 12.6 
ENSP00000265028 Q9UBS4  DnaJ homolog subfamily B 
member 11 
DNAJB11 chaperone 9.07 
ENSP00000254322 P25685  DnaJ homolog subfamily B 
member 1 
DNAJB1 chaperone 8.39 
ENSP00000300026 P23284  Peptidyl‐prolyl cis‐trans 
isomerase B 
PPIB chaperone 5.77 
ENSP00000356989 Q9UHV9  Prefoldin subunit 2 PFDN2 chaperone 4.97 
ENSP00000262455 Q9BS26  Endoplasmic reticulum 
resident protein 44 
ERP44 chaperone 2.86 
ENSP00000270586 P28072  Proteasome subunit beta 
type‐6 
PSMB6 DNA damage 5.66 
ENSP00000384246 P35244  Replication protein A 14 kDa 
subunit 
RPA3 DNA damage 3.94 
ENSP00000292644 P35998  26S protease regulatory 
subunit 7 
PSMC2 DNA damage 3.17 
ENSP00000265304 Q04837  Single‐stranded DNA‐
binding protein, 
mitochondrial 
SSBP1 DNA replication 23.4 
ENSP00000363641 P10599  Thioredoxin TXN electron 
transport 
13.9 
ENSP00000234454 P35270  Sepiapterin reductase SPR electron 
transport 
11.8 
ENSP00000306397 P47985  Cytochrome b‐c1 complex 
subunit Rieske, 
mitochondrial 
UQCRFS1 electron 
transport 
5.85 
ENSP00000253452 P13073  Cytochrome c oxidase 
subunit 4 isoform 1, 
mitochondrial 
COX4I1 electron 
transport 
5.79 
ENSP00000341625 P00167  Cytochrome b5 CYB5A electron 
transport 
5.47 
ENSP00000364649 P21912  Succinate dehydrogenase 
[ubiquinone] iron‐sulfur 
subunit, mitochondrial 
SDHB electron 
transport 
4.97 
ENSP00000331897 P48735  Isocitrate dehydrogenase 
[NADP], mitochondrial 
IDH2 electron 
transport 
4.62 
ENSP00000260985 O75874  Isocitrate dehydrogenase 
[NADP] cytoplasmic 
IDH1 electron 
transport 
3.16 
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ENSP00000307786 P99999  Cytochrome c CYCS electron 
transport 
2.96 
ENSP00000270776 P52209  6‐phosphogluconate 
dehydrogenase, 
decarboxylating 
PGD electron 
transport 
2.72 
ENSP00000264932 P31040  Succinate dehydrogenase 
[ubiquinone] flavoprotein 
subunit, mitochondrial 
SDHA electron 
transport 
2.59 
ENSP00000303356 Q7Z4W1  L‐xylulose reductase DCXR electron 
transport 
2.52 
ENSP00000203407 P31930  Cytochrome b‐c1 complex 
subunit 1, mitochondrial 
UQCRC1 electron 
transport 
2.33 
ENSP00000340305 NA ubiquitin‐conjugating 
enzyme E2 variant 1 
[Source:HGNC 
Symbol;Acc:12494] 
NA NA 9.07 
ENSP00000272067 NA acid phosphatase 1, soluble 
[Source:HGNC 
Symbol;Acc:122] 
NA NA 8.39 
ENSP00000381237 NA histocompatibility (minor) 
13 [Source:HGNC 
Symbol;Acc:16435] 
NA NA 7.71 
ENSP00000370376 NA deoxyuridine 
triphosphatase 
[Source:HGNC 
Symbol;Acc:3078] 
NA NA 7.00 
ENSP00000376841 NA ubiquitin‐conjugating 
enzyme E2N (UBC13 
homolog, yeast) 
[Source:HGNC 
Symbol;Acc:12492] 
NA NA 5.13 
ENSP00000337669 NA cell division cycle 42 (GTP 
binding protein, 25kDa) 
[Source:HGNC 
Symbol;Acc:1736] 
NA NA 5.09 
ENSP00000252440 NA ECSIT homolog (Drosophila) 
[Source:HGNC 
Symbol;Acc:29548] 
NA NA 4.97 
ENSP00000085068 NA isochorismatase domain 
containing 2 [Source:HGNC 
Symbol;Acc:26278] 
NA NA 3.55 
ENSP00000379725 NA OCIA domain containing 1 
[Source:HGNC 
Symbol;Acc:16074] 
NA NA 3.35 
ENSP00000377939 NA UDP‐glucose 
pyrophosphorylase 2 
[Source:HGNC 
Symbol;Acc:12527] 
NA NA 2.08 
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ENSP00000196551 P46782  40S ribosomal protein S5 RPS5 protein 
biosynthesis 
4.90 
ENSP00000265537 Q15031  Probable leucyl‐tRNA 
synthetase, mitochondrial 
LARS2 protein 
biosynthesis 
6.38 
ENSP00000363559 P56537  Recommended name: 
Eukaryotic translation 
initiation factor 6 
EIF6 protein 
biosynthesis 
3.19 
ENSP00000326381 Q14240  Eukaryotic initiation factor 
4A‐II 
EIF4A2 protein 
biosynthesis 
2.53 
ENSP00000324438 P63220  40S ribosomal protein S21 RPS21 ribosomal 
protein 
16.0 
ENSP00000233609 P62841  40S ribosomal protein S15 RPS15 ribosomal 
protein 
12.5 
ENSP00000009589 P60866  40S ribosomal protein S20 RPS20 ribosomal 
protein 
12.4 
ENSP00000251453 P62249  40S ribosomal protein S16 RPS16 ribosomal 
protein 
11.2 
ENSP00000379381 NA ribosomal protein L30 
[Source:HGNC 
Symbol;Acc:10333] 
 ribosomal 
protein 
11.1 
ENSP00000270625 P62280  40S ribosomal protein S11 RPS11 ribosomal 
protein 
11.0 
ENSP00000311028 P62263  40S ribosomal protein S14 RPS14 ribosomal 
protein 
7.81 
ENSP00000347271 P46783  40S ribosomal protein S10 RPS10 ribosomal 
protein 
5.60 
ENSP00000221975 P39019  40S ribosomal protein S19 RPS19 ribosomal 
protein 
5.09 
ENSP00000360498 Q8IXM3  39S ribosomal protein L41, 
mitochondrial 
MRPL41 ribosomal 
protein 
4.97 
ENSP00000306548 Q9BYD1  39S ribosomal protein L13, 
mitochondrial 
MRPL13 ribosomal 
protein 
4.97 
ENSP00000322419 P05387  60S acidic ribosomal protein 
P2 
RPLP2 ribosomal 
protein 
4.67 
ENSP00000339095 P62081  40S ribosomal protein S7 RPS7 ribosomal 
protein 
2.40 
ENSP00000375798 P62316  Small nuclear 
ribonucleoprotein Sm D2 
SNRPD2 RNA processing 10.4 
ENSP00000254878 P52758  Ribonuclease UK114 HRSP12 RNA processing 8.39 
ENSP00000366997 Q9Y2L1  Exosome complex 
exonuclease RRP44 
DIS3 RNA processing 7.02 
ENSP00000266735 P62306  Small nuclear 
ribonucleoprotein F 
SNRPF RNA processing 5.66 
ENSP00000244020 Q13247  Serine/arginine‐rich splicing 
factor 6 
SRSF6 RNA processing 3.73 
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ENSP00000216038 Q9Y3I0  tRNA‐splicing ligase RtcB 
homolog 
C22orf28 RNA processing 2.90 
ENSP00000361927 P55795  Heterogeneous nuclear 
ribonucleoprotein H2 
HNRNPH2 RNA processing 2.56 
ENSP00000377892 Q13243  Serine/arginine‐rich splicing 
factor 5 
SRSF5 RNA processing 2.52 
ENSP00000361891 Q01518  Adenylyl cyclase‐associated 
protein 1 
CAP1 RNA processing 2.50 
ENSP00000349168 P31943  Heterogeneous nuclear 
ribonucleoprotein H 
HNRNPH1 RNA processing 2.08 
ENSP00000374777 P01834  Ig kappa chain C region IGKC structual protein 15.2 
ENSP00000349238 A6NC98  Coiled‐coil domain‐
containing protein 88B 
CCDC88B structual protein 7.77 
ENSP00000372873 O75955  Flotillin‐1 FLOT1 structual protein 7.26 
ENSP00000308383 P33241  Lymphocyte‐specific protein 
1 
LSP1 structual protein 2.28 
ENSP00000238688 Q9GZT3  SRA stem‐loop‐interacting 
RNA‐binding protein, 
mitochondrial 
SLIRP transcription 11.8 
ENSP00000265073 P53999  Activated RNA polymerase II 
transcriptional coactivator 
p15 
SUB1 transcription 8.10 
ENSP00000351410 P10644  cAMP‐dependent protein 
kinase type I‐alpha 
regulatory subunit 
PRKAR1A transcription 6.58 
ENSP00000284811 Q15369  Transcription elongation 
factor B polypeptide 1 
TCEB1 transcription 6.34 
ENSP00000218364 O43719  HIV Tat‐specific factor 1 HTATSF1 transcription 4.97 
ENSP00000365572 P22392  Nucleoside diphosphate 
kinase B 
NME2 transcription 4.70 
ENSP00000258531 Q13610  Periodic tryptophan protein 
1 homolog 
PWP1 transcription 3.94 
ENSP00000358983 Q00653  Nuclear factor NF‐kappa‐B 
p100 subunit 
NFKB2 transcription 3.33 
ENSP00000295066 Q9C005  Protein dpy‐30 homolog DPY30 transcription 3.17 
ENSP00000228251 P16989  DNA‐binding protein A CSDA transcription 2.93 
ENSP00000361626 P67809  Nuclease‐sensitive element‐
binding protein 1 
YBX1 transcription 2.85 
ENSP00000361453 Q96I24  Far upstream element‐
binding protein 3 
FUBP3 transcription 2.33 
ENSP00000377642 Q9H0U4  Ras‐related protein Rab‐1B RAB1B transport 19.3 
ENSP00000360184 Q9HD45  Transmembrane 9 
superfamily member 3 
TM9SF3 transport 14.7 
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ENSP00000367044 Q9P2E9  Ribosome‐binding protein 1 RRBP1 transport 14.7 
ENSP00000362728 O60684  Importin subunit alpha‐7 KPNA6 transport 10.1 
ENSP00000251595 P69905  Hemoglobin subunit alpha HBA1 transport 9.07 
ENSP00000345689 P51148  Ras‐related protein Rab‐5C RAB5C transport 7.71 
ENSP00000331201 O14964  Hepatocyte growth factor‐
regulated tyrosine kinase 
substrate 
HGS transport 4.95 
ENSP00000297540 Q9H814  Phosphorylated adapter 
RNA export protein 
PHAX transport 2.79 
ENSP00000355518 P07954  Fumarate hydratase, 
mitochondrial 
FH tumor 
suppressor 
2.69 
ENSP00000325548 Q96KP4  Cytosolic non‐specific 
dipeptidase 
CNDP2 tumor 
suppressor 
2.63 
ENSP00000205061 Q92896 Golgi apparatus protein 1 GLG1 uncharacterized 
protein 
7.43 
ENSP00000385059 B5MCW9  Uncharacterized protein EML4  uncharacterized 
protein 
12.5 
ENSP00000356632 Q9P1F3  Costars family protein 
C6orf115 
C6orf115 uncharacterized 
protein 
7.02 
ENSP00000333298 P11279  Lysosome‐associated 
membrane glycoprotein 1 
LAMP1 uncharacterized 
protein 
4.18 
ENSP00000350063 C9J7I6  Uncharacterized protein  PSAP  uncharacterized 
protein 
3.55 
ENSP00000225777 O43760  Synaptogyrin‐2 SYNGR2 uncharacterized 
protein 
3.36 
ENSP00000346785 A8K8J9  Dynactin 2 (P50), isoform 
CRA_b  
DCTN2  uncharacterized 
protein 
3.04 
ENSP00000355599 Q99598  Translin‐associated protein 
X 
TSNAX uncharacterized 
protein 
2.07 
a
Gene identifier is generated by global proteome machine (GPM) software with NCBI human protein database. 
b
Accession numbers were derived from the 2012_03 version of UniProtKB/Swiss‐Prot database. 
c
Protein names 
were protein names as in the  2012_03 version UniProtKB/Swiss‐Prot database. 
d
Gene names were gene names 
as in the 2012_03 version UniProtKB/Swiss‐Prot database. 
e
Biological processes were assigned using the 2012_03 
version UniProtKB/Swiss‐Prot database. 
f
Ratios were calculated based on NSAF value of triplicate SNX‐7081 
(100nM, 48h) treated MEC1 samples (SNF‐7081) and triplicate MEC1 control samples (Ctr) (p‐value < 0.05). 
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ENSP00000354558 P42345 Serine/threonine‐protein kinase 
mTOR 
MTOR apoptosis 0.15 
ENSP00000261359 Q9NR09  Baculoviral IAP repeat‐containing 
protein 6 
BIRC6 apoptosis 0.27 
ENSP00000365576 Q9UMX0  Ubiquilin‐1 UBQLN1 apoptosis 0.11 
ENSP00000368540 Q5T6F2  Ubiquitin‐associated protein 2 UBAP2 apoptosis 0.19 
ENSP00000220959 O95071  E3 ubiquitin‐protein ligase UBR5 UBR5 apoptosis 0.24 
ENSP00000347184 P42858  Huntingtin HTT apoptosis 0.10 
ENSP00000238616 Q8TD19  Serine/threonine‐protein kinase 
Nek9 
NEK9 cell cycle 0.09 
ENSP00000265872 Q8IX12  Cell division cycle and apoptosis 
regulator protein 1 
CCAR1 cell cycle 0.15 
ENSP00000251496 Q9BPX3  Condensin complex subunit 3 NCAPG cell cycle 0.18 
ENSP00000339109 Q9H1A4  Anaphase‐promoting complex 
subunit 1 
ANAPC1 cell cycle 0.19 
ENSP00000264714 O15355  Protein phosphatase 1G PPM1G cell cycle 0.22 
ENSP00000349961 Q9NTJ3  Structural maintenance of 
chromosomes protein 4 
SMC4 cell cycle 0.34 
ENSP00000286398 O95347  Structural maintenance of 
chromosomes protein 2 
SMC2 cell cycle 0.36 
ENSP00000273130 Q9Y6G9  Cytoplasmic dynein 1 light 
intermediate chain 1 
DYNC1LI1 cell cycle 0.49 
ENSP00000312262 P25098 Beta‐adrenergic receptor kinase 1 ADRBK1 cell metabolism 0.06 
ENSP00000279036 Q969N2  GPI transamidase component PIG‐
T 
PIGT cell metabolism 0.13 
ENSP00000271610 P08575  Receptor‐type tyrosine‐protein 
phosphatase C 
PTPRC cell metabolism 0.15 
ENSP00000349078 P14324  Farnesyl pyrophosphate synthase FDPS cell metabolism 0.19 
ENSP00000274335 P27986  Phosphatidylinositol 3‐kinase 
regulatory subunit alpha 
PIK3R1 cell metabolism 0.19 
ENSP00000265986 P14735  Insulin‐degrading enzyme IDE cell metabolism 0.20 
ENSP00000311130 Q9Y5P6  Mannose‐1‐phosphate 
guanyltransferase beta 
GMPPB cell metabolism 0.24 
ENSP00000222388 Q9UG63 ATP‐binding cassette sub‐family F 
member 2 
ABCF2 cell metabolism 0.05 
ENSP00000220584 P37268  Squalene synthase FDFT1 cell metabolism 0.36 
ENSP00000377404 Q13057 Bifunctional coenzyme A synthase COASY cell metabolism 0.05 
ENSP00000290573 P52789  Hexokinase‐2 HK2 cell metabolism 0.33 
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ENSP00000350012 O95573 Long‐chain‐fatty‐acid‐‐CoA ligase 3 ACSL3 cell metabolism 0.03 
ENSP00000264167 O00116  Alkyldihydroxyacetonephosphate 
synthase, peroxisomal 
AGPS cell metabolism 0.13 
ENSP00000355777 Q9H3P7  Golgi resident protein GCP60 ACBD3 cell metabolism 0.17 
ENSP00000198765 O75131  Copine‐3  CPNE3 cell metabolism 0.35 
ENSP00000337196 Q8N543  2‐oxoglutarate and iron‐
dependent oxygenase domain‐
containing protein 1 
OGFOD1 cell metabolism 0.13 
ENSP00000286091 P13667  Protein disulfide‐isomerase A4  PDIA4 cell metabolism 0.23 
ENSP00000291576 Q15269  Periodic tryptophan protein 2 
homolog 
PWP2 cell signaling 0.09 
ENSP00000341905 Q86YV0  RAS protein activator like‐3 RASAL3 cell signaling 0.10 
ENSP00000362664 Q6Y7W6 PERQ amino acid‐rich with GYF 
domain‐containing protein 2 
GIGYF2 cell signaling 0.02 
ENSP00000359045 Q86UY3  ARHGAP4 protein  ARHGAP4  cell signaling 0.10 
ENSP00000342278 P29728  2'‐5'‐oligoadenylate synthase 2 OAS2 cell signaling 0.08 
ENSP00000343032 Q8TCT9 Minor histocompatibility antigen 
H13 
HM13 DNA damage 0.05 
ENSP00000295640 Q9H4A4  Aminopeptidase B RNPEP DNA damage 0.25 
ENSP00000309474 Q99460  26S proteasome non‐ATPase 
regulatory subunit 1 
PSMD1 DNA damage 0.35 
ENSP00000264156 Q14566  DNA replication licensing factor 
MCM6 
MCM6 DNA replication 
and repair 
0.17 
ENSP00000307288 P33993  DNA replication licensing factor 
MCM7 
MCM7 DNA replication 
and repair 
0.20 
ENSP00000265056 P49736  DNA replication licensing factor 
MCM2 
MCM2 DNA replication 
and repair 
0.41 
ENSP00000216122 P33992  DNA replication licensing factor 
MCM5 
MCM5 DNA replication 
and repair 
0.42 
ENSP00000313420 P78527 DNA‐dependent protein kinase 
catalytic subunit 
DNA‐PK, 
PRKDC 
DNA replication 
and repair 
0.00 
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ENSP00000278412 Q08945  FACT complex subunit SSRP1 SSRP1 DNA replication 
and repair 
0.15 
ENSP00000353770 P31350  Ribonucleoside‐diphosphate 
reductase subunit M2 
RRM2 DNA replication 
and repair 
0.29 
ENSP00000264705 P27708  CAD protein CAD  DNA replication 
and repair 
0.33 
ENSP00000254108 P35637  RNA‐binding protein FUS FUS DNA replication 
and repair 
0.49 
ENSP00000313490 O15067  Phosphoribosylformylglycinamidin
e synthase 
PFAS DNA replication 
and repair 
0.49 
ENSP00000362963 Q15233  Non‐POU domain‐containing 
octamer‐binding protein 
NONO DNA replication 
and repair 
0.50 
ENSP00000375978 P13010  X‐ray repair cross‐complementing 
protein 5 
XRCC5 
(Ku80) 
DNA replication 
and repair 
0.50 
ENSP00000305480 P39748  Flap endonuclease 1 FEN1 DNA replication 
and repair 
0.50 
ENSP00000227471 Q9H1C4  Protein unc‐93 homolog B1 UNC93B1 immunity 0.19 
ENSP00000320324 P55786  Puromycin‐sensitive 
aminopeptidase 
NPEPPS immunity 0.31 
ENSP00000301453 Q96FW1  Ubiquitin thioesterase OTUB1 OTUB1 immunity 0.32 
ENSP00000239690 Q96RS6  NudC domain‐containing protein 1  NUDCD1 immunity 0.34 
ENSP00000381027 O15042 U2 snRNP‐associated SURP motif‐
containing protein 
NA NA 0.42 
ENSP00000378879 NA ATPase, Ca++ transporting, cardiac 
muscle, fast twitch 1 
[Source:HGNC Symbol;Acc:811] 
NA NA 0.02 
ENSP00000309314 NA WDFY family member 4 
[Source:HGNC Symbol;Acc:29323] 
NA NA 0.04 
ENSP00000378322 NA protein phosphatase 3, catalytic 
subunit, alpha isozyme 
[Source:HGNC Symbol;Acc:9314] 
NA NA 0.04 
ENSP00000337632 P82979 SAP domain‐containing 
ribonucleoprotein 
NA NA 0.05 
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ENSP00000265453 NA WDFY family member 4 
[Source:HGNC Symbol;Acc:29323] 
NA NA 0.06 
ENSP00000349378 NA parvin, gamma [Source:HGNC 
Symbol;Acc:14654] 
NA NA 0.07 
ENSP00000378278 NA small nucleolar RNA, C/D box 19B 
[Source:HGNC Symbol;Acc:33570] 
NA NA 0.10 
ENSP00000366756 NA scribbled homolog (Drosophila) 
[Source:HGNC Symbol;Acc:30377] 
NA NA 0.11 
ENSP00000300027 NA Fanconi anemia, 
complementation group I 
[Source:HGNC Symbol;Acc:25568] 
NA NA 0.11 
ENSP00000314075 NA A kinase (PRKA) anchor protein 1 
[Source:HGNC Symbol;Acc:367] 
NA NA 0.11 
ENSP00000378768 NA HLA class II histocompatibility 
antigen, DQ alpha 1 chain 
precursor  [Source:RefSeq 
peptide;Acc:NP_002113] 
NA NA 0.12 
ENSP00000380000 NA CTD (carboxy‐terminal domain, 
RNA polymerase II, polypeptide A) 
small phosphatase like 2 
[Source:HGNC Symbol;Acc:26936] 
NA NA 0.12 
ENSP00000356424 NA ubiquitin carboxyl‐terminal 
hydrolase L5 [Source:HGNC 
Symbol;Acc:19678] 
NA NA 0.13 
ENSP00000376167 NA G protein pathway suppressor 1 
[Source:HGNC Symbol;Acc:4549] 
NA NA 0.13 
ENSP00000371265 NA nucleoporin 155kDa 
[Source:HGNC Symbol;Acc:8063] 
NA NA 0.14 
ENSP00000302993 NA FIP1 like 1 (S. cerevisiae) 
[Source:HGNC Symbol;Acc:19124] 
NA NA 0.18 
ENSP00000347404 NA nucleoporin 98kDa [Source:HGNC 
Symbol;Acc:8068] 
NA NA 0.19 
ENSP00000293362 NA proteasome (prosome, 
macropain) activator subunit 3 
(PA28 gamma; Ki) [Source:HGNC 
Symbol;Acc:9570] 
NA NA 0.22 
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ENSP00000385157 NA acyl‐CoA synthetase long‐chain 
family member 3 [Source:HGNC 
Symbol;Acc:3570] 
NA NA 0.24 
ENSP00000354742 NA importin 9 [Source:HGNC 
Symbol;Acc:19425] 
 NA 0.25 
ENSP00000345352 NA TRAF2 and NCK interacting kinase 
[Source:HGNC Symbol;Acc:30765] 
NA NA 0.27 
ENSP00000264263 NA G elongation factor, mitochondrial 
1 [Source:HGNC 
Symbol;Acc:13780] 
NA NA 0.29 
ENSP00000347396 NA nucleoporin 50kDa [Source:HGNC 
Symbol;Acc:8065] 
NA NA 0.30 
ENSP00000374296 NA cell cycle associated protein 1 
[Source:HGNC Symbol;Acc:6743] 
NA NA 0.32 
ENSP00000346246 NA adaptor‐related protein complex 
2, alpha 1 subunit [Source:HGNC 
Symbol;Acc:561] 
NA NA 0.34 
ENSP00000304161 NA mucosa associated lymphoid 
tissue lymphoma translocation 
gene 1 [Source:HGNC 
Symbol;Acc:6819] 
NA NA 0.36 
ENSP00000296754 NA endoplasmic reticulum 
aminopeptidase 1 [Source:HGNC 
Symbol;Acc:18173] 
NA NA 0.42 
ENSP00000368129 NA apoptosis inhibitor 5 
[Source:HGNC Symbol;Acc:594] 
NA NA 0.43 
ENSP00000034275 NA RAN binding protein 3 
[Source:HGNC Symbol;Acc:9850] 
NA NA 0.49 
ENSP00000257347 Q9HA77  Probable cysteinyl‐tRNA 
synthetase, mitochondrial 
CARS2 Protein 
biosynthesis 
0.10 
ENSP00000358060 Q9BW92  Threonyl‐tRNA synthetase, 
mitochondrial 
TARS2 Protein 
biosynthesis 
0.19 
ENSP00000377845 P08243  Asparagine synthetase [glutamine‐
hydrolyzing] 
ASNS Protein 
biosynthesis 
0.22 
ENSP00000265112 P26639  Threonyl‐tRNA synthetase, 
cytoplasmic 
TARS Protein 
biosynthesis 
0.31 
ENSP00000307567 P47897  Glutaminyl‐tRNA synthetase QARS protein 
biosynthesis 
0.41 
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ENSP00000380300 P49589  Cysteinyl‐tRNA synthetase, 
cytoplasmic 
CARS Protein 
biosynthesis 
0.41 
ENSP00000303279 Q9NSE4  Isoleucyl‐tRNA synthetase, 
mitochondrial 
IARS2 Protein 
biosynthesis 
0.42 
ENSP00000281828 Q9NSD9  Phenylalanyl‐tRNA synthetase 
beta chain 
FARSB Protein 
biosynthesis 
0.46 
ENSP00000385657 Q15435 Protein phosphatase 1 regulatory 
subunit 7 
PPP1R7 protein 
biosynthesis 
0.04 
ENSP00000228506 Q14165  Malectin MLEC protein 
biosynthesis 
0.07 
ENSP00000358115 Q5TB20  Acidic (Leucine‐rich) nuclear 
phosphoprotein 32 family, 
member E 
ANP32E  protein 
biosynthesis 
0.27 
ENSP00000258960 P30419  Glycylpeptide N‐
tetradecanoyltransferase 1 
NMT1 protein 
biosynthesis 
0.42 
ENSP00000262832 Q9Y262  Eukaryotic translation initiation 
factor 3 subunit L 
EIF3L protein 
biosynthesis 
0.21 
ENSP00000289371 O60841  Eukaryotic translation initiation 
factor 5B 
EIF5B protein 
biosynthesis 
0.27 
ENSP00000319910 Q7L2H7  Eukaryotic translation initiation 
factor 3 subunit M 
EIF3M protein 
biosynthesis 
0.30 
ENSP00000380206 P55884  Eukaryotic translation initiation 
factor 3 subunit B 
EIF3B protein 
biosynthesis 
0.34 
ENSP00000372199 O60287 Nucleolar pre‐ribosomal‐
associated protein 1 
URB1 ribosomal 
protein 
0.04 
ENSP00000307889 P26373  60S ribosomal protein L13 RPL13 ribosomal 
protein 
0.18 
ENSP00000331815 Q12788  Transducin beta‐like protein 3 TBL3 RNA processing 0.16 
ENSP00000261973 P49756 RNA‐binding protein 25 RBM25 RNA processing 0.03 
ENSP00000297990 Q9H6R4 Nucleolar protein 6 NOL6 RNA processing 0.04 
ENSP00000340557 Q14004  Cyclin‐dependent kinase 13 CDK13 RNA processing 0.04 
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ENSP00000268482 Q92620 Pre‐mRNA‐splicing factor ATP‐
dependent RNA helicase PRP16 
DHX38 RNA processing 0.06 
ENSP00000285873 Q8TEQ6  Gem‐associated protein 5 GEMIN5 RNA processing 0.07 
ENSP00000298875 Q9P2I0  Cleavage and polyadenylation 
specificity factor subunit 2 
CPSF2 RNA processing 0.08 
ENSP00000261741 Q9Y4C8  Probable RNA‐binding protein 19 RBM19 RNA processing 0.11 
ENSP00000225388 Q7Z417  Nuclear fragile X mental 
retardation‐interacting protein 2 
NUFIP2 RNA processing 0.12 
ENSP00000362532 Q9NQG5  Regulation of nuclear pre‐mRNA 
domain‐containing protein 1B 
RPRD1B RNA processing 0.12 
ENSP00000356476 Q7Z2T5  TRMT1‐like protein TRMT1L RNA processing 0.12 
ENSP00000203001 Q9UJA5  tRNA (adenine‐N(1)‐)‐
methyltransferase non‐catalytic 
subunit TRM6 
TRMT6 RNA processing 0.13 
ENSP00000319771 Q8NI36  WD repeat‐containing protein 36 WDR36 RNA processing 0.14 
ENSP00000345456 B4DDG8  cDNA FLJ58764, highly similar to 
Poly(A)‐specific ribonuclease 
PARN (EC3.1.13.4)  
PARN RNA processing 0.14 
ENSP00000328854 Q9BVI4  Nucleolar complex protein 4 
homolog 
NOC4L RNA processing 0.15 
ENSP00000236051 Q99848  Probable rRNA‐processing protein 
EBP2 
EBNA1BP2 RNA processing 0.15 
ENSP00000221448 P08621  U1 small nuclear 
ribonucleoprotein 70 kDa 
SNRNP70 RNA processing 0.15 
ENSP00000304350 Q6P2Q9  Pre‐mRNA‐processing‐splicing 
factor 8 
PRPF8 RNA processing 0.18 
ENSP00000380738 P13489  Ribonuclease inhibitor RNH1 RNA processing 0.19 
ENSP00000360828 Q96GQ7  Probable ATP‐dependent RNA 
helicase DDX27 
DDX27 RNA processing 0.19 
ENSP00000359988 Q05519  Serine/arginine‐rich splicing factor 
11 
SRSF11 RNA processing 0.20 
ENSP00000346236 Q7L014  Probable ATP‐dependent RNA 
helicase DDX46 
DDX46 RNA processing 0.20 
ENSP00000301740 Q9UQ35  Serine/arginine repetitive matrix 
protein 2 
SRRM2 RNA processing 0.25 
ENSP00000336741 O43143  Putative pre‐mRNA‐splicing factor 
ATP‐dependent RNA helicase 
DHX15 
DHX15 RNA processing 0.25 
ENSP00000326261 Q8IYB3  Serine/arginine repetitive matrix 
protein 1 
SRRM1 RNA processing 0.27 
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ENSP00000312059 P52594  Arf‐GAP domain and FG repeats‐
containing protein 1 
AGFG1 RNA processing 0.30 
ENSP00000315791 Q12996  Cleavage stimulation factor 
subunit 3 
CSTF3 RNA processing 0.30 
ENSP00000305556 Q15365  Poly(rC)‐binding protein 1 PCBP1 RNA processing 0.36 
ENSP00000307863 P26368  Splicing factor U2AF 65 kDa 
subunit 
U2AF2 RNA processing 0.37 
ENSP00000317123 O75643  U5 small nuclear 
ribonucleoprotein 200 kDa 
helicase 
SNRNP200 RNA processing 0.41 
ENSP00000258962 Q07955  Serine/arginine‐rich splicing factor 
1 
SRSF1 RNA processing 0.42 
ENSP00000320663 Q9HC35 Echinoderm microtubule‐
associated protein‐like 4 
EML4 structrual 
protein 
0.02 
ENSP00000324020 Q9NS87 Kinesin‐like protein KIF15 KIF15 structrual 
protein 
0.07 
ENSP00000267812 P55081  Microfibrillar‐associated protein 1 MFAP1 structrual 
protein 
0.08 
ENSP00000327077 Q15154  Pericentriolar material 1 protein PCM1 structrual 
protein 
0.15 
ENSP00000347719 Q9BTW9  Tubulin‐specific chaperone D TBCD structrual 
protein 
0.26 
ENSP00000286713 P27105  Erythrocyte band 7 integral 
membrane protein 
STOM structrual 
protein 
0.27 
ENSP00000349259 Q01082  Spectrin beta chain, brain 1 SPTBN1 structrual 
protein 
0.33 
ENSP00000365891 P42768  Wiskott‐Aldrich syndrome protein WAS structrual 
protein 
0.34 
ENSP00000360305 O00151  PDZ and LIM domain protein 1 PDLIM1 structrual 
protein 
0.39 
ENSP00000374280 Q92541  RNA polymerase‐associated 
protein RTF1 homolog 
RTF1 transcription 0.09 
ENSP00000302640 P17480  Nucleolar transcription factor 1 UBTF transcription 0.11 
ENSP00000327436 Q86TU7  Histone‐lysine N‐
methyltransferase setd3 
SETD3 transcription 0.12 
ENSP00000306123 Q9BWH6  RNA polymerase II‐associated 
protein 1 
RPAP1 transcription 0.13 
ENSP00000369887 Q9NWH9  SAFB‐like transcription modulator SLTM transcription 0.15 
ENSP00000377969 P35269  General transcription factor IIF 
subunit 1 
 GTF2F1 transcription 0.19 
ENSP00000361219 Q9UKN8  General transcription factor 3C 
polypeptide 4 
GTF3C4 transcription 0.27 
ENSP00000307260 Q9Y4P3  Transducin beta‐like protein 2 TBL2 transcription 0.27 
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ENSP00000296543 Q9BXJ9  N‐alpha‐acetyltransferase 15, 
NatA auxiliary subunit 
NAA15 transcription 0.30 
ENSP00000354394 P42224  Signal transducer and activator of 
transcription 1‐alpha/beta 
STAT1 transcription 0.34 
ENSP00000254718 Q9BQG0  Myb‐binding protein 1A MYBBP1A transcription 0.35 
ENSP00000318195 P19338  Nucleolin NCL transcription 0.40 
ENSP00000253363 Q14498 RNA‐binding protein 39 RBM39 transcription 0.03 
ENSP00000303623 Q15758 Neutral amino acid transporter 
B(0) 
SLC1A5 transport 0.02 
ENSP00000381823 O95486 Protein transport protein Sec24A SEC24A transport 0.03 
ENSP00000367721 Q12769 Nuclear pore complex protein 
Nup160 
NUP160 transport 0.07 
ENSP00000285968 Q92621  Nuclear pore complex protein 
Nup205 
NUP205 transport 0.11 
ENSP00000310668 Q8N1F7  Nuclear pore complex protein 
Nup93 
NUP93 transport 0.14 
ENSP00000378555 Q8NBI5  Solute carrier family 43 member 3 SLC43A3 transport 0.15 
ENSP00000350692 B7ZA04  cDNA, FLJ79018, highly similar to 
Cytoplasmic dynein 1 
intermediate chain 2  
DYNC1I2 transport 0.19 
ENSP00000266544 Q96P70  Importin‐9 IPO9 transport 0.26 
ENSP00000336712 Q92973  Transportin‐1 TNPO1 transport 0.28 
ENSP00000252512 Q9UIA9  Exportin‐7 XPO7 transport 0.31 
ENSP00000316651 Q9UI26  Importin‐11 IPO11 transport 0.34 
ENSP00000359000 Q92538  Golgi‐specific brefeldin A‐
resistance guanine nucleotide 
exchange factor 1 
GBF1 uncharacterized 
protein 
0.23 
ENSP00000380647 E9PAL7  Uncharacterized protein SSR1  uncharacterized 
protein 
0.27 
ENSP00000361059 Q5T8U5  Surfeit 4 SURF4  uncharacterized 
protein 
0.29 
ENSP00000371767 E9PFM1  Uncharacterized protein EIF4G1 uncharacterized 
protein 
0.35 
ENSP00000381779 E2QRM3  Uncharacterized protein  XPO5  uncharacterized 
protein 
0.42 
ENSP00000383444 F2Z2X4 Uncharacterized protein  XPO4 uncharacterized 
protein 
0.04 
ENSP00000385067 E7ERC1 Uncharacterized protein  CDK11A uncharacterized 
protein 
0.06 
ENSP00000363952 C9JXC9  Uncharacterized protein  RNF20 uncharacterized 
protein 
0.10 
ENSP00000360401 A6NJZ9  Uncharacterized protein  NOC3L uncharacterized 
protein 
0.11 
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ENSP00000313953 Q6P3X3  Tetratricopeptide repeat protein 
27 
TTC27 uncharacterized 
protein 
0.12 
ENSP00000347626 Q8IVD9  NudC domain‐containing protein 3 NUDCD3 uncharacterized 
protein 
0.13 
ENSP00000253247 Q9H8H0  Nucleolar protein 11 NOL11 uncharacterized 
protein 
0.13 
ENSP00000368219 A6NFX8  Uncharacterized protein  NUDT5  uncharacterized 
protein 
0.13 
ENSP00000297440 Q86Y56  HEAT repeat‐containing protein 2 HEATR2 uncharacterized 
protein 
0.13 
ENSP00000269230 A6NDZ9  Uncharacterized protein  PELP1  uncharacterized 
protein 
0.19 
ENSP00000296126 C9IZK7  WD repeat‐containing protein 43 WDR43  uncharacterized 
protein 
0.21 
ENSP00000383086 E7EU96  Uncharacterized protein CSNK2A1  uncharacterized 
protein 
0.23 
ENSP00000369599 Q5VW36  Uncharacterized protein KIAA1797 KIAA1797 uncharacterized 
protein 
0.11 
a
Gene identifier is generated by global proteome machine (GPM) software with NCBI human protein database. 
b
Accession numbers were derived from the 2012_03 version of UniProtKB/Swiss‐Prot database. 
c
Protein names 
were protein names as in the  2012_03 version UniProtKB/Swiss‐Prot database. 
d
Gene names were gene names 
as in the 2012_03 version UniProtKB/Swiss‐Prot database. 
e
Biological processes were assigned using the 2012_03 
version UniProtKB/Swiss‐Prot database. 
f
Ratios were calculated based on NSAF value of triplicate  SNX‐7081 
(100nM, 48h) treated MEC1 samples (SNF‐7081) and triplicate MEC1 control samples (Ctr) (p‐value < 0.05). 
 
 
 
 
Table A3. Proteins increased in abundance after 2-FaraA (10 µM, 48h) treatment (n = 3, p < 0.05) in MEC1 cell. 
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ENSP00000288266 Q9UKG1  DCC‐interacting protein 13‐
alpha 
APPL1 apoptosis 9.87 
ENSP00000246535 Q9BRP1  Programmed cell death 
protein 2‐like 
PDCD2L apoptosis 3.76 
ENSP00000241052 P04040  Catalase CAT apoptosis 2.44 
ENSP00000323687 Q9C0C9  Ubiquitin‐conjugating enzyme 
E2 O 
UBE2O apoptosis 5.33 
ENSP00000231487 P63208  S‐phase kinase‐associated 
protein 1 
SKP1 cell cycle 14.3 
ENSP00000261819 Q9UJX4  Anaphase‐promoting complex 
subunit 5 
ANAPC5 cell cycle 9.87 
ENSP00000325618 Q53GL7  Poly [ADP‐ribose] polymerase 
10 
PARP10 cell cycle 7.65 
Appendix Tables 
220 
 
Gene identifier
a
 Accession 
number
b
 
Protein names
c
 Gene name
d
  Biological 
processes
e
  
2‐
FaraA/Ctr 
ratio
f
 
ENSP00000264893 Q9NVA2  Septin‐11 40787 cell cycle 2.47 
ENSP00000234454 P35270  Sepiapterin reductase SPR cell metabolism 11.0 
ENSP00000217456 Q9HDC9  Adipocyte plasma membrane‐
associated protein 
APMAP cell metabolism 4.76 
ENSP00000277865 P00367  Glutamate dehydrogenase 1, 
mitochondrial 
GLUD1 cell metabolism 3.66 
ENSP00000275072 Q8IYS1  Peptidase M20 domain‐
containing protein 2 
PM20D2 cell metabolism 3.01 
ENSP00000303147 P31153  S‐adenosylmethionine 
synthase isoform type‐2 
MAT2A cell metabolism 2.86 
ENSP00000364403 Q5T4S7  E3 ubiquitin‐protein ligase 
UBR4 
UBR4 cell metabolism 2.17 
ENSP00000378995 P30049  ATP synthase subunit delta, 
mitochondrial 
ATP5D cell metabolism 9.87 
ENSP00000284719 Q9NTK5  Obg‐like ATPase 1 OLA1 cell metabolism 2.30 
ENSP00000317310 Q9NZU7 Calcium‐binding protein 1 CABP1 cell metabolism 8.76 
ENSP00000320043 O75608  Acyl‐protein thioesterase 1 LYPLA1 cell metabolism 7.80 
ENSP00000325136 P55084  Trifunctional enzyme subunit 
beta, mitochondrial 
HADHB cell metabolism 3.21 
ENSP00000260985 O75874  Isocitrate dehydrogenase 
[NADP] cytoplasmic 
IDH1 cell metabolism 2.80 
ENSP00000342026 P30041  Peroxiredoxin‐6 PRDX6 cell metabolism 4.44 
ENSP00000245796 Q8NDX1  PH and SEC7 domain‐
containing protein 4 
PSD4 cell signalling 9.87 
ENSP00000262948 P36507  Dual specificity mitogen‐
activated protein kinase 
kinase 2 
MAP2K2 cell signalling 8.90 
ENSP00000349629 P50851  Lipopolysaccharide‐
responsive and beige‐like 
anchor protein 
LRBA cell signalling 7.75 
ENSP00000296446 Q9BUB1  PRKAR2A protein PRKAR2A  cell signalling 3.11 
ENSP00000302486 Q02750  Dual specificity mitogen‐
activated protein kinase 
kinase 1 
MAP2K1 cell signalling 2.87 
ENSP00000265028 Q9UBS4  DnaJ homolog subfamily B 
member 11 
DNAJB11 chaperone 24.3 
ENSP00000356989 Q9UHV9  Prefoldin subunit 2 PFDN2 chaperone 18.7 
ENSP00000383003 P62942  Peptidyl‐prolyl cis‐trans 
isomerase FKBP1A 
FKBP1A chaperone 12.1 
ENSP00000255631 Q9NZL4  Hsp70‐binding protein 1  HSPBP1 chaperone 9.87 
ENSP00000350894 P50454  Serpin H1  SERPINH1 chaperone 6.47 
ENSP00000040738 Q8NFC6  Biorientation of chromosomes 
in cell division protein 1‐like 
BOD1L DNA damage 9.87 
ENSP00000350217 C9J5P2  DNA topoisomerase 2  TOP2A  DNA damage 12.5 
ENSP00000339957 Q96K76  Ubiquitin carboxyl‐terminal 
hydrolase 47 
USP47 DNA damage 9.87 
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ENSP00000262193 P20618  Proteasome subunit beta 
type‐1 
PSMB1 DNA damage 7.39 
ENSP00000349667 A6NP15  Proteasome (Prosome, 
macropain) 26S subunit, non‐
ATPase, 12, isoform CRA_c 
PSMD12  DNA damage 6.47 
ENSP00000360367 Q9ULC4  Malignant T cell‐amplified 
sequence 1 
MCTS1 DNA damage 5.18 
ENSP00000044462 P25789  Proteasome subunit alpha 
type‐4 
PSMA4 DNA damage 4.76 
ENSP00000353701 Q9NY33  Dipeptidyl peptidase 3 DPP3 DNA damage 3.03 
ENSP00000371267 P27348  14‐3‐3 protein theta YWHAQ DNA damage 2.60 
ENSP00000265304 Q04837  Single‐stranded DNA‐binding 
protein, mitochondrial 
SSBP1 DNA replication 
and repair 
21.0 
ENSP00000361777 Q01105  Protein SET SET DNA replication 
and repair 
2.46 
ENSP00000375693 E7EVW0  DNA polymerase POLD1  DNA replication 
and repair 
2.27 
ENSP00000221413 Q9Y230  RuvB‐like 2 RUVBL2 DNA replication 
and repair 
2.03 
ENSP00000363641 P10599  Thioredoxin TXN electron transport 25.4 
ENSP00000306397 P47985  Cytochrome b‐c1 complex 
subunit Rieske, mitochondrial 
UQCRFS1 electron transport 9.37 
ENSP00000307786 P99999  Cytochrome c CYCS electron transport 2.00 
ENSP00000379978 P61769  Beta‐2‐microglobulin B2M Immunity 8.76 
ENSP00000334564 Q9BUI4  DNA‐directed RNA 
polymerase III subunit RPC3 
POLR3C immunity 6.23 
ENSP00000381237 NA histocompatibility (minor) 13 
[Source:HGNC 
Symbol;Acc:16435] 
NA NA 23.2 
ENSP00000370376 NA deoxyuridine triphosphatase 
[Source:HGNC 
Symbol;Acc:3078] 
NA NA 13.0 
ENSP00000340305 NA ubiquitin‐conjugating enzyme 
E2 variant 1 [Source:HGNC 
Symbol;Acc:12494] 
NA NA 9.87 
ENSP00000359328 NA mitochondrial translation 
optimization 1 homolog (S. 
cerevisiae) [Source:HGNC 
Symbol;Acc:19261] 
NA NA 8.76 
ENSP00000337669 NA cell division cycle 42 (GTP 
binding protein, 25kDa) 
[Source:HGNC 
Symbol;Acc:1736] 
NA NA 7.80 
ENSP00000355069 NA paired box 2 [Source:HGNC 
Symbol;Acc:8616] 
NA NA 7.65 
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ENSP00000382743 NA CUGBP, Elav‐like family 
member 2 [Source:HGNC 
Symbol;Acc:2550] 
NA NA 5.51 
ENSP00000380013 NA zinc finger protein 384 
[Source:HGNC 
Symbol;Acc:11955] 
NA NA 5.18 
ENSP00000249837 NA vacuolar protein sorting 13 
homolog C (S. cerevisiae) 
[Source:HGNC 
Symbol;Acc:23594] 
NA NA 5.07 
ENSP00000339283 NA neurolysin (metallopeptidase 
M3 family) [Source:HGNC 
Symbol;Acc:16058] 
NA NA 4.42 
ENSP00000258123 NA ubiquitin specific peptidase 15 
[Source:HGNC 
Symbol;Acc:12613] 
NA NA 4.42 
ENSP00000378705 NA CUGBP, Elav‐like family 
member 1 [Source:HGNC 
Symbol;Acc:2549] 
NA NA 4.30 
ENSP00000244815 NA leucine rich repeat (in FLII) 
interacting protein 1 
[Source:HGNC 
Symbol;Acc:6702] 
NA NA 3.55 
ENSP00000320493 NA thyroid hormone receptor 
interactor 10 [Source:HGNC 
Symbol;Acc:12304] 
NA NA 2.82 
ENSP00000265754 NA eukaryotic translation 
initiation factor 4H 
[Source:HGNC 
Symbol;Acc:12741] 
NA NA 2.72 
ENSP00000362548 NA adenylate kinase 2 
[Source:HGNC 
Symbol;Acc:362] 
NA NA 2.67 
ENSP00000257721 NA testis derived transcript (3 LIM 
domains) [Source:HGNC 
Symbol;Acc:14620] 
NA NA 2.61 
ENSP00000360771 NA SEC16 homolog A (S. 
cerevisiae) [Source:HGNC 
Symbol;Acc:29006] 
NA NA 2.43 
ENSP00000354075 NA notchless homolog 1 
(Drosophila) [Source:HGNC 
Symbol;Acc:19889] 
NA NA 2.41 
ENSP00000302919 NA SWI/SNF related, matrix 
associated, actin dependent 
regulator of chromatin, 
subfamily c, member 2 
[Source:HGNC 
Symbol;Acc:11105] 
NA NA 2.38 
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ENSP00000377939 NA UDP‐glucose 
pyrophosphorylase 2 
[Source:HGNC 
Symbol;Acc:12527] 
NA NA 2.23 
ENSP00000348279 NA reticulon 3 [Source:HGNC 
Symbol;Acc:10469] 
NA NA 2.21 
ENSP00000320658 Q9Y2Z4  Tyrosyl‐tRNA synthetase, 
mitochondrial 
YARS2 protein 
biosynthesis 
8.85 
ENSP00000221431 Q9NP81  Seryl‐tRNA synthetase, 
mitochondrial 
SARS2 protein 
biosynthesis 
7.50 
ENSP00000265537 Q15031  Probable leucyl‐tRNA 
synthetase, mitochondrial 
LARS2 protein 
biosynthesis 
5.32 
ENSP00000244230 O00566  U3 small nucleolar 
ribonucleoprotein protein 
MPP10 
MPHOSPH10 protein 
biosynthesis 
3.68 
ENSP00000304668 P12081 Histidyl‐tRNA synthetase, 
cytoplasmic 
HARS protein 
biosynthesis 
2.33 
ENSP00000176763 O94804  Serine/threonine‐protein 
kinase 10 
STK10 protein 
biosynthesis 
2.89 
ENSP00000205402 P09622  Dihydrolipoyl dehydrogenase, 
mitochondrial 
DLD protein 
biosynthesis 
2.08 
ENSP00000269349 P38919  Eukaryotic initiation factor 4A‐
III 
EIF4A3 protein 
biosynthesis 
2.14 
ENSP00000233609 P62841  40S ribosomal protein S15 RPS15 ribosomal protein 12.1 
ENSP00000311028 P62263  40S ribosomal protein S14 RPS14 ribosomal protein 9.10 
ENSP00000379381 NA ribosomal protein L30 
[Source:HGNC 
Symbol;Acc:10333] 
 ribosomal protein 8.76 
ENSP00000270625 P62280  40S ribosomal protein S11 RPS11 ribosomal protein 4.08 
ENSP00000359645 P38159  Heterogeneous nuclear 
ribonucleoprotein G 
RBMX RNA processing 3.56 
ENSP00000327543 Q8IY67  Ribonucleoprotein PTB‐
binding 1 
RAVER1 RNA processing 55.3 
ENSP00000339353 Q10570  Cleavage and polyadenylation 
specificity factor subunit 1 
CPSF1 RNA processing 14.3 
ENSP00000356146 Q9UPN6  Protein SCAF8 SCAF8 RNA processing 12.1 
ENSP00000325377 Q9C0J8  pre‐mRNA 3' end processing 
protein WDR33 
WDR33 RNA processing 11.0 
ENSP00000266735 P62306  Small nuclear 
ribonucleoprotein F 
SNRPF RNA processing 9.87 
ENSP00000375798 P62316  Small nuclear 
ribonucleoprotein Sm D2 
SNRPD2 RNA processing 8.76 
ENSP00000261167 Q9Y2W2  WW domain‐binding protein 
11 
WBP11 RNA processing 7.65 
ENSP00000244020 Q13247  Serine/arginine‐rich splicing 
factor 6 
SRSF6 RNA processing 3.56 
ENSP00000351811 Q6P2E9  Enhancer of mRNA‐decapping 
protein 4 
EDC4 RNA processing 2.44 
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ENSP00000320503 Q96F86  Enhancer of mRNA‐decapping 
protein 3 
EDC3 RNA processing 2.09 
ENSP00000262570 Q9NX63  Coiled‐coil‐helix‐coiled‐coil‐
helix domain‐containing 
protein 3, mitochondrial 
CHCHD3 structural protein 18.7 
ENSP00000360184 Q9HD45  Transmembrane 9 superfamily 
member 3 
TM9SF3 structural protein 13.3 
ENSP00000372873 O75955  Flotillin‐1 FLOT1 structural protein 10.2 
ENSP00000298229 O15357  Phosphatidylinositol‐3,4,5‐
trisphosphate 5‐phosphatase 
2 
INPPL1 structural protein 7.65 
ENSP00000357110 O43491  Band 4.1‐like protein 2 EPB41L2 structural protein 4.40 
ENSP00000346785 A8K8J9  Dynactin 2 (P50), isoform 
CRA_b  
DCTN2  structural protein 2.90 
ENSP00000245932 P50552  Vasodilator‐stimulated 
phosphoprotein 
VASP structural protein 2.22 
ENSP00000290858 Q13951  Core‐binding factor subunit 
beta 
CBFB transcription 17.6 
ENSP00000218364 O43719  HIV Tat‐specific factor 1 HTATSF1 transcription 11.0 
ENSP00000238688 Q9GZT3  SRA stem‐loop‐interacting 
RNA‐binding protein, 
mitochondrial 
SLIRP transcription 10.2 
ENSP00000360582 O15226  NF‐kappa‐B‐repressing factor NKRF transcription 8.76 
ENSP00000284811 Q15369  Transcription elongation 
factor B polypeptide 1 
TCEB1 transcription 8.76 
ENSP00000367784 O00267  Transcription elongation 
factor SPT5 
SUPT5H transcription 4.34 
ENSP00000319104 Q7KZ85  Transcription elongation 
factor SPT6 
SUPT6H transcription 3.63 
ENSP00000356177 Q5VYJ4  Putative small nuclear 
ribonucleoprotein 
polypeptide E‐like protein 1 
SNRPEL1 transcription 2.84 
ENSP00000361626 P67809  Nuclease‐sensitive element‐
binding protein 1 
YBX1 transcription 2.83 
ENSP00000361453 Q96I24  Far upstream element‐binding 
protein 3 
FUBP3 transcription 2.50 
ENSP00000370109 O75475  PC4 and SFRS1‐interacting 
protein 
PSIP1 transcription 2.45 
ENSP00000320949 A5YKK6  CCR4‐NOT transcription 
complex subunit 1 
CNOT1 transcription 2.10 
ENSP00000261622 Q01650  Large neutral amino acids 
transporter small subunit 1 
SLC7A5 transport 19.9 
ENSP00000368185 Q6PJE1  NUP107 protein  NUP107  transport 17.8 
ENSP00000367044 Q9P2E9  Ribosome‐binding protein 1 RRBP1 transport 12.5 
ENSP00000297540 Q9H814  Phosphorylated adapter RNA 
export protein 
PHAX transport 9.89 
ENSP00000358640 P53985  Monocarboxylate transporter 
1 
SLC16A1 transport 9.87 
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ENSP00000303585 P30622  CAP‐Gly domain‐containing 
linker protein 1 
CLIP1 transport 7.65 
ENSP00000369862 Q9Y5P4  Collagen type IV alpha‐3‐
binding protein 
COL4A3BP transport 6.75 
ENSP00000362728 O60684  Importin subunit alpha‐7 KPNA6 transport 6.75 
ENSP00000381634 Q9H2H9  Sodium‐coupled neutral 
amino acid transporter 1 
SLC38A1 transport 4.19 
ENSP00000264932 P31040  Succinate dehydrogenase 
[ubiquinone] flavoprotein 
subunit, mitochondrial 
 SDHA transport 2.75 
ENSP00000309142 Q6L8Q7  2',5'‐phosphodiesterase 12 PDE12 tumour 
suppressor 
2.11 
ENSP00000284274 Q96BN8  Protein FAM105B FAM105B uncharacterized 
protein  
6.23 
ENSP00000384088 Q9NXC5  WD repeat‐containing protein 
mio 
MIOS uncharacterized 
protein  
4.13 
ENSP00000358546 E9PGZ0  Uncharacterized protein  CSDE1  uncharacterized 
protein  
3.56 
a
Gene identifier is generated by global proteome machine (GPM) software with NCBI human protein database. 
b
Accession numbers were derived from the 2012_03 version of UniProtKB/Swiss‐Prot database. 
c
Protein names 
were protein names as in the  2012_03 version UniProtKB/Swiss‐Prot database. 
d
Gene names were gene names 
as in the 2012_03 version UniProtKB/Swiss‐Prot database. 
e
Biological processes were assigned using the 2012_03 
version UniProtKB/Swiss‐Prot database. 
f
Ratios were calculated based on NSAF value of triplicate 2‐FaraA (10 
µM, 48h) treated MEC1 samples (2‐FaraA) and triplicate MEC1 control samples (Ctr) (p‐value < 0.05). 
 
 
 
 
 
 
 
Table A4. Proteins decreased in abundance after 2-FaraA (10 µM, 48h) treatment (n = 3, p < 0.05) in MEC1 cell. 
Gene identifier
a
 Accession 
number
b
 
Protein names
c
 Gene name
d
  Biological 
processes
e
  
2‐
FaraA/Ctr 
ratio
f
 
ENSP00000369887 Q9NWH9  SAFB‐like transcription 
modulator 
SLTM apoptosis 0.13 
ENSP00000365576 Q9UMX0  Ubiquilin‐1 UBQLN1 apoptosis 0.26 
ENSP00000229239 P04406  Glyceraldehyde‐3‐phosphate 
dehydrogenase 
GAPDH apoptosis 0.48 
ENSP00000368540 Q5T6F2  Ubiquitin‐associated protein 2 UBAP2 apoptosis 0.47 
ENSP00000361625 Q86YN1  Dolichyldiphosphatase 1 DOLPP1 cell metabolism 0.11 
ENSP00000307260 Q9Y4P3  Transducin beta‐like protein 2 TBL2 cell metabolism 0.13 
ENSP00000378405 O14874  [3‐methyl‐2‐oxobutanoate 
dehydrogenase [lipoamide]] 
kinase, mitochondrial 
BCKDK cell metabolism 0.19 
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ENSP00000222388 Q9UG63  ATP‐binding cassette sub‐family 
F member 2 
ABCF2 cell metabolism 0.09 
ENSP00000341905 Q86YV0  RAS protein activator like‐3 RASAL3 cell signaling 0.05 
ENSP00000359045 Q86UY3  ARHGAP4 protein ARHGAP4  cell signaling 0.08 
ENSP00000225698 Q07021  Complement component 1 Q 
subcomponent‐binding protein, 
mitochondrial 
C1QBP cell signaling 0.24 
ENSP00000365891 P42768  Wiskott‐Aldrich syndrome 
protein 
WAS cell signaling 0.38 
ENSP00000222005 Q16543  Hsp90 co‐chaperone Cdc37 CDC37 chaperone 0.42 
ENSP00000219313 P51665  26S proteasome non‐ATPase 
regulatory subunit 7 
PSMD7 DNA damage 0.19 
ENSP00000216407 P62333  26S protease regulatory subunit 
10B 
PSMC6 DNA damage  0.47 
ENSP00000266544 Q16795  NADH dehydrogenase 
[ubiquinone] 1 alpha 
subcomplex subunit 9, 
mitochondrial 
NDUFA9 electron transport 0.04 
ENSP00000343032 Q8TCT9  Minor histocompatibility 
antigen H13 
 HM13 immunity 0.04 
ENSP00000252593 Q10589  Bone marrow stromal antigen 2 BST2 immunity 0.13 
ENSP00000378879 NA ATPase, Ca++ transporting, 
cardiac muscle, fast twitch 1 
[Source:HGNC Symbol;Acc:811] 
NA NA 0.02 
ENSP00000380000 NA CTD (carboxy‐terminal domain, 
RNA polymerase II, polypeptide 
A) small phosphatase like 2 
[Source:HGNC 
Symbol;Acc:26936] 
NA NA 0.10 
ENSP00000349378 NA parvin, gamma [Source:HGNC 
Symbol;Acc:14654] 
NA NA 0.13 
ENSP00000381027 NA U2‐associated protein SR140 
(140 kDa Ser/Arg‐rich domain 
protein) 
[Source:UniProtKB/Swiss‐
Prot;Acc:O15042] 
NA NA 0.17 
ENSP00000319910 Q7L2H7  Eukaryotic translation initiation 
factor 3 subunit M 
EIF3M protein 
biosynthesis 
0.26 
ENSP00000303279 Q9NSE4  Isoleucyl‐tRNA synthetase, 
mitochondrial 
IARS2 protein 
biosynthesis 
0.29 
ENSP00000378551 P29692  Elongation factor 1‐delta EEF1D protein 
biosynthesis 
0.46 
ENSP00000361076 P62424  60S ribosomal protein L7a RPL7A ribosomal protein 0.03 
ENSP00000310785 P82650  28S ribosomal protein S22, 
mitochondrial 
MRPS22 ribosomal protein 0.06 
ENSP00000359988 Q05519  Serine/arginine‐rich splicing 
factor 11 
SRSF11 RNA processing 0.06 
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ENSP00000360828 Q96GQ7  Probable ATP‐dependent RNA 
helicase DDX27 
DDX27 RNA processing 0.09 
ENSP00000362532 Q9NQG5  Regulation of nuclear pre‐mRNA 
domain‐containing protein 1B 
RPRD1B RNA processing 0.10 
ENSP00000261973 P49756  RNA‐binding protein 25 RBM25 RNA processing 0.15 
ENSP00000221448 P08621  U1 small nuclear 
ribonucleoprotein 70 kDa 
SNRNP70 RNA processing 0.15 
ENSP00000268482 Q92620  Pre‐mRNA‐splicing factor ATP‐
dependent RNA helicase PRP16 
DHX38 RNA processing 0.16 
ENSP00000379760 O76021  Ribosomal L1 domain‐
containing protein 1 
RSL1D1 RNA processing 0.20 
ENSP00000312981 Q53GS9  U4/U6.U5 tri‐snRNP‐associated 
protein 2 
USP39 RNA processing 0.21 
ENSP00000246662 P35527  Keratin, type I cytoskeletal 9 KRT9 structural protein 0.02 
ENSP00000252244 P04264  Keratin, type II cytoskeletal 1 KRT1 structural protein 0.06 
ENSP00000263097 Q99439  Calponin‐2 CNN2 structural protein 0.07 
ENSP00000267812 P55081  Microfibrillar‐associated protein 
1 
MFAP1 structural protein 0.07 
ENSP00000303908 Q6IBS0  Twinfilin‐2 TWF2 structural protein 0.10 
ENSP00000253363 Q14498  RNA‐binding protein 39 RBM39 transcription 0.02 
ENSP00000302640 P17480  Nucleolar transcription factor 1 UBTF transcription 0.19 
ENSP00000324628 Q99747  Gamma‐soluble NSF 
attachment protein 
NAPG transport 0.06 
ENSP00000336566 P55735  Protein SEC13 homolog SEC13 transport 0.09 
ENSP00000361900 Q15785  Mitochondrial import receptor 
subunit TOM34 
TOMM34 transport 0.10 
ENSP00000222124 Q6UW68  Transmembrane protein 205 TMEM205 transport 0.41 
ENSP00000380647 E9PAL7  Uncharacterized protein SSR1  uncharacterized 
protein 
0.05 
ENSP00000360401 A6NJZ9  Uncharacterized protein NA  uncharacterized 
protein 
0.09 
ENSP00000363952 C9JXC9  Uncharacterized protein RNF20  uncharacterized 
protein 
0.10 
ENSP00000354079 A6NJ11  Uncharacterized protein  NA  uncharacterized 
protein 
0.11 
ENSP00000383086 E7EU96  Uncharacterized protein  CSNK2A1  uncharacterized 
protein 
0.12 
ENSP00000368219 A6NFX8  Uncharacterized protein  NUDT5  uncharacterized 
protein 
0.18 
a
Gene identifier is generated by global proteome machine (GPM) software with NCBI human protein database. 
b
Accession numbers were derived from the 2012_03 version of UniProtKB/Swiss‐Prot database. 
c
Protein names 
were protein names as in the  2012_03 version UniProtKB/Swiss‐Prot database. 
d
Gene names were gene names 
as in the 2012_03 version UniProtKB/Swiss‐Prot database. 
e
Biological processes were assigned using the 2012_03 
version UniProtKB/Swiss‐Prot database. 
f
Ratios were calculated based on NSAF value of triplicate  2‐FaraA (10 
µM, 48h) treated MEC1 samples (2‐FaraA) and triplicate MEC1 control samples (Ctr) (p‐value < 0.05). 
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Table A5. Proteins increased in abundance after 100nM SNX-7081 + 10 µM 2-FaraA (48h) treatment (n = 3, p < 
0.05) in MEC1 cell. 
Gene identifier
a
 Accession 
number
b
 
Protein names
c
 Gene 
name
d
  
Biological 
processes
e
  
SF/Ctr 
ratio
f
 
ENSP00000318822 P55957  BH3‐interacting domain death 
agonist 
BID apoptosis 18.7 
ENSP00000354201 Q9H832  Ubiquitin‐conjugating enzyme E2 
Z 
UBE2Z apoptosis 11.7 
ENSP00000343458 P51572  B‐cell receptor‐associated 
protein 31 
BCAP31 apoptosis 9.38 
ENSP00000215909 P09382  Galectin‐1 LGALS1 apoptosis 8.16 
ENSP00000370109 O75475  PC4 and SFRS1‐interacting 
protein 
PSIP1 apoptosis 2.80 
ENSP00000370074 P50453  Serpin B9 SERPINB9 apoptosis 2.19 
ENSP00000361777 Q01105  Protein SET SET apoptosis 2.14 
ENSP00000231487 P63208  S‐phase kinase‐associated 
protein 1 
SKP1 cell cycle 11.1 
ENSP00000256496 Q9NVJ2  ADP‐ribosylation factor‐like 
protein 8B 
ARL8B cell cycle 5.98 
ENSP00000176763 O94804  serine/threonine kinase 10 
[Source:HGNC 
Symbol;Acc:11388] 
 STK10 cell cycle 3.82 
ENSP00000358921 P61163  Alpha‐centractin ACTR1A cell cycle 2.85 
ENSP00000264893 Q9NVA2  Septin‐11 Sep‐11 cell cycle 2.35 
ENSP00000337060 P15531  Nucleoside diphosphate kinase A NME1 cell metabolism 156 
ENSP00000054950 Q15293  Reticulocalbin‐1 RCN1 cell metabolism 22.1 
ENSP00000367263 Q09666  Neuroblast differentiation‐
associated protein AHNAK 
AHNAK cell metabolism 21.3 
ENSP00000282272 Q8N8A2  Serine/threonine‐protein 
phosphatase 6 regulatory 
ankyrin repeat subunit B 
ANKRD44 cell metabolism 8.53 
ENSP00000205061 Q92896  Golgi apparatus protein 1 GLG1 cell metabolism 8.44 
ENSP00000318852 O95861  3'(2'),5'‐bisphosphate 
nucleotidase 1 
BPNT1 cell metabolism 6.36 
ENSP00000381007 Q8IVL0  Neuron navigator 3 NAV3 cell metabolism 5.98 
ENSP00000370748 Q13907  Isopentenyl‐diphosphate Delta‐
isomerase 1 
IDI1 cell metabolism 5.21 
ENSP00000210444 Q9NR45  Sialic acid synthase NANS cell metabolism 4.95 
ENSP00000225777 O43760  Synaptogyrin‐2 SYNGR2 cell metabolism 3.81 
ENSP00000265174 O43252  Bifunctional 3'‐
phosphoadenosine 5'‐
phosphosulfate synthase 1 
PAPSS1 cell metabolism 3.77 
ENSP00000289382 Q9UKZ1  UPF0760 protein C2orf29 C2orf29 cell metabolism 3.48 
ENSP00000241052 P04040  Catalase CAT cell metabolism 3.33 
ENSP00000333298 P11279  Lysosome‐associated membrane 
glycoprotein 1 
LAMP1 cell metabolism 2.82 
ENSP00000375724 Q5E949  protein arginine 
methyltransferase 1 
[Source:HGNC Symbol;Acc:5187] 
HRMT1L2  cell metabolism 2.79 
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ENSP00000303147 P31153  S‐adenosylmethionine synthase 
isoform type‐2 
MAT2A cell metabolism 2.13 
ENSP00000378995 P30049  ATP synthase subunit delta, 
mitochondrial 
ATP5D cell metabolism 10.2 
ENSP00000284719 Q9NTK5  Obg‐like ATPase 1 OLA1 cell metabolism 2.88 
ENSP00000345931 O43852  Calumenin CALU cell metabolism 6.83 
ENSP00000258947 Q13137  Calcium‐binding and coiled‐coil 
domain‐containing protein 2 
CALCOCO2 cell metabolism 6.51 
ENSP00000198939 Q8IWX8  Calcium homeostasis 
endoplasmic reticulum protein 
CHERP cell metabolism 5.78 
ENSP00000291295 P62158  Calmodulin CALM1 cell metabolism 4.95 
ENSP00000301012 P53602  Diphosphomevalonate 
decarboxylase 
MVD cell metabolism 12.8 
ENSP00000347717 Q9UBM7  7‐dehydrocholesterol reductase DHCR7 cell metabolism 6.83 
ENSP00000325136 P55084  Trifunctional enzyme subunit 
beta, mitochondrial 
HADHB cell metabolism 4.13 
ENSP00000359878 P11310  Medium‐chain specific acyl‐CoA 
dehydrogenase, mitochondrial 
ACADM cell metabolism 3.86 
ENSP00000229270 P60174  Triosephosphate isomerase TPI1 cell metabolism 2.85 
ENSP00000261875 Q9P035  3‐hydroxyacyl‐CoA dehydratase 3 PTPLAD1 cell metabolism 2.77 
ENSP00000349053 Q14697  Neutral alpha‐glucosidase AB GANAB cell metabolism 142 
ENSP00000368119 P07902  Galactose‐1‐phosphate 
uridylyltransferase 
GALT cell metabolism 7.68 
ENSP00000304006 P68402  Platelet‐activating factor 
acetylhydrolase IB subunit beta 
PAFAH1B2 cell metabolism 5.98 
ENSP00000348762 P48449  Lanosterol synthase LSS cell metabolism 3.45 
ENSP00000196371 P55809  Succinyl‐CoA:3‐ketoacid‐
coenzyme A transferase 1, 
mitochondrial 
OXCT1 cell metabolism 2.99 
ENSP00000310275 O75531  Barrier‐to‐autointegration factor BANF1 cell metabolism 9.38 
ENSP00000342026 P30041  Peroxiredoxin‐6 PRDX6 cell metabolism 7.72 
ENSP00000369081 Q8NBS9  Thioredoxin domain‐containing 
protein 5 
TXNDC5 cell metabolism 5.61 
ENSP00000262746 Q06830  Peroxiredoxin‐1 PRDX1 cell metabolism 2.81 
ENSP00000205402 P09622  Dihydrolipoyl dehydrogenase, 
mitochondrial 
DLD cell metabolism 2.43 
ENSP00000248450 Q13685  Angio‐associated migratory cell 
protein 
AAMP cell signaling 7.38 
ENSP00000374576 B4DTU0  cDNA FLJ59249, highly similar to 
CD166 antigen  
ALCAM cell signaling 7.38 
ENSP00000344742 O95630  STAM‐binding protein STAMBP cell signaling 7.28 
ENSP00000339467 P84095  Rho‐related GTP‐binding protein 
RhoG 
RHOG cell signaling 6.83 
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ENSP00000331201 O14964  Hepatocyte growth factor‐
regulated tyrosine kinase 
substrate 
HGS cell signaling 5.04 
ENSP00000160262 P32942  Intercellular adhesion molecule 3 ICAM3 cell signaling 3.73 
ENSP00000228945 P52566  Rho GDP‐dissociation inhibitor 2 ARHGDIB cell signaling 3.59 
ENSP00000349629 P50851  Lipopolysaccharide‐responsive 
and beige‐like anchor protein 
LRBA cell signaling 3.14 
ENSP00000385866 P46060  Ran GTPase‐activating protein 1 RANGAP1 cell signaling 2.43 
ENSP00000262948 P36507  Dual specificity mitogen‐
activated protein kinase kinase 2 
MAP2K2 cell signaling 8.93 
ENSP00000302486 Q02750  mitogen‐activated protein kinase 
kinase 1 [Source:HGNC 
Symbol;Acc:6840] 
MAP2K1 cell signaling 2.59 
ENSP00000315630 Q9UH65  Switch‐associated protein 70 SWAP70 cell signaling 2.53 
ENSP00000252934 Q9UBB4  Ataxin‐10 ATXN10 cell signaling 2.43 
ENSP00000248553 P04792  Heat shock protein beta‐1 HSPB1 chaperone 16.9 
ENSP00000350894 P50454  Serpin H1 SERPINH1 chaperone 12.8 
ENSP00000265028 Q9UBS4  DnaJ homolog subfamily B 
member 11 
DNAJB11 chaperone 10.2 
ENSP00000262570 Q9NX63  Coiled‐coil‐helix‐coiled‐coil‐helix 
domain‐containing protein 3, 
mitochondrial 
CHCHD3 chaperone 10.2 
ENSP00000255631 Q9NZL4  Hsp70‐binding protein 1  HSPBP1 chaperone 7.68 
ENSP00000356989 Q9UHV9  Prefoldin subunit 2 PFDN2 chaperone 7.68 
ENSP00000303920 Q8WU39  Plasma cell‐induced resident 
endoplasmic reticulum protein 
PACAP chaperone 7.68 
ENSP00000262455 Q9BS26  Endoplasmic reticulum resident 
protein 44 
ERP44 chaperone 2.57 
ENSP00000357244 P49368  T‐complex protein 1 subunit 
gamma 
CCT3 chaperone 2.10 
ENSP00000268058 P29590  Protein PML PML DNA damage 65.5 
ENSP00000308405 Q71UI9  Histone H2A.V H2AFV DNA damage 52.7 
ENSP00000262193 P20618  Proteasome subunit beta type‐1 PSMB1 DNA damage 10.2 
ENSP00000270586 P28072  Proteasome subunit beta type‐6 PSMB6 DNA damage 10.2 
ENSP00000362334 P49721  Proteasome subunit beta type‐2 PSMB2 DNA damage 9.11 
ENSP00000350217 C9J5P2  DNA topoisomerase 2  TOP2A  DNA damage 6.51 
ENSP00000360367 Q9ULC4  Malignant T cell‐amplified 
sequence 1 
MCTS1 DNA damage 6.51 
ENSP00000264331 Q02880  DNA topoisomerase 2‐beta TOP2B DNA damage 5.98 
ENSP00000225426 P49720  Proteasome subunit beta type‐3 PSMB3 DNA damage 3.95 
ENSP00000353701 Q9NY33  Bardet‐Biedl syndrome 1  DPP3 DNA damage 3.38 
ENSP00000261942 Q96CS3  FAS‐associated factor 2 FAF2 DNA damage 3.07 
ENSP00000379287 P63104  14‐3‐3 protein zeta/delta YWHAZ DNA damage 2.43 
ENSP00000300161 P31946  14‐3‐3 protein beta/alpha YWHAB DNA damage 2.12 
ENSP00000371267 P27348  14‐3‐3 protein theta YWHAQ DNA damage 2.60 
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ENSP00000265304 Q04837  Single‐stranded DNA‐binding 
protein, mitochondrial 
SSBP1 DNA replication 
and repair 
20.4 
ENSP00000371419 Q9UKK3  Poly [ADP‐ribose] polymerase 4 PARP4 DNA replication 
and repair 
6.83 
ENSP00000363641 P10599  Thioredoxin TXN electron transport 17.0 
ENSP00000234454 P35270  Sepiapterin reductase SPR electron transport 15.3 
ENSP00000306397 P47985  Cytochrome b‐c1 complex 
subunit Rieske, mitochondrial 
UQCRFS1 electron transport 8.25 
ENSP00000354876 P00403  Cytochrome c oxidase subunit 2  MT‐CO2 electron transport 4.60 
ENSP00000253452 P13073  Cytochrome c oxidase subunit 4 
isoform 1, mitochondrial 
COX4I1 electron transport 4.52 
ENSP00000277865 P00367  Glutamate dehydrogenase 1, 
mitochondrial 
GLUD1 electron transport 4.19 
ENSP00000264932 P31040  Succinate dehydrogenase 
[ubiquinone] flavoprotein 
subunit, mitochondrial 
SDHA electron transport 3.67 
ENSP00000260985 O75874  Isocitrate dehydrogenase [NADP] 
cytoplasmic 
IDH1 electron transport 3.44 
ENSP00000270776 P52209  6‐phosphogluconate 
dehydrogenase, decarboxylating 
PGD electron transport 2.44 
ENSP00000215754 P14174  Macrophage migration inhibitory 
factor 
MIF immunity 4.39 
ENSP00000323889 Q14258  E3 ubiquitin/ISG15 ligase TRIM25 TRIM25 immunity 2.45 
ENSP00000337213 NA SH3‐domain binding protein 1 
[Source:HGNC 
Symbol;Acc:10824] 
NA NA 18.7 
ENSP00000252440 NA ECSIT homolog (Drosophila) 
[Source:HGNC 
Symbol;Acc:29548] 
NA NA 10.2 
ENSP00000337669 NA cell division cycle 42 (GTP 
binding protein, 25kDa) 
[Source:HGNC Symbol;Acc:1736] 
NA NA 9.11 
ENSP00000370376 NA deoxyuridine triphosphatase 
[Source:HGNC Symbol;Acc:3078] 
NA NA 8.68 
ENSP00000349721 NA tumor susceptibility gene 101 
[Source:HGNC 
Symbol;Acc:15971] 
NA NA 8.53 
ENSP00000369235 NA endoplasmic reticulum 
aminopeptidase 2 [Source:HGNC 
Symbol;Acc:29499] 
NA NA 8.53 
ENSP00000356024 NA complement component 
(3d/Epstein Barr virus) receptor 
2 [Source:HGNC 
Symbol;Acc:2336] 
NA NA 8.32 
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ENSP00000315122 NA apoptosis‐inducing factor, 
mitochondrion‐associated, 1 
[Source:HGNC Symbol;Acc:8768] 
NA NA 8.20 
ENSP00000359039 NA PRP38 pre‐mRNA processing 
factor 38 (yeast) domain 
containing B [Source:HGNC 
Symbol;Acc:25512] 
NA NA 5.98 
ENSP00000379016 NA transforming growth factor beta 
regulator 4 [Source:HGNC 
Symbol;Acc:17443] 
NA NA 5.98 
ENSP00000085068 NA isochorismatase domain 
containing 2 [Source:HGNC 
Symbol;Acc:26278] 
NA NA 5.21 
ENSP00000347969 NA small nucleolar RNA, C/D box 4A 
[Source:HGNC 
Symbol;Acc:10097] 
NA NA 4.66 
ENSP00000379643 NA nudE nuclear distribution gene E 
homolog 1 (A. nidulans) 
[Source:HGNC 
Symbol;Acc:17619] 
NA NA 4.35 
ENSP00000382743 NA CUGBP, Elav‐like family member 
2 [Source:HGNC 
Symbol;Acc:2550] 
NA NA 3.52 
ENSP00000340940 NA protein kinase, cAMP‐
dependent, catalytic, alpha 
[Source:HGNC Symbol;Acc:9380] 
NA NA 3.48 
ENSP00000188376 NA solute carrier family 25 
(mitochondrial carrier; 
phosphate carrier), member 3 
[Source:HGNC 
Symbol;Acc:10989] 
NA NA 3.36 
ENSP00000362548 NA adenylate kinase 2 [Source:HGNC 
Symbol;Acc:362] 
NA NA 2.97 
ENSP00000371626 NA transformer 2 beta homolog 
(Drosophila) [Source:HGNC 
Symbol;Acc:10781] 
NA NA 2.86 
ENSP00000355922 NA centromere protein F, 
350/400kDa (mitosin) 
[Source:HGNC Symbol;Acc:1857] 
NA NA 2.79 
ENSP00000221431 Q9NP81  Seryl‐tRNA synthetase, 
mitochondrial 
SARS2 protein 
biosynthesis 
6.41 
ENSP00000265537 Q15031  Probable leucyl‐tRNA synthetase, 
mitochondrial 
LARS2 protein 
biosynthesis 
5.04 
ENSP00000320309 Q9Y285  Phenylalanyl‐tRNA synthetase 
alpha chain 
FARSA protein 
biosynthesis 
2.85 
ENSP00000304668 P12081  Histidyl‐tRNA synthetase, 
cytoplasmic 
HARS protein 
biosynthesis 
2.37 
ENSP00000271764 P41214  Eukaryotic translation initiation 
factor 2D 
EIF2D protein 
biosynthesis 
11.6 
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ENSP00000251636 Q7Z478  ATP‐dependent RNA helicase 
DHX29 
DHX29 protein 
biosynthesis 
7.68 
ENSP00000220849 P60228  Eukaryotic translation initiation 
factor 3 subunit E 
EIF3E protein 
biosynthesis 
2.22 
ENSP00000367044 Q9P2E9  Ribosome‐binding protein 1 RRBP1 ribosomal protein 25.6 
ENSP00000009589 P60866  40S ribosomal protein S20 RPS20 ribosomal protein 25.1 
ENSP00000251453 P62249  40S ribosomal protein S16 RPS16 ribosomal protein 22.5 
ENSP00000379381 NA ribosomal protein L30 
[Source:HGNC 
Symbol;Acc:10333] 
 ribosomal protein 17.0 
ENSP00000233609 P62841  40S ribosomal protein S15 RPS15 ribosomal protein 13.6 
ENSP00000270625 P62280  40S ribosomal protein S11 RPS11 ribosomal protein 9.89 
ENSP00000311028 P62263  40S ribosomal protein S14 RPS14 ribosomal protein 6.84 
ENSP00000196551 P46782  40S ribosomal protein S5 RPS5 ribosomal protein 5.86 
ENSP00000333837 P52815  39S ribosomal protein L12, 
mitochondrial 
MRPL12 ribosomal protein 4.35 
ENSP00000366997 Q9Y2L1  Exosome complex exonuclease 
RRP44 
DIS3 RNA processing 12.8 
ENSP00000375798 P62316  Small nuclear ribonucleoprotein 
Sm D2 
SNRPD2 RNA processing 11.1 
ENSP00000266735 P62306  Small nuclear ribonucleoprotein 
F 
SNRPF RNA processing 9.38 
ENSP00000265069 Q96KR1  Zinc finger RNA‐binding protein ZFR RNA processing 6.95 
ENSP00000238688 Q9GZT3  SRA stem‐loop‐interacting RNA‐
binding protein, mitochondrial 
SLIRP RNA processing 6.70 
ENSP00000343054 P52756  RNA‐binding protein 5 RBM5 RNA processing 6.08 
ENSP00000252622 Q9UK45  U6 snRNA‐associated Sm‐like 
protein LSm7 
LSM7 RNA processing 3.48 
ENSP00000244020 Q13247  Serine/arginine‐rich splicing 
factor 6 
SRSF6 RNA processing 3.37 
ENSP00000359645 P38159  Heterogeneous nuclear 
ribonucleoprotein G 
RBMX RNA processing 3.15 
ENSP00000361626 P67809  Nuclease‐sensitive element‐
binding protein 1 
YBX1 RNA processing 2.84 
ENSP00000269349 P38919  Eukaryotic initiation factor 4A‐III EIF4A3 RNA processing 2.16 
ENSP00000361891 Q01518  Adenylyl cyclase‐associated 
protein 1 
CAP1 RNA processing 2.04 
ENSP00000374777 P01834  Ig kappa chain C region IGKC structual protein 17.9 
ENSP00000245932 P50552  Vasodilator‐stimulated 
phosphoprotein 
VASP structual protein 2.17 
ENSP00000349238 A6NC98  Coiled‐coil domain‐containing 
protein 88B 
CCDC88B structual protein 23.8 
ENSP00000263867 P40121  Macrophage‐capping protein CAPG structual protein 19.6 
ENSP00000254286 Q9NZ32  Actin‐related protein 10 ACTR10 structual protein 9.38 
ENSP00000372873 O75955  Flotillin‐1 FLOT1 structual protein 9.31 
ENSP00000357110 O43491  Band 4.1‐like protein 2 EPB41L2 structual protein 3.79 
ENSP00000348886 Q9UJZ1  Stomatin‐like protein 2 STOML2 structual protein 2.40 
ENSP00000218364 O43719  HIV Tat‐specific factor 1 HTATSF1 transcription 11.1 
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ENSP00000319829 Q8N1G0  Zinc finger protein 687 ZNF687 transcription 11.1 
ENSP00000290858 Q13951  Core‐binding factor subunit beta CBFB transcription 9.38 
ENSP00000299601 Q8WVC0  RNA polymerase‐associated 
protein LEO1 
LEO1 transcription 9.38 
ENSP00000284811 Q15369  Transcription elongation factor B 
polypeptide 1 
TCEB1 transcription 9.38 
ENSP00000351410 P10644  cAMP‐dependent protein kinase 
type I‐alpha regulatory subunit 
PRKAR1A transcription 7.11 
ENSP00000299299 P61457  Pterin‐4‐alpha‐carbinolamine 
dehydratase 
PCBD1 transcription 6.83 
ENSP00000319281 P80723  Brain acid soluble protein 1 BASP1 transcription 5.53 
ENSP00000296446 Q9BUB1  PRKAR2A protein  PRKAR2A  transcription 3.91 
ENSP00000367784 O00267  Transcription elongation factor 
SPT5 
SUPT5H transcription 3.77 
ENSP00000228251 P16989  DNA‐binding protein A CSDA transcription 3.48 
ENSP00000358983 Q00653  Nuclear factor NF‐kappa‐B p100 
subunit 
NFKB2 transcription 3.40 
ENSP00000361453 Q96I24  Far upstream element‐binding 
protein 3 
FUBP3 transcription 2.50 
ENSP00000229314 Q9Y3E0  Vesicle transport protein GOT1B GOLT1B transport 6.83 
ENSP00000360184 Q9HD45  Transmembrane 9 superfamily 
member 3 
TM9SF3 transport 15.7 
ENSP00000345689 P51148  Ras‐related protein Rab‐5C RAB5C transport 14.5 
ENSP00000362728 O60684  Importin subunit alpha‐7 KPNA6 transport 13.4 
ENSP00000251595 P69905  Hemoglobin subunit alpha HBA1 transport 12.8 
ENSP00000368185 Q6PJE1  NUP107 protein  NUP107  transport 9.98 
ENSP00000369862 Q9Y5P4  Collagen type IV alpha‐3‐binding 
protein 
COL4A3BP transport 9.11 
ENSP00000378760 Q14764  Major vault protein MVP transport 8.54 
ENSP00000238256 Q5T1M5  FK506‐binding protein 15 FKBP15 transport 6.35 
ENSP00000379995 Q9UI12  V‐type proton ATPase subunit H ATP6V1H transport 6.08 
ENSP00000379779 C0H5W9  SNX6 protein  SNX6  transport 5.98 
ENSP00000297540 Q9H814  Phosphorylated adapter RNA 
export protein 
PHAX transport 5.21 
ENSP00000276390 P21281  V‐type proton ATPase subunit B, 
brain isoform 
ATP6V1B2 transport 4.68 
ENSP00000216034 Q9NS69  Mitochondrial import receptor 
subunit TOM22 homolog 
TOMM22 transport 4.08 
ENSP00000346785 A8K8J9  Dynactin 2 (P50), isoform CRA_b DCTN2  transport 3.84 
ENSP00000303145 P49755  Transmembrane emp24 domain‐
containing protein 10 
TMED10 transport 3.50 
ENSP00000252487 O96008  Mitochondrial import receptor 
subunit TOM40 homolog 
TOMM40 transport 2.94 
ENSP00000284320 O94826  Mitochondrial import receptor 
subunit TOM70 
TOMM70A transport 2.35 
ENSP00000299980 O43747  AP‐1 complex subunit gamma‐1 AP1G1 transport 2.14 
ENSP00000221957 O60664  Perilipin‐3 PLIN3 transport 2.03 
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ENSP00000325548 Q96KP4  Cytosolic non‐specific 
dipeptidase 
CNDP2 tumor suppressor 3.59 
ENSP00000216832 Q9H307  Pinin PNN tumor suppressor 2.87 
ENSP00000385059 B5MCW9  Uncharacterized protein EML4  uncharacterized 
protein 
45.9 
ENSP00000385012 B5MCY6  Uncharacterized protein PPP1R7  uncharacterized 
protein 
11.1 
ENSP00000377322 E9PCM6  Uncharacterized protein ARHGAP4  uncharacterized 
protein 
10.2 
ENSP00000284274 Q96BN8  Protein FAM105B FAM105B uncharacterized 
protein 
5.65 
a
Gene identifier is generated by global proteome machine (GPM) software with NCBI human protein database. 
b
Accession numbers were derived from the 2012_03 version of UniProtKB/Swiss‐Prot database. 
c
Protein names 
were protein names as in the  2012_03 version UniProtKB/Swiss‐Prot database. 
d
Gene names were gene names 
as in the 2012_03 version UniProtKB/Swiss‐Prot database. 
e
Biological processes were assigned using the 2012_03 
version UniProtKB/Swiss‐Prot database. 
f
Ratios were calculated based on NSAF value of triplicate 100nM SNX‐
7081+10 µM 2‐FaraA (48h) treated MEC1 samples (SF) and triplicate MEC1 control samples (Ctr) (p‐value < 0.05). 
 
 
 
 
 
 
Table A6. Proteins decreased in abundance after 100nM SNX-7081 + 10 µM 2-FaraA (48h) treatment (n = 3, p < 
0.05) in MEC1 cell. 
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ENSP00000261359 Q9NR09  Baculoviral IAP repeat‐containing 
protein 6 
BIRC6 apoptosis 0.13 
ENSP00000365576 Q9UMX0  Ubiquilin‐1 UBQLN1 apoptosis 0.18 
ENSP00000368540 Q5T6F2  Ubiquitin‐associated protein 2 UBAP2 apoptosis 0.08 
ENSP00000356424 NA ubiquitin carboxyl‐terminal 
hydrolase L5 
NA apoptosis 0.10 
ENSP00000351298 P62140  Serine/threonine‐protein 
phosphatase PP1‐beta catalytic 
subunit 
PPP1CB cell cycle 0.02 
ENSP00000238616 Q8TD19  Serine/threonine‐protein kinase 
Nek9 
NEK9 cell cycle 0.08 
ENSP00000350692 B7ZA04  cDNA, FLJ79018, highly similar to 
Cytoplasmic dynein 1 
intermediate chain 2  
DYNC1I2 cell cycle 0.14 
ENSP00000251496 Q9BPX3  Condensin complex subunit 3 NCAPG cell cycle 0.31 
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ENSP00000273130 Q9Y6G9  Cytoplasmic dynein 1 light 
intermediate chain 1 
DYNC1LI
1 
cell cycle 0.46 
ENSP00000356476 Q7Z2T5  TRMT1‐like protein TRMT1L cell metabolism 0.10 
ENSP00000347314 Q8N0X7  Spartin SPG20 cell metabolism 0.13 
ENSP00000291565 O00764  Pyridoxal kinase PDXK cell metabolism 0.44 
ENSP00000368031 D2K8Q1  AAA domain containing 3A 
protein 
ATAD3A  cell metabolism 0.43 
ENSP00000222388 Q9UG63  ATP‐binding cassette sub‐family F 
member 2 
ABCF2 cell metabolism 0.17 
ENSP00000290573 P52789  Hexokinase‐2 HK2 cell metabolism 0.50 
ENSP00000198765 O75131  Copine‐3  CPNE3 cell metabolism 0.27 
ENSP00000362329 Q15181  Inorganic pyrophosphatase PPA1 cell metabolism 0.43 
ENSP00000264167 O00116  Alkyldihydroxyacetonephosphate 
synthase, peroxisomal 
AGPS cell metabolism 0.06 
ENSP00000385657 Q15435  Protein phosphatase 1 regulatory 
subunit 7 
PPP1R7 cell metabolism 0.03 
ENSP00000341905 Q86YV0  RAS protein activator like‐3 RASAL3 cell signaling 0.05 
ENSP00000359045 Q86UY3  ARHGAP4 protein ARHGAP
4  
cell signaling 0.08 
ENSP00000312262 P25098  Beta‐adrenergic receptor kinase 1 ADRBK1 cell signaling 0.10 
ENSP00000314075 Q92667  A‐kinase anchor protein 1, 
mitochondrial 
AKAP1 cell signaling 0.11 
ENSP00000307260 Q9Y4P3  Transducin beta‐like protein 2 TBL2 cell signaling 0.13 
ENSP00000352320 A8K7B5  EDAR‐associated death domain, 
isoform CRA_e  
EDARAD
D  
cell signaling 0.28 
ENSP00000264156 Q14566  DNA replication licensing factor 
MCM6 
MCM6 DNA replication 
and repair 
0.30 
ENSP00000229043 E9PBA2  replication factor C 5, 36.5kDa  RFC5  DNA replication 
and repair 
0.06 
ENSP00000264220 Q06203  Amidophosphoribosyltransferase PPAT DNA replication 
and repair 
0.10 
ENSP00000324020 Q9NS87  Kinesin‐like protein KIF15 KIF15 DNA replication 
and repair 
0.12 
ENSP00000296273 P35249  Replication factor C subunit 4 RFC4 DNA replication 
and repair 
0.15 
ENSP00000234420 P52701  DNA mismatch repair protein 
Msh6 
MSH6 DNA replication 
and repair 
0.22 
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ENSP00000307288 P33993  DNA replication licensing factor 
MCM7 
MCM7 DNA replication 
and repair 
0.40 
ENSP00000263801 Q12888  Tumor suppressor p53‐binding 
protein 1 
TP53BP1 DNA replication 
and repair 
0.50 
ENSP00000375978 P13010  X‐ray repair cross‐complementing 
protein 5 
XRCC5 
(KU80) 
DNA replication 
and repair 
0.50 
ENSP00000378768 NA HLA class II histocompatibility 
antigen, DQ alpha 1 chain 
precursor 
NA immunity 0.10 
ENSP00000252593 Q10589  Bone marrow stromal antigen 2 BST2 immunity 0.13 
ENSP00000340466 NA glucosidase, alpha; neutral AB 
[Source:HGNC Symbol;Acc:4138] 
NA NA 0.01 
ENSP00000378879 NA ATPase, Ca++ transporting, 
cardiac muscle, fast twitch 1 
[Source:HGNC Symbol;Acc:811] 
NA NA 0.02 
ENSP00000381027 NA U2‐associated protein SR140 (140 
kDa Ser/Arg‐rich domain protein) 
[Source:UniProtKB/Swiss‐
Prot;Acc:O15042] 
NA NA 0.04 
ENSP00000319910 Q7L2H7 Eukaryotic translation initiation 
factor 3 subunit M 
NA NA 0.04 
ENSP00000300027 NA Fanconi anemia, 
complementation group I 
[Source:HGNC Symbol;Acc:25568] 
NA NA 0.05 
ENSP00000265453 NA WDFY family member 4 
[Source:HGNC Symbol;Acc:29323] 
NA NA 0.05 
ENSP00000342242 NA PTK2B protein tyrosine kinase 2 
beta [Source:HGNC 
Symbol;Acc:9612] 
NA NA 0.10 
ENSP00000345352 NA TRAF2 and NCK interacting kinase 
[Source:HGNC Symbol;Acc:30765] 
NA NA 0.13 
ENSP00000378278 NA small nucleolar RNA, C/D box 19B 
[Source:HGNC Symbol;Acc:33570] 
NA NA 0.14 
ENSP00000349378 NA parvin, gamma [Source:HGNC 
Symbol;Acc:14654] 
NA NA 0.18 
ENSP00000376167 NA G protein pathway suppressor 1 
[Source:HGNC Symbol;Acc:4549] 
NA NA 0.22 
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ENSP00000368129 NA apoptosis inhibitor 5 
[Source:HGNC Symbol;Acc:594] 
NA NA 0.30 
ENSP00000385157 NA acyl‐CoA synthetase long‐chain 
family member 3 [Source:HGNC 
Symbol;Acc:3570] 
NA NA 0.35 
ENSP00000354347 NA glutamine‐‐fructose‐6‐phosphate 
transaminase 1 [Source:HGNC 
Symbol;Acc:4241] 
NA NA 0.44 
ENSP00000377845 P08243  Asparagine synthetase 
[glutamine‐hydrolyzing] 
ASNS protein 
biosynthesis 
0.32 
ENSP00000289371 O60841  Eukaryotic translation initiation 
factor 5B 
EIF5B protein 
biosynthesis 
0.38 
ENSP00000378551 P29692  Elongation factor 1‐delta EEF1D protein 
biosynthesis 
0.43 
ENSP00000305682 NA mitochondrial ribosomal protein 
L39 [Source:HGNC 
Symbol;Acc:14027] 
NA ribosomal 
protein 
0.07 
ENSP00000372199 O60287 Nucleolar pre‐ribosomal‐
associated protein 1 
URB1 ribosomal 
protein 
0.28 
ENSP00000340557 Q14004  Cyclin‐dependent kinase 13 CDK13 RNA processing 0.02 
ENSP00000385067 E7ERC1  Uncharacterized protein  CDK11A  RNA processing 0.05 
ENSP00000360828 Q96GQ7  Probable ATP‐dependent RNA 
helicase DDX27 
DDX27 RNA processing 0.09 
ENSP00000362532 Q9NQG5  Regulation of nuclear pre‐mRNA 
domain‐containing protein 1B 
RPRD1B RNA processing 0.10 
ENSP00000225388 Q7Z417  Nuclear fragile X mental 
retardation‐interacting protein 2 
NUFIP2 RNA processing 0.10 
ENSP00000285873 Q8TEQ6  Gem‐associated protein 5 GEMIN5 RNA processing 0.13 
ENSP00000359988 Q05519  Serine/arginine‐rich splicing 
factor 11 
SRSF11 RNA processing 0.13 
ENSP00000328854 Q9BVI4  Nucleolar complex protein 4 
homolog 
NOC4L RNA processing 0.14 
ENSP00000268482 Q92620  Pre‐mRNA‐splicing factor ATP‐
dependent RNA helicase PRP16 
DHX38 RNA processing 0.15 
ENSP00000321706 P57678  Component of gems 4 GEMIN4 RNA processing 0.16 
ENSP00000331815 ENSP0000033
1815 
Transducin beta‐like protein 3 TBL3 RNA processing 0.22 
ENSP00000306123 Q9BWH6  RNA polymerase II‐associated 
protein 1 
RPAP1 RNA processing 0.22 
ENSP00000221448 P08621  U1 small nuclear 
ribonucleoprotein 70 kDa 
SNRNP70 RNA processing 0.25 
ENSP00000345456 B4DDG8  cDNA FLJ58764, highly similar to 
Poly(A)‐specific ribonuclease 
PARN (EC3.1.13.4)  
 RNA processing 0.31 
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ENSP00000346236 Q7L014  Probable ATP‐dependent RNA 
helicase DDX46 
DDX46 RNA processing 0.33 
ENSP00000380738 P13489  Ribonuclease inhibitor RNH1 RNA processing 0.34 
ENSP00000261973 P49756 RNA‐binding protein 25 RBM25 RNA processing 0.35 
ENSP00000301740 Q9UQ35  Serine/arginine repetitive matrix 
protein 2 
SRRM2 RNA processing 0.41 
ENSP00000254108 P35637  RNA‐binding protein FUS FUS RNA processing 0.42 
ENSP00000305556 Q15365  Poly(rC)‐binding protein 1 PCBP1 RNA processing 0.47 
ENSP00000320663 Q9HC35  Echinoderm microtubule‐
associated protein‐like 4 
EML4 structrual 
protein 
0.02 
ENSP00000267812 P55081  Microfibrillar‐associated protein 1 MFAP1 structrual 
protein 
0.07 
ENSP00000318195 P19338  Nucleolin NCL structrual 
protein 
0.40 
ENSP00000360305 O00151  PDZ and LIM domain protein 1 PDLIM1 structrual 
protein 
0.43 
ENSP00000323967 Q969G3  SWI/SNF‐related matrix‐
associated actin‐dependent 
regulator of chromatin subfamily 
E member 1 
SMARCE
1 
transcription 0.04 
ENSP00000327436 Q86TU7  Histone‐lysine N‐
methyltransferase setd3 
SETD3 transcription 0.10 
ENSP00000374280 Q92541  RNA polymerase‐associated 
protein RTF1 homolog 
RTF1 transcription 0.12 
ENSP00000358115 Q5TB20  Acidic (Leucine‐rich) nuclear 
phosphoprotein 32 family, 
member E 
ANP32E  transcription 0.13 
ENSP00000316651 Q9UI26  Importin‐11 IPO11 transcription 0.41 
ENSP00000291576 Q15269  Periodic tryptophan protein 2 
homolog 
PWP2 transcription 0.15 
ENSP00000361219 Q9UKN8  General transcription factor 3C 
polypeptide 4 
GTF3C4 transcription 0.16 
ENSP00000337632 P82979  SAP domain‐containing 
ribonucleoprotein 
SARNP transcription 0.19 
ENSP00000256429 Q9UBB5  Methyl‐CpG‐binding domain 
protein 2 
MBD2 transcription 0.22 
ENSP00000320485 O14497  AT‐rich interactive domain‐
containing protein 1A 
ARID1A transcription 0.25 
ENSP00000377969 P35269  General transcription factor IIF 
subunit 1 
 GTF2F1 transcription 0.33 
ENSP00000302640 P17480  Nucleolar transcription factor 1 UBTF transcription 0.44 
ENSP00000303623 Q15758  Neutral amino acid transporter 
B(0) 
SLC1A5 transport 0.06 
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ENSP00000297440 Q86Y56  HEAT repeat‐containing protein 2 HEATR2 transport 0.11 
ENSP00000263246 Q9UNF0  Protein kinase C and casein 
kinase substrate in neurons 
protein 2 
PACSIN2 transport 0.25 
ENSP00000367721 Q12769 Nuclear pore complex protein 
Nup160 
NUP160 transport 0.28 
ENSP00000368219 A6NFX8  Uncharacterized protein  NUDT5  uncharacterized 
protein  
0.04 
ENSP00000380647 E9PAL7  Uncharacterized protein SSR1  uncharacterized 
protein  
0.05 
a
Gene identifier is generated by global proteome machine (GPM) software with NCBI human protein database. 
b
Accession numbers were derived from the 2012_03 version of UniProtKB/Swiss‐Prot database. 
c
Protein names 
were protein names as in the  2012_03 version UniProtKB/Swiss‐Prot database. 
d
Gene names were gene names as 
in the 2012_03 version UniProtKB/Swiss‐Prot database. 
e
Biological processes were assigned using the 2012_03 
version UniProtKB/Swiss‐Prot database. 
f
Ratios were calculated based on NSAF value of triplicate 100nM SNX‐
7081+10 µM 2‐FaraA (48h) treated MEC1 samples (SF) and triplicate MEC1 control samples (Ctr) (p‐value < 0.05). 
 
 
